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Medium spiny neurons (MSNs) are among the most 
vulnerable cell populations in Huntington’s Disease (HD). 
Within this population, striatopallidal MSNs are more 
vulnerable than striatonigral MSNs, which may explain the 
typical progression in HD of chorea to hypokinesis.  The 
biological basis for this differential vulnerability is 
unknown, although differences in transcriptional 
dysfunction caused by mutant huntingtin (mhtt) have been 
proposed as a possible mechanism.  In order to determine 
the differences in gene expression caused by mhtt in these 
two populations, we selectively isolated translated mRNAs 
from striatopallidal and striatonigral MSNs in the R6-2 and 
YAC128 HD mouse models at pre- and post-symptomatic time 
points using the BACTRAP technique (Heiman et al, 2008). 
We re-characterized the behavioral phenotype of the HD 
model mice on the D1 and D2 TRAP backgrounds and found many 
changes in the translated mRNA profiles of these two 
classes of medium spiny neurons, including known changes in 
the literature as well as novel pathways.  One novel 
pathway was sphingosine-1-phosphate (S1P) signaling.  
Because the S1P-receptor G-protein coupled receptor 6 
(GPR6) is enriched in striatopallidal cells, we 
hypothesized that changes in this pathway might play a role 
in striatopallidal medium spiny neuron vulnerability.  
Using mass spectrometry, we have shown that S1P levels, as 
well as other complex sphingolipid species, are decreased 
in the striatum of R6-2 mice early in disease progression. 
We have preliminary evidence to suggest Sphk2 and Sgpl1, 
the enzymes responsible for the production and degradation 
of S1P, are altered in HD mouse models in patterns that 
might explain the changes in S1P levels. We have shown that 
S1P can have pro-survival effects in an in vitro model of 
striatal origin. Together, these results implicate 
alterations in S1P signaling in the pathogenesis of 
Huntington’s Disease and offer an approach for moving from 
clinical observations of a disease toward the beginning of 
a mechanistic understanding of the underlying causes of 
specific cell vulnerability in other diseases. 
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Introduction 
Most neurological diseases do not affect the brain 
diffusely, killing all cell types indiscriminately, but 
rather attack certain classes of neurons with precision.  
For example, Parkinson’s Disease affects dopamine-producing 
cells of the substantia nigra pars compacta, but not nearby 
dopamine-producing cells of the ventral tegmental area. 
Amyotrophic Lateral Sclerosis kills upper and lower motor 
neurons, but not afferent sensory neurons. The pathology of 
Alzheimer’s Disease, although eventually widespread, begins 
with a stereotyped progression of amyloid plaques in layer 
II of the entorhinal cortex, but the disease never affects 
neurons in the visual cortex. It is this selectivity that 
creates each disease’s unique presentation: the 
pathognomonic akinesia of Parkinson’s Disease is caused by 
the damage to the substantia nigra; the slow onset 
paralysis that is the hallmark of ALS results from the 
gradual destruction of motor neurons. 
 In all of these diseases, selective vulnerability is 
poorly understood.  Investigation of this question has been 
hindered by technological limitations. The cellular 
heterogeneity of brain tissue, which underlies the richness 
of the brain’s many functions, makes it difficult to detect 
changes in a single cell type among networks of vast 
complexity.  But the potential rewards of answering this 
question are great: if we can understand why some cells 
succumb while others do not, we may learn a great deal 
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about how to protect vulnerable neurons and thereby treat 
disease.    
 
The Polyglutamine Diseases 
The conundrum of selective vulnerability is well 
illustrated by a group of diseases collectively known as 
the polyglutamine diseases. Unlike the examples mentioned 
above, which are all complex, polygenic diseases, the 
polyglutamine disorders are monogenic neurological diseases 
of known genetic cause.  There are nine known polyglutamine 
diseases: Huntington’s Disease (HD), 
dentatorubralpallidoluysian atrophy (DRPLA), spinal and 
bulbar muscular atrophy (SBMA), and the spinocerebellar 
ataxias (SCAs) 1, 2, 3, 6, 7, and 17 (for review, see 
(Bates, Harper et al. 2002); (Gatchel and Zoghbi 2005)). 
The nine polyglutamine diseases are caused by a germline 
expansion of CAG repeats in different genes, and they all 
follow a typical course of mid-life onset followed by 
unrelenting, progressive deterioration.  These diseases 
have a heterogeneous clinical presentation, with some 
distinct, and some overlapping, features, but they are best 
distinguished through genetic means.   
Despite a shared genetic lesion and overlapping 
clinical manifestations, five polyglutamine diseases can be 
distinguished by distinct patterns of cell death (see 
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Figure 1). For most of these diseases, with the exception 
of SBMA, the CAG expansion leads to the expression of extra 
glutamines in a protein, conferring a toxic gain-of-
function that leads to cell death. Studies from model 
organisms demonstrate that these polyglutamine-expanded 
proteins can be toxic even in non-neuronal cells: when 
expressed in yeast, human mutant huntingtin (mhtt) forms 
aggregates and causes cellular toxicity (Muchowski, 
Schaffar et al. 2000; Meriin, Zhang et al. 2002). These two 
observations present a paradox, namely: how can 
ubiquitously expressed proteins, which can be toxic even in 
yeast, create differential patterns of cell death in the 
human central nervous system? 
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Figure 1: Selective vulnerability in polyglutamine 
diseases.  Despite a shared genetic lesion, polyglutamine 
disorders have distinct patterns of vulnerability. Figure 
originally from (Bates, Harper et al. 2002). Shaded areas 
represent regions where the most cell death occurs in each 
disease.
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Huntington’s Disease 
Huntington’s Disease (HD) is the most prevalent of the 
polyglutamine disorders. Like the others, it is a 
progressive genetic neurodegenerative disorder.  The 
disease typically presents during middle age with cognitive 
changes and the development of dance-like uncontrolled 
movements, termed “Huntington’s chorea.” These symptoms 
worsen over a period of ten to fifteen years and eventually 
progress to hypokinesis and rigidity. Patients slowly and 
inevitably succumb to complications from this loss of 
movement, frequently dying from causes such as aspiration 
pneumonia or starvation due to dysphagia (for review, see 
(Bates, Harper et al. 2002)).  
 Pathological studies of brains from HD patients reveal 
a selective degeneration of the striatum with a resultant 
widening of the lateral ventricles. Cell loss in the 
striatum progresses dorsolaterally to ventromedially, 
usually preserving the nucleus accumbens (Vonsattel 1985).   
While the greatest cell loss occurs earliest in the 
striatum, neuronal death has also been observed in several 
other brain regions, most notably the cortex, particularly 
in pyramidal projection neurons of layers III, V, and VI 
(Rosas, Liu et al. 2002; Rosas 2008). 
 Histologically, the striatum is composed of an almost-
uniform population of projection neurons called “medium-
spiny neurons” (MSNs), named for their characteristic 
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dendritic spine morphology. Two distinct but closely 
related subpopulations of neurons can be found within the 
MSNs that express different neurochemical markers, project 
to different brain regions, and have different functions 
(see Figure 2).  The striatonigral cells express dopamine-1 
receptors (D1Rs), which are coupled to Gαs, and project to 
the output nuclei of the basal ganglia—the internal segment 
of the globus pallidus in humans or the endopeduncular 
nucleus and substantia nigra pars reticulata in mice, which 
in turn project to the thalamus and then the cortex.  
Activation of striatonigral cells leads to a loss of 
inhibition of the thalamus, and the initiation of cortical 
movement pattern generators. In contrast, the 
striatopallidal cells express dopamine-2 receptors (D2Rs), 
which are coupled to Gi subunits, and first project to the 
globus pallidus externa, which inhibits movement by 
enhancing thalamic inhibition.  MSNs are defined by several 
other neurochemical markers, including opioid peptides 
substance P (striatonigral) and enkephalin 
(striatopallidal).  Besides these few differences, however, 
striatonigral and striatopallidal MSNs have similar 
origins, innervation, morphologies, and, to a large degree, 
gene expression profiles (Steiner H 1998) for review). 
Despite the many similarities of striatonigral and 
striatopallidal cells, human pathological studies have 
suggested that D2-expressing striatopallidal MSNs die first 
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in Huntington’s disease (see Figure 3 and, (Reiner A 
1988);(Albin, Reiner et al. 1992) ; (Sapp, Ge et al. 1995).  
One small-scale recent study showed increased firing in GPe 
and decreased firing in GPi in an HD patient undergoing 
deep-brain stimulation, which is consistent with a 
selective loss of striatopallidal neurons (Starr, Kang et 
al. 2008). This observation fits with the clinical picture 
of HD, in which uncontrolled movements, caused by the 
dysfunction of indirect pathway cells, is followed by 
hypokinesis after loss of the direct pathway neurons. 
Understanding the molecular basis for this selective 
vulnerability could offer tremendous therapeutic potential, 
by both enhancing our knowledge of HD pathophysiology and 
also providing potential drug targets. 
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Figure 2: Mouse Basal Ganglia Circuitry.  Glutamatergic 
input from the cortex to the striatum is processed by MSNs 
of the striatum (inset) through two parallel pathways, with 
opposing function and distinct, though related, gene 
expression signatures. Striatonigral (blue) MSNs project 
directly to the output nuclei of the basal ganglia, whereas 
striatopallidal MSNs (red), project first to the globus 
pallidum and subthalamic nucleus before projecting to the 
output nuclei. These two MSN populations are anatomically 
intermixed and morphologically indistinguishable, but it is 
the striatopallidal MSNs that are most vulnerable in HD. 
Adapted from Gerfen, 1992  
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Figure 3: Striatopallidal fibers are selectively vulnerable 
in human HD post-mortem tissue. Immunohistochemistry for 
substance P (striatonigral marker) and enkephalin 
(striatopallidal marker) in human post-mortem tissue at 
worsening stages of HD.  In early stage HD, striatopallidal 
fibers degenerate, while striatonigral fibers remain 
intact. In late stage HD, both striatonigral and 
striatopallidal fibers degenerate. Figure adapted from 
(Reiner, Albin et al. 1988).  
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HD mouse models 
 Human HD studies have yielded tremendous insight into 
the pathophysiology of the disease.  A large-scale 
collaborative effort twenty years ago in Venezuela, led by 
the Huntington’s Disease Collaborative Research Group, 
resulted in the identification of the CAG repeat expansion 
in the htt gene as the causative genetic factor in the 
disease (Gusella, Wexler et al. 1983; Group 1993).  Post-
mortem pathological studies have provided a wealth of 
information that has given rise to the current 
understanding of selective vulnerability.  To further 
dissect the cellular pathways underlying disease, however, 
it is necessary to turn to model systems.  HD research in 
simple model organisms has resulted in many insights into 
the direct toxicities of mutant huntingtin and provides 
good model systems for pharmacological screens. 
(Willingham, Outeiro et al. 2003), (Voisine, Varma et al. 
2007). Work in simple model organisms cannot address the 
question of selective vulnerability, however, because these 
organisms do not share the neuronal circuitry of the 
striatum found in mammals. For this reason, many groups 
have turned to mouse models, which do offer the opportunity 
to study the effects of mhtt in the conserved circuitry of 
the basal ganglia. 
A variety of HD mouse models have been developed, each 
model recapitulating different aspects of the disease.  The 
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models differ by the strategy of their construction (knock-
in vs. transgenic) the portion of htt gene expressed (full-
length vs. truncation), their expression of human htt 
versus mouse htt, and the number of CAG repeats included 
(from about 90-250).  These strategies produce mice with 
varying phenotypic severity. This study will focus on two 
of the most commonly used models, the R6-2 and the YAC128 
mice, which correspond to a more severe and a milder 
phenotype, respectively (see Figure 4 for schematic and 
Table 1 for phenotype summary).   
 The R6-2 transgene, as originally published, was 
created in the laboratory of Dr. Gillian Bates, and is 
composed of ~1 kb of the 5’ UTR of the human htt gene, htt 
exon 1, 150 CAG repeats, and the first 262 bp of intron 1 
(Mangiarini, Sathasivam et al. 1996). R6-2 mice appear 
normal at the time of weaning, but quickly develop a 
behavioral phenotype that includes gait disturbances, 
resting tremor, and hind-limb clasping. On gross pathology, 
the mice demonstrate decreased brain size; 
histopathologically, the mice develop both cytoplasmic and 
nuclear huntingtin aggregates in neurons (Mangiarini et al. 
1997). Surprisingly, typical markers of apoptotic cell 
death are not observed in these animals, although a 
histologically novel neurodegenerative cellular phenotype 
has been observed in the anterior cingulate cortex, the 
dorsal striatum, and in Purkinje neurons of the cerebellum 
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(Turmaine et al. 2000). The advantages of the R6-2 mouse 
include its rapid phenotypic development, its wide use, and 
its thorough characterization.  
The YAC128 model was constructed in Dr. Michael 
Hayden’s laboratory by inserting 128 CAG repeats through 
homologous recombination into a yeast artificial chromosome 
that expressed human htt with full regulatory sequences.  
The mice express mutant human htt in a similar tissue 
distribution pattern and at similar levels to that observed 
for mouse htt.  Disease progression in this model is much 
slower than in the R6-2 model.  At 3 months of age, the 
mice display slight hyperactivity in an open field and 
gradually develop a hypokinesis at 6 months that worsens at 
9 and 12 months (Slow et al., 2003); (Van Raamsdonk, 
Pearson et al. 2005). On the rotarod, the mice demonstrate 
a motor learning phenotype at 2 months, without any gross 
motor deficits.  A true motor deficit on the rotarod 
emerges at 6 months of age, and worsens with time. The mice 
have a normal life expectancy, unlike human patients with 
HD. In pathological studies, the mice develop a specific 
cell loss in the striatum, losing 15% of striatal volume by 
12 months of age.  The mice also develop nuclear aggregates 
of huntingtin, mostly in the striatum and cortex by 2 
months of age (Van Raamsdonk, Pearson et al. 2005).  
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Figure 4: HD transgenic mouse models contain varying 
portions of htt and different numbers of CAG repeats. 
The R6-2 mouse was created by transgenic expression of a 
construct that included 1kb of the 5’UTR, exon 1 of human 
htt, and 150 CAG repeats. The YAC128 model includes the 
entire human htt gene, including introns and regulatory 
elements.  	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Table 1: Summary of Mouse Model Phenotypes 
Feature of 
human HD 
R6-2 B6/CBA 
background 
YAC128 FVB/N 
Motor 
Dysfunction 
Tremor – 6 weeks 
 
Possible 
hyperactivity– 6-12 
weeks 
 
Worsening rotarod 
deficits beginning 
at 6 weeks  
 
No tremor 
 
Hyperactivity at 3 
months 
 
Worsening rotarod 
deficits beginning 
at 6 months, severe 
by 1 year 
Hypokinesis By 12 weeks By 1 year 
Dystonias Hind-limb clasping 
– 6 weeks 
Not reported 
Neuronal 
degeneration 
“Dark body” 
degeneration 
primarily in 
anterior cingulate 
(Turmaine, 2000) 
Cell loss in striatum 
found by 
neurostereological 
approaches 
Life span 10-13 weeks 
 
Normal 
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Endogenous function of htt 
 While most proposed mechanisms of neurodegeneration in 
HD assume that the initial insult results from a toxic 
gain-of-function mutation in mhtt, several groups propose a 
contributory loss-of-function pathway as well, through a 
dominant-negative effect. A thorough understanding of the 
physiological role of htt remains elusive because 
constitutive knockout of the mouse huntingtin disease gene 
homologue (hdh) leads to an early embryological death.  In 
mouse embryos lacking Hdh, extra-embryonic tissues fail to 
develop properly, leading to an early developmental arrest 
of the embryo (Dragatsis et al., 1998). Conditional 
knockout of hdh in post-mitotic neurons using the Cre/lox 
system causes an adult-onset neurodegeneration, implicating 
a functional role for Hdh in maintenance of cell survival 
(Dragatsis et al., 2000).  
 Htt is a very large protein, nearly 350 kDA, with 
several HEAT repeat domains. One theory is that the protein 
serves as a molecular scaffold that allows the binding of 
many proteins in a complex (Seong et al., 2009) A great 
number of endogenous functions for htt have been proposed, 
but the best-described functions concern transcriptional 
regulation and vesicular transport.  As mentioned above, 
htt binds to many transcription factors, and it may bind 
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DNA itself.  Seong et al. have also shown that Hdh binds to 
Polycomb Repressor Complex 2 (PRC2), a histone 
methyltransferase responsible for regulating developmental 
gene networks.  Knockout of Hdh closely mimics loss of 
function of PRC2, further suggesting a complementary role 
for the two genes— but a true genetic rescue experiment 
between the two genes has not been described. 
 The evidence implicating htt in vesicular transport is 
fairly robust. In isolated rat sciatic nerves, htt is 
transported in both anterograde and retrograde directions 
(Block-Galarza et al., 1997).   Htt binds dynein and 
facilitates microtubule transport in vitro (Caviston et 
al., 2007). Mutant htt impairs fast axonal transport in 
isolated squid axoplasm (Trushina et al., 2004; Morfini et 
al., 2009).  Yeast-two hybrid screens have shown myriad 
binding partners of htt in vesicular transport, including 
HAP1, which is involved in clathrin-mediated endocytosis of 
BDNF (Gauthier et al., 2004). 
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Existing Hypotheses 
Investigation of HD mouse models, combined with data 
from human post mortem studies, has led to several 
hypotheses in the field to explain the differential 
vulnerability of MSNs in HD (for review, see (Han, You et 
al.2010).   
Neurochemical Specificity 
A longstanding hypothesis in the field, which predates 
the identification of the CAG expansion in huntingtin as 
the causative mutation in HD, is that neurochemical 
differences in MSNs underlie their selective 
vulnerablility.  The striatum receives two major sources of 
neurochemical input: glutamate from the cortex and 
thalamus, and dopamine from the substantia nigra pars 
compacta.  Both of these neurotransmitters have been 
considered as a possible precipitant of toxicity: excess 
glutamate can cause cell death through “excitotoxicity,” a 
term coined by John Olney in 1969 to explain a phenomenon 
in which over-stimulation of neurons, usually via glutamate 
receptors, can lead to altered calcium homeostasis, 
mitochondrial dysfunction, and activation of apoptotic 
cascades.  Early pharmacological models of HD, such as the 
stereotactic injection of glutamate receptor agonists 
kainic or quinolinic acid into the striatum, created 
lesions that resembled those of HD (Coyle and Schwarcz 
1976).  However, there have been few convincing arguments 
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linking these pharmacological models to the genetic cause 
of the disease. In genetic HD models, there have been 
reports of electrophysiological changes at the 
glutamatergic-corticostriatal synapse in genetic HD mouse 
models (Cepeda, Hurst et al. 2003). Transcriptional changes 
of the levels of NMDA receptor subunits have also been 
reported; however, there has been no mechanism shown to 
explain why striatal glutamate transmission would be 
altered over other strongly glutamatergic non-vulnerable 
regions, like the hippocampus or olfactory bulb (Han, You 
et al. 2010).  
The arguments in favor of alterations in dopamine 
signaling causing pathology in HD also have a long history 
in the field.  After Arvid Carlsson published his studies 
on the use of L-dopa to treat Parkinson’s Disease in the 
1960s, it was hypothesized that HD could be the “mirror 
image” of PD, where an excess of dopamine was responsible 
for uncontrolled movements. Pathological studies, however, 
revealed no differences in the amount of tyrosine 
hydroxylase, the enzyme that produces dopamine, in the 
substantia nigra (McGeer and McGeer 1976).  On the other 
hand, tetrabenazine, recently approved by the FDA for the 
symptomatic treatment of HD chorea, acts by inhibiting 
vesicular monoamine transporter 2, which actively 
transports dopamine into synaptic vesicles. 
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Symptomatically, dopamine depletion seems to have benefit 
for the chorea of some HD patients. 
While the pre-synaptic production of dopamine does not 
seem to change in HD, there is ample evidence for 
alterations in dopamine signaling post-synaptically.  As 
mentioned previously, the expression of dopamine receptors 
changes dramatically early in the disease, in the pattern 
explained above, in which loss of Drd2 receptors precede 
Drd1a receptor changes. Other critical components of 
dopamine signaling are changed early in HD mouse models, 
including loss of DARRP-32 (Bibb, Yan et al. 2000).  
Further studies into the significance of changes in 
dopamine signaling in HD are warranted. 
Aggregation of mhtt 
 Several years after the publication of the R6-2 mouse, 
Gillian Bates’s group discovered that immunohistochemical 
staining of the R6-2 mouse brain revealed the presence of 
aggregate structures in the neuropil, cell bodies, and 
nuclei of neurons, but not glia (Davies, Turmaine et al. 
1997).  Subsequent work showed that these aggregates were 
also present in post mortem tissue from human HD patients 
(Davies, Turmaine et al.; DiFiglia, Sapp et al. 1997; 
Gutekunst, Li et al. 1999). While initial studies suggested 
that the appearance of aggregates correlated with 
vulnerability to disease, subsequent careful analysis 
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suggested that the two processes are not so easily linked. 
Aggregates appear early in the disease course of HD, but 
their appearance does not correlate strongly with 
pathology; for example, in human tissue, the great 
preponderance of aggregates are found in the cortex, not 
the striatum. Furthermore, in a mouse model of HD in which 
mhtt is expressed only in MSNs, striatal aggregates occur 
in the absence of motor symptoms or other pathology (Gray, 
Shirasaki et al. 2008). These results have lead some to 
argue that the presence of aggregates may actually protect 
cells from a more toxic fibrillar form of mhtt. 
Somatic CAG repeat instability 
One intriguing hypothesis to explain selective 
vulnerability relates to the instability of CAG repeats. 
Since 1988, when Ridley and coworkers analyzed the U.S. 
National Huntington’s Disease Roster, HD has been known to 
display anticipation, a phenomenon whereby the age of onset 
decreases in successive generations (Ridley, Frith et al. 
1988). For HD, anticipation only occurs through paternal 
inheritance. The molecular underpinning of anticipation is 
an expansion in the number of CAG repeats in huntingtin. 
The mechanism by which the CAG expansion occurs in the male 
germline is still not understood, but may involve DNA 
repair pathways (Dragileva, Hendricks et al. 2009).  Recent 
work has shown that the number of CAG repeats in HD 
patients is unstable somatically, and more suggestively, 
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the CAG repeats are longest in vulnerable brain regions 
(Shelbourne, Keller-McGandy et al. 2007); (Swami, Hendricks 
et al. 2009). These observations lead to the hypothesis 
that the most vulnerable neurons are those that have the 
longest somatic expansion of CAG repeats. Work in HD mouse 
models seemed to support this hypothesis, as crossing the 
HD knock-in mouse to a constitutive knockout of the gene 
Msh2 abrogated somatic CAG expansion and delayed symptom 
onset (Wheeler, Lebel et al. 2003). This experiment showed 
that Msh2 is necessary for somatic CAG expansion to occur, 
and suggested that this loss of somatic CAG expansion could 
interfere with the disease process. This model suffered a 
strong setback, however, when Gray et al.  showed that mice 
containing a Bacterial Artificial Chromosome (BAC) with 
alternating CAA-CAG repeats, which are stable in somatic 
tissues, still develop selective striatal and cortical 
pathology (Gray, Shirasaki et al. 2008). 
Axonal Transport 
Another hypothesis, advocated by Han et al. in their 
review of the huntingtin literature, is mhtt’s interference 
of axonal transport. All of the most vulnerable cells in HD 
are projection neurons, or neurons that send axons to brain 
regions that are relatively far away.  The interneurons of 
the striatum and cortex are unaffected. Additionally, the 
cell death that occurs in HD seems to occur via a “dying 
back” process, in which there is a loss of axon fibers and 
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synaptic proteins before outright cell body loss. 
Furthermore, mhtt has been shown to interfere with axonal 
transport in preparations of isolated squid axoplasm, 
suggesting that deficits in transport are independent of 
effects in the cell body, including transcription (Morfini 
et al., 2009).  The proposed pathway through which mhtt 
exerts these effects is through alteration of 
phosphorylation of microtubule motor proteins, acting 
through the JNK pathways.   
While these initial findings are intriguing, they do 
not explain why other projection neurons, which also 
express mhtt, are not as vulnerable in HD. Indeed, neurons 
of the corticospinal tract, which extend from the cortex to 
the very base of the spinal column and are vulnerable in 
ALS, are not vulnerable in HD.  If deficits in axonal 
transport are responsible for the selective vulnerability 
of MSNs, then they must first reside in differences 
upstream of transport itself, most likely in differences of 
gene expression between different projection neuron 
populations. 
Transcriptional Dysfunction 
 The literature implicating transcriptional dysfunction 
in HD is extensive (for review, see Cha 2007).  Early 
pathological studies of post mortem human tissue from HD 
patients demonstrated decreased expression of many genes in 
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Grade 0 and Grade 1 HD cases measure by in situ 
hybridization, before overt cell loss is observed (Albin et 
al. 1991). These genes included markers of striatopallidal 
MSN identity, such as Drd2 and enkephalin (Reiner et al., 
1998), as well as glutamate receptors (Arzberger et al., 
1997), and cannabinoid receptors (Glass et al., 1993).  
Although the decreased expression of these genes was 
thought to precede cell loss, definitive proof that this 
loss of expression was due to transcriptional changes 
instead of cell loss was difficult to obtain in human 
pathological studies. However, many of these same gene 
expression changes also occur in mouse models of HD, and in 
the mice, gene expression changes are not confounded by 
cell death, because in all mouse models of HD, very little 
or no actual cell loss occurs (Cha et al., 1998, 1999).   
Despite the lack of overt cell death in HD mouse 
models, transcriptional changes abound. Transcriptional 
changes in HD mouse models were first measured at the 
single gene level, and then with genome-wide approaches, 
once microarray technology became available (Cha et al., 
1998, Luthi-Carter, 2000; Strand et al., 2007; Brochier et 
al., 2008).  In a microarray study of whole mouse striatum 
of R6-2 mice, Luthi-Carter et al. found that 1.7% of all 
genes were changed by 12 weeks of age. The genes fell into 
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many functional categories possibly related to 
neurodegeneration including neurotransmitter receptors and 
genes involved in signal transduction, calcium homeostasis, 
and regulation of nuclear hormones (Luthi-Carter et al., 
2000). Interestingly, the vast majority of gene changes 
were loss-of-expression: very few genes were found to be 
upregulated.  
Several mechanisms have been proposed to explain 
mhtt’s effects on transcription.  One theory is that the 
polyglutamine-rich region that causes mhtt to aggregate 
inappropriately binds and sequesters other proteins, 
including transcription factors, which thereby changes gene 
expression. Mutant huntingtin has been shown to 
preferentially bind CBP, Sp1, p53, and NCoR (Kazantsev et 
al., 1999; McCampbell et al., 1999; Stefan et al., 2000; 
Dunah et al., 2002; Boutell et al., 1999).  Differences in 
transcription factor expression or aggregate formation in 
vulnerable and non-vulnerable cell-types could then explain 
differences in cell vulnerability. There has not yet been a 
systematic meta-analysis of all gene-expression studies in 
the HD literature to search for conserved patterns of 
promoter elements common to the most highly affected genes 
– such an unbiased approach might reveal novel pathways for 
transcriptional dysregulation in HD. 
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Htt’s proposed regulation of BDNF transcription 
represents a slight variation on these ideas. Instead of 
proposing that mhtt inappropriately sequesters 
transcription factors in the cytosol, Zuccato et al., 
proposed that one of wild-type htt’s roles is to sequester 
a powerful transcriptional repressor outside of the 
nucleus. They have shown that wt htt binds to 
transcriptional repressor element-1 transcription 
factor/neuron restrictive silencer factor (REST/NRSF) in an 
in vitro system and that mhtt fails to perform this 
function adequately. The failure to sequester REST was then 
shown to decrease the expression of BDNF.  Thus, the theory 
postulates a dominant-negative effect of mhtt on wt htt 
function.  
  Benn et al. have proposed a third mechanism through 
which mhtt could alter transcription: by binding directly 
to DNA itself (Benn et al., 2008).  Using chromatin immuno-
precipitation in several in vitro systems, Benn et al. show 
that htt and mhtt bind differentially to promoters. Using a 
micrococcal nuclease assay in the STHdh cell-line, Benn et 
al. show that mhtt opens DNA conformation in the cells, 
making it more accessible to cleavage by the nuclease, and, 
perhaps, by extension, explaining observed changes in 
transcription.	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All cell types share the same DNA, so their 
differences reside in how they express genes.  Neurons 
acquire their identity through the expression of a series 
of transcription factors, and they differentiate further 
into neuronal subtypes through the actions of a series of 
more specialized signals.  While these processes are 
incompletely understood, it is now possible to 
differentiate stem cells into dopaminergic neurons (Studer 
2001).	  
 In HD, medium spiny neurons seem to lose markers that 
define their identity before they die. As mentioned 
previously, markers for striatopallidal MSNs, Drd2 and 
preproenkaphlin, disappear in early disease stages, well 
before disappearance of striatonigral markers Drd1a and 
substance P.  These losses of markers are recapitulated in 
HD mouse models, in the absence of overt cell death. Mhtt 
aggregates in the nucleus of neurons, can bind directly to 
DNA, and has been shown to alter gene expression very early 
in the disease process (Benn, Sun et al. 2008); (Cha 2007). 
These observations have lead to the hypothesis that gene 
expression changes are responsible for the selective cell 
death in HD. 
Many groups have attempted to characterize HD gene 
expression changes in both human post-mortem tissue and in 
HD mouse models without separating cellular populations.  
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Hodges and coworkers performed a large-scale microarray 
study with 44 post-mortem HD brains and 36 age-and sex-
matched controls (Hodges, Strand et al. 2006). While this 
exhaustive study confirmed that the greatest gene 
expression changes corresponded to regions with the 
greatest pathology (caudate and cortex), the insights into 
the pathophysiology of HD from this work have been limited.  
Studies using human tissue have many obstacles: samples are 
often from advanced disease, so it is difficult to know 
whether changes are secondary or initial insults; there are 
rarely perfectly-matched controls available; differences in 
post-mortem handling of tissue can lead to the appearance 
of artifacts in the data; and there is a great degree of 
variability between samples.  
Microarray studies of whole striatum from HD 
transgenic mouse models have been somewhat consistent with 
human data, but have also yielded disappointingly few 
therapeutic leads (Luthi-Carter, Strand et al. 2000);(Chan, 
Luthi-Carter et al. 2002) ; (Ferrante, Kubilus et al. 
2003); (Benn, Landles et al. 2005), (Kuhn, Goldstein et al. 
2007), see (Cha 2007)for review.  Some of these studies 
have found decreases in known striatopallidal markers Drd2 
and enkephalin (Luthi-Carter, Strand et al. 2000); 
(Menalled, Zanjani et al. 2000), while others have shown 
primary decreases in striatonigral markers, like Drd1a (Cha 
2000). The time of harvesting these mRNAs was often quite 
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late in the disease process, however, making it difficult 
to isolate any initial insults. Pathways found to be 
altered in HD from these studies include changes in: 
neurotransmission (receptors, second-messengers, 
neurotransmitter synthesis), synaptic structural proteins, 
mitochondrial proteins, calcium homeostasis, proteasomal 
regulation, inflammatory pathways, and many others (Cha 
2007).  In addition to their focus upon late-stage disease, 
these studies have been limited by the cellular 
heterogeneity of the striatum.  Studies in the Greengard 
lab have shown that signaling within striatonigral and 
striatopallidal cells is frequently divergent, and 
sometimes opposite in nature (Bateup, Svenningsson et al. 
2008); (Heiman, Schaefer et al. 2008).  Thus, gene 
expression changes in one population may mask changes in 
the other. In addition to these different striatonigral and 
striatopallidal MSN populations, the striatum is composed 
of interneurons, glia, and many other supporting cells.  
This heterogeneity introduces noise into the data that 
makes it difficult to identify important early changes from 
secondary or tertiary effects. 
The BACTRAP technology 
Until recently, there have been few ways of separating 
mRNAs from distinct cellular populations to reduce noise 
from heterogeneity. Existing methods are not perfect, and 
FACS sorting can suffer from long periods of tissue 
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disruption, during which loss of intrinsic signals can lead 
to major changes in gene expression and a loss of 
sensitivity.  
A new technology developed in the Heintz and Greengard 
laboratories takes a complementary approach by using a 
genetic approach to mRNA isolation.  The “BACTRAP” 
technology utilizes a GFP-tagged ribosomal protein to co-
immunoprecipitate mRNAs incorporated into polysomes (see 
Figure 5).  This GFP-tagged ribosomal protein can be 
genetically driven in a cell population of interest – in 
striatopallidal cells, for example – by inserting the GFP-
tagged ribosomal protein within a large swath of DNA 
regulatory sequences for the gene of interest in a 
bacterial artificial chromosome (BAC).  (Gong, Zheng et al. 
2003).  These modified BACs can then be inserted into the 
mouse genome, and expression of the transgene of interest 
is controlled by endogenous regulatory elements, 
independent of the point of insertion. Because the tagged 
ribosomal protein is expressed only in striatonigral or 
striatopallidal neurons, mRNAs can be selectively isolated 
from one population.  These mRNAs can then be analyzed to 
monitor changes in gene translation.  The BACTRAP technique 
(abbreviated as “TRAP”) thus provides a snapshot of all the 
messages being translated in a given cell population at one 
time.   
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In this study, we have used the TRAP technique to 
investigate differences between striatopallidal and 
striatonigral medium spiny neurons in HD mouse models.  We 
have found that these two closely related neuronal 
populations, with varying susceptibility to the toxic 
insult of mutant huntingtin, have different gene expression 
responses to this perturbation. Correlating gene expression 
changes to behavioral phenotypes, we have observed that 
increasing phenotypic severity of the mouse models is 
mirrored by increasing numbers of changes in translational 
profiles. Choosing from the changes we have observed in 
these cell types, we have followed those in sphingosine-1-
phosphate (S1P) signaling.  We have seen that S1P levels 
are decreased in HD mouse models, and we have shown that 
S1P can exert pro-survival effects on striatal-derived cell 
lines. Changes in S1P signaling may therefore affect 
disease progression in HD. The following chapters detail 
the results that have led to these conclusions. 
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Figure 5: BACTRAP technology allows isolation of translated 
mRNAs from genetically defined cell populations. Striatal 
tissue is dissected from brain tissue, immediately 
homogenized, and mRNAs are co-immunoprecipitated with 
tagged ribosomal proteins. mRNAs are extracted and analyzed 
by Affymetrix GeneChip microarrays. 
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Results 
 
Section 1: Behavioral and Phenotypic Characterization of 
HD/TRAP Models 
Background 
We wanted to correlate gene expression changes to 
behavioral deficits, because we reasoned that changes in 
translational profiles immediately preceding behavioral 
symptom onset would be most relevant to disease pathology. 
Mouse behavior assays are highly sensitive to experimental 
variation, including, in our case, mouse strain, CAG repeat 
number, and possible unknown variables. Indeed, striking 
variability has even been seen when mouse behavior assays 
were performed at the same time in three different 
geographic testing locations, despite controlling for 
numerous environmental parameters (Crabbe, Wahlsten et al. 
1999). For these reasons, and because our strains contained 
the D1 and D2 TRAP transgenes, it was critical to re-
characterize the behavior of the established HD models 
under our testing regime and after having crossed them to 
the D1 and D2 TRAP lines, to ensure that we could select 
behaviorally relevant time-points for harvesting mRNAs.   
Mouse strain and behavior 
The behavior of the R6-2 mouse has been extensively 
characterized, which made it an attractive model for study 
(Mangiarini, Sathasivam et al. 1996; Menalled, El-Khodor et 
al. 2009).  The R6-2 line was originally derived with 144 
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CAG repeats and maintained on a hybrid F1 C57BL/6 x CBA 
background in order to maximize litter size (Mangiarini, 
Sathasivam et al. 1996). On this background, the R6-2 mice 
exhibit resting tremor, weight loss, diabetes, and 
spontaneous epileptic seizures. They develop progressively 
worsening motor impairments early in life, measurable on 
the rotarod as early as 4 weeks of age and a hypokinesis in 
the open field beginning at 6 weeks of age (Menalled, El-
Khodor et al. 2009).  
The D1 and D2 TRAP lines are maintained on a C57Bl/6J 
inbred background.  To avoid confounds in the data due to 
strain differences between animals, a version of the R6-2 
model congenic on the line C57Bl6/J was obtained from Dr. 
Gillian Bates and from Dr. David Howland of the HighQ 
Foundation.  These mice originally had 240 CAG repeats and 
were reported to have a later age of onset than the 
published line (G. Bates, personal communication).  Over 
the course of the experiments presented here, Menalled et 
al. published a thorough behavioral characterization of the 
R6-2 line on the C57Bl/6 background. Consistent with the 
observation that the C57Bl/6 background delays phenotype 
onset, they found a progressively worsening phenotype on 
the rotarod beginning at 8 weeks of age and a worsening 
hypoactive locomotor behavior at 6 weeks in females and 8 
weeks in males (Menalled, El-Khodor et al. 2009).  R6-2 
C57BL/6 mice also showed reduced grip strength, reduced 
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body weight, abnormalities in gait analysis, as well as 
deficits in pre-pulse inhibition and light-dark choice. 
The phenotype of the YAC128 mice has also been 
characterized, and its phenotype is also strain-dependent. 
The YAC128 model was created on an FVB/N background, and 
was shown to exhibit a rotarod deficit beginning at 6 
months of age that was constant with respect to wild-type 
performance over time. In the open field, YAC128 mice were 
hyperkinetic at 3 months of age, but then gradually 
exhibited an increasing hypokinetic phenotype that became 
statistically significant at 12 months of age (Slow, van 
Raamsdonk et al. 2003).   However, in an extensive study 
characterizing YAC128 mice on three different inbred strain 
backgrounds (FVB/N, C57BL/6, and 129), van Raamsdonk and 
co-workers show significant differences in the extent and 
timing of these phenotypes, with the most severe phenotypes 
observed on an FVB/N background, and the mildest phenotype 
on the C57Bl/6 background (Van Raamsdonk, Metzler et al. 
2007). Menalled et al. attempted to reproduce these results 
in both the FVB/N and C57Bl/6J backgrounds: their results 
confirmed the rotarod results from the Slow   study, but 
they found no statistically significant locomotor changes 
in the open field. 
  As the D1 and D2 TRAP mice were not available on the 
FVB/N background, we used the Swiss-Webster background 
instead.  Although outbred Swiss-Webster mice and the 
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inbred FVB/N strain are related – the FVB/N line was 
derived from the Swiss-Webster background in the 1970s at 
the NIH (Taketo, Schroeder et al. 1991) – the progeny of 
this cross are no longer inbred.  For all these reasons, we 
paid special attention to establishing baseline behavioral 
testing in our experimental strain background. 
 
 
Behavioral Tests 
In our study, we hoped to identify differences between 
D1 and D2 MSN gene expression that would mirror behavioral 
deficits caused by dysfunction of these two neuronal cell 
types. As mentioned earlier, stimulation of D1 MSNs is 
thought to stimulate locomotion, whereas activation of D2 
MSNs is thought to inhibit movement. Direct evidence in 
support of this model was recently shown in mice by using 
light to selectively activate D1 or D2 MSNs that had been 
engineered to express a channelrhodopsin construct 
(Kravitz, Freeze et al. 2010).  Upon activation of D2 MSNs 
with light, the mice exhibited freezing behaviors and a 
loss of movement reminiscent of Parkinsonism. In contrast, 
activating D1 MSNs lead to increased locomotion and fewer 
instances of freezing. 
Several assays are widely used to characterize motor 
behaviors that reflect striatal function (for review, see 
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(Crawley 2000). The rotarod is the most commonly used assay 
to monitor changes in motor coordination and balance.  
Essentially a mouse treadmill, the rotarod apparatus 
consists of a motorized plastic cylinder raised to a 
standard height that is then rotated. Mice walk on the 
rotating cylinder until they fall off. The time to fall 
off, or fall latency, is measured.  Rotarods can be driven 
at constant or accelerating speeds; the latter is thought 
to add a component of motor learning to the task.  The 
rotarod task is thought to depend on several circuits: mice 
with cerebellar deficits show impaired rotarod performance 
(Lalonde, Filali et al. 1996), (Schaefer, O'Carroll et al. 
2007), but the task depends on striatal function as well. 
For example, one radio-ligand imaging study found that rats 
exercised consistently on a rotarod showed increased 
metabolic activity in cerebellar-thalamic circuits and 
decreased activity in basal ganglia-thalamic-cortical 
circuits compared to rats exposed only once to the rotarod 
(Holschneider, Yang et al. 2007).  The authors argue that 
during training phases, basal ganglia control is important, 
whereas after training, cerebellar-thalamic loops become 
more prominent in controlling the behavior.  
The rotarod is advantageous as a behavioral test 
because it produces quantifiable results that are 
reproducible, computer-controlled, and easily scaled to 
larger cohorts of animals. Its wide use in the field allows 
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for comparison of results across laboratories, to the 
degree that behavioral results can be compared.  On the 
other hand, it is not a specific readout of striatal 
function, and it cannot differentiate between D1 and D2 MSN 
deficits. 
To complement the data from the rotarod, we therefore 
also chose to test the mice for locomotor deficits in the 
open field. Like the rotarod, open field tests are easily 
automated. Commercially available photocell-equipped boxes 
are often used, which track mice through breaks in infrared 
light beams. Measured parameters include total distance 
traveled over a given time period, number of beam breaks, 
and time spent moving or resting. The open field can also 
illustrate anxiety behaviors by measuring thigmotaxis, or 
the time spend on the edges of the open field versus the 
center. Unlike the rotarod, the open field would be capable 
of detecting a hyperkinetic locomotor phenotype as expected 
in selective D2 MSN dysfunction. We hypothesized that the 
published hyperkinesis in the YAC128 model at 3 months 
reflected a period when D2 MSN tone was lower than D1 MSN 
output, leading to an overall hyperkinesis in the animal’s 
locomotor behavior. 
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R6-2 C57Bl/6J Behavioral results 
R6-2 TRAP lines exhibit profound behavioral phenotypes at 
12 weeks 
For the R6-2 C57Bl/6J line, open field behavior was 
tested as early as three weeks of age, immediately upon 
weaning the mice. Mice were left in the open field for one 
hour, during which total distance and horizontal activity 
were measured in 10-min bins. At 3 weeks of age, there were 
no statistically significant differences among any of the 
groups tested at any point in the hour-long test (Figure 
6).  Motor coordination was initially tested on the rotarod 
at 4 weeks of age, one week after weaning and genotyping, 
using an accelerating protocol from 4 rpm to 40 rpm over 5 
min on five consecutive days, after three initial training 
trials on the first testing day. As with the open field 
test, there were no significant differences in rotarod fall 
latency between double transgenic mice (carrying both the 
R6-2 and D2-TRAP construct) versus single-transgenic 
controls (carrying the D2-TRAP construct alone) at this 
early time point, (N=10 each group) (Figure 7).  
Motor behaviors were again tested later in the disease 
course, at 6, 9 (Dr. Wenjie Luo, personal communication), 
12 and 14 weeks of age.  By the 12 and 14 week timepoints, 
there was a statistically significant hypokinesis in both 
the R6-2 D1 and R6-2 D2 TRAP mice compared to TRAP alone in 
total distance traveled in the open field test (Figure 7). 
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There was also a significant impairment in the R6-2 D2 TRAP 
mice on the rotarod (Figure 8). These deficits were present 
on the first day of testing and persisted throughout the 
week.  The exact age of onset at which behavioral deficits 
are detectable in the R6-2 is about 6-8 weeks of age for 
the open field, and 10-12 weeks for the rotarod. These 
results are consistent with the phenotype published for 
this line by Menalled et al., although our line had a 
slightly later age of onset, and open field deficits could 
be detected prior to rotarod deficits.  For a complete list 
of ages tested and results, see Table 2. 
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Figure 6: R6-2 movement at 3 weeks of age in the open 
field.  At 3 weeks of age, there were no locomotor 
differences found among R6-2, WT, or TRAP mice in any 
groups. Data represents total distance traveled in open 
field in 1 hour (R6-2 group n=49, WT n=46, R6-2 D1 TRAP 
n=19, D1 TRAP n=20, R6-2 D2 TRAP n= 10, D2 TRAP n=23; 1-Way 
ANOVA, p=0.81). 
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Open Field, Total Distance Traveled, R6-2 12 weeks
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Figure 7: R6-2 12 week Open Field Behavior. At 12 weeks of 
age, both R6-2 D1 TRAP and R6-2 D2 TRAP mice exhibit 
hypokinesis with respect to their controls (D1 TRAP n=6, 
R6-2 D1 TRAP n=6, D2 TRAP n= 13, R6-2 D2 TRAP n=11, Two-
tailed Unpaired Student’s T-test p=.006 (D1) and p=.02 
(D2). 
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Rotarod R6-2 D2 TRAP at 4 and 12 weeks
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Figure 8: R6-2 D2 TRAP rotarod behavior: At 4 weeks of age, 
R6-2 D2 TRAP mice perform as well as D2 TRAP littermates on 
the accelerating rotarod task.  At 12 weeks of age, R6-2 
mice have a profound motor deficit (Repeated Measures Two-
Way ANOVA p=.91 and p=.0006, respectively, n=9 per group). 
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Model Age 
Open Field 
Tested? Significance? 
Rotarod 
Tested? Significance? 
R6-2 
2.5 
weeks Yes No No N/A 
R6-2 
3.5 
weeks Yes No Yes No 
R6-2 
4.5 
weeks 
Yes 
  D2 only No Yes No 
R6-2 
6 
weeks Yes D1 only No No N/A 
R6-2 
9 
weeks 
Yes * data 
from Dr. 
Wenjie Luo, 
personal 
communicati
on Yes 
Yes *Dr. 
Luo, 
personal 
communica
tion No 
R6-2 
12 
weeks Yes Yes Yes Yes 
R6-2 
14 
weeks Yes Yes Yes Yes 
Table 2: Behavioral Time-points tested in R6-2 model 
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YAC128 TRAP lines exhibit a variable late-onset behavioral 
phenotype 
On the rotarod, YAC128 D1 and D2 TRAP animals 
exhibited a constant deficit that appeared at 15 weeks of 
age and remained as the mice aged (Figure 9), although this 
difference is only statistically significant in the D1 TRAP 
line; this difference is largely in agreement with the 
results of Slow et al. and Menalled et al.    For the 
YAC128 D1 TRAP mice, latency to fall was significantly less 
than D1 TRAP controls on all days tested (Two-way ANOVA, 
repeated measures, genotype p<.001). In the D2 TRAP line, 
the results were more variable: the effects due to genotype 
were not statistically significant on any day tested, 
although they approach significance on Day 3 (Two-way 
ANOVA, repeated measures, genotype p=0.053). The data shown 
in Figure 9 represents the average score of all mice in a 
cohort at each time point.   
YAC128 mice have been reported to initially exhibit 
hyperkinesis in the open field beginning at 3 months of age 
and then a gradually worsening hypokinesis beginning at 6 
months of age (Slow, van Raamsdonk et al. 2003). To confirm 
this phenotype in the hybrid background, two cohorts of 
YAC128 mice were crossed to D1 and D2 TRAP mice (~n=8 mice 
per group) and were tested approximately every 3 weeks from 
7 weeks of age through 13 months of age.  The behavior in 
these mice in the open field was variable and not 
statistically significant until 13 months of age, when the 
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interaction term between age and genotype reached 
significance (Repeated measures ANOVA, F=3.2; p=.01, Figure 
10).  Although one cohort of YAC D2 TRAP mice exhibited a 
statistically significant hyperkinesis at 12 weeks (data 
not shown), this result was not reproducible across other 
cohorts.   
 
Baseline TRAP phenotype  
Also of note upon analysis of the data, there was a 
highly significant hyperkinesis, nearly two-fold the 
distance traveled during an hour, present in both the D2 
TRAP and YAC D2 TRAP animals in comparison to the D1 TRAP 
lines (Figure 10, Two-Way ANOVA, p<.001). The onset of this 
hyperkinesis began as early as 12 weeks and persisted 
throughout testing. Similar hyperactive phenotypes have 
been communicated to us from investigators using other D2 
BAC lines, and we have seen a similar effect in the D2 BAC 
GFP and D2 BAC CRE lines (Myriam Heiman, personal 
communication; data not shown).  As these lines involve 
independent integration events, the phenotype likely 
results from sequences present on the BAC itself. Seen in 
both strain backgrounds used (BL/6, mixed), and worsens 
with age.  
The hyperkinesis in the D2 TRAP lines is consistent 
with reduced activity of D2 MSNs in these lines. This 
baseline hypo-function, present in both control and HD 
 46 
groups, may have obscured a period of selective 
vulnerability of the D2 MSNs in the HD models by reducing 
the background against which the deficit would have been 
measured.  The presence of the TRAP transgene in both 
control and HD populations limits confounding effects of 
the transgene. 
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Figure 9: YAC128 TRAP rotarod data.  YAC128 mice exhibit 
constant deficit on rotarod from 11 (D1) or 15 (D2) weeks 
of age—this result is significant in D1 TRAP line (D1 TRAP 
n=9, YAC D1 TRAP n=10, Two-way ANOVA, repeated measures, 
genotype p<.001), but just misses significance in D2 TRAP 
(D2 TRAP n=7, YAC D2 TRAP n=10, Two-way ANOVA, repeated 
measures Day 3, genotype p=0.053). Data plotted represent 
average taken from all mice over all trials over all days, 
error bars represent +/- standard deviation over all days.
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Figure 10: YAC128 Open field behavior (selected time 
points). YAC mice do not exhibit a behavioral phenotype in 
the open field until 13 months, when YAC D1 TRAP mice have 
a significant hypokinesis (D1 TRAP n=7, YAC D1 TRAP n=7, D2 
TRAP n=9, YAC D2 TRAP n=8. Repeated measures ANOVA, F=3.2; 
p=.01). Error bars represent mean +/- standard error.
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Gross Pathological studies 
 In order to characterize the gross pathology of R6-2 
mice on the C57Bl/6J background, we sent 12-week-old 
animals (n=7 transgenic, n=5 wild-type littermates) for 
gross and microscopic pathological analysis at the MSKCC 
Laboratory of Comparative Pathology, directed by Dr. Julie 
White. For the analysis, tissue from skeletal muscle, 
heart, lungs, esophagus, kidney, salivary glands, lymph 
nodes, stomach, small and large intestine, pancreas, 
spleen, liver, gallbladder, genitourinary tract, and skin 
were compared at gross and microscopic levels. The 
laboratory found that, like the R6-2 mice on the hybrid 
strain background, the C57Bl/6J mice all had elevated blood 
glucose, indicative of diabetes. The pancreatic islet cells 
were shrunken in the mice, but there was no TUNEL staining 
present. There were no gross abnormalities in the brain, 
and no staining by TUNEL or GFAP.  
 Although there has been an extensive characterization 
of the diabetes phenotype in mouse models of Huntington’s 
Disease (Andreassen, Dedeoglu et al. 2002), there are 
conflicting reports about whether there is actually an 
increased incidence of diabetes in human patients with HD 
(Farrer 1985). 
 A cohort of YAC128 mice was also sent for analysis 
(n=6 transgenic, n=6 wild-type controls) and showed no 
gross pathological phenotypes.   
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 Thus, consistent with previous observations, we found 
that these models display HD-like behavioral deficits 
without the concomitant cell death observed in human 
patients.  While this distinction highlights the limits of 
the mouse model, it also may open the door to dissecting 
the cellular events underlying the specific motor 
dysfunctions of the disease without the confounding effects 
on the tissue that would be produced by cell death. 
 
CAG Repeat Expansion in the R6-2 Line 
Since the year after the R6-2 model was first 
reported, it was known that the CAG repeats in the model 
are unstable, particularly when passed through the male 
germ line (Mangiarini, Sathasivam et al. 1996). The 
molecular basis of this instability is unknown, although in 
somatic cells, CAG expansion may depend on the protein OGG1 
(Kovtun, Liu et al. 2007). It has also been shown that, as 
in humans, changes in CAG repeat length can affect 
phenotype (Morton et al, 2009).   
 To monitor the number of CAG repeats in our mouse 
colony, we attempted several strategies. First, we 
attempted to develop PCR genotyping protocols that 
contained the CAG repeat region. Due to the highly 
repetitive nature of the sequence, this technique requires 
special modifications. We used genotyping primers based on 
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sequences found on The Jackson Laboratory website, and 
attempted to optimize the PCR protocol for G-C rich 
regions: we separately, and in combination, adjusted 
concentrations of MgCl2, dNTPs, added stabilizing agents 
DMSO and/or BSA, adjusted annealing temperatures, and used 
a polymerase specialized for amplifying GC rich regions.  
We also applied the “Slowdown PCR” technique published in 
(Frey, Bachmann et al. 2008), which was specially designed 
for amplification of GC-rich and repetitive sequences.  
Thus, there may be additional barriers to PCR amplification 
of the CAG repeats than their GC-rich nature.  
We were unable to obtain reproducible genotyping of 
CAG repeat number with any of these approaches, and 
therefore decided to outsource the CAG repeat sizing to the 
Laragen Corporation. Laragen has optimized a protocol for 
CAG repeat sequencing using fluorescently-labeled PCR 
products and an Applied Biosystems GeneMapper 
electrophoresis system.  We sent them tail clippings from 
mice that had been born over the course of two years in the 
colony.  During this time, the R6-2 mice in the colony 
began living longer, from an average of 6 months to as much 
as a year. It is known that, paradoxically, very long 
stretches of CAG repeats can ameliorate the phenotype in 
the R6-2 mice (Dragatsis, Goldowitz et al. 2009); (Morton, 
Glynn et al. 2009). In accordance with this observation, 
the results show that the number of CAG repeats had 
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expanded linearly over the course of the life of the colony 
by over 100 CAG repeats (Figure 11). This phenomenon is 
specific to the R6-2 line, as the CAG repeat number 
remained constant at 128 repeats in all YAC128 mice tested 
(n=20, data not shown).  
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Figure 11: CAG repeat sizing in R6-2 colony. Tail clips 
from R6-2 mice born at different points in the colony were 
sent to Laragen Inc. for CAG repeat sizing.  Repeats have 
expanded by nearly 100 repeats since colony originated. 
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YAC128 Aggression 
 Over the course of the longitudinal behavioral studies 
in the YAC128 lines, we observed an increased incidence of 
littermate fighting in the males in the D2 TRAP line. 
Severe fights occurred in nearly half of the cages of males 
being aged for the study. Thus, we decided to separate and 
single-house all males. Because social isolation can have a 
profound affect on behavior (Crawley 2000), we placed an 
ovarectomized female (to prevent breeding), with each male. 
This phenotype was specific for the D2 TRAP line, but for 
consistency, we also separated D1 TRAP males as well. This 
phenotype was specific to the YAC line, as we never 
observed this phenotype in the R6-2 mice but may be due to 
strain differences, as we have not yet tested whether the 
aggression was predominant in mice of any particular 
genotype. 
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Discussion 
 Human patients with Huntington’s Disease typically 
live several decades of normal life before showing any 
symptoms of their disease. This period of normalcy is both 
a blessing and a curse for these patients: on the one hand, 
they can live disease-free for many years, but on the other 
hand, the late onset of symptoms means that the disease is 
often passed to the next generation. The two HD mouse 
models chosen for this study are imperfect reflections of 
the full disease state they were designed to mirror; 
however, these models both share with human HD a period of 
normal behavior that precedes symptom onset. This shared 
characteristic is not trivial: it suggests that to a large 
degree, normal development of the nervous system has 
occurred and that accumulation of some form of toxic damage 
must happen to create the behavioral syndrome. 
  In HD patients, the appearance of symptoms is often 
experienced as abrupt: one day a patient will fall down a 
flight of stairs, but the cellular pathology has most 
likely burned slowly for many years before this day of 
onset. Prospective imaging studies of patients at risk for 
developing HD demonstrates that there are volumetric 
changes in the striatum and cortex that precede overt 
symptom development by years (Tabrizi, Scahill et al. 
2010). Likewise in the mice, many biochemical changes have 
been shown to take place before symptom onset.  
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Therapeutic interventions for HD have the best chance 
to be viable if they target changes that occur early in the 
disease course. One hypothesis about disease progression in 
HD is that the disease begins with an early insult or set 
of insults caused directly by the mutant htt (mhtt), which 
are then followed by a series of secondary and tertiary 
effects as the cell attempts to compensate to its stressed 
state (for review, (Cha 2007)).  But to isolate these early 
insults, it would be necessary to harvest the gene 
expression profile of the MSNs before and after the initial 
insults occur.  
Since there is no a priori way to determine the 
correct time to harvest mRNAs to identify these primary 
insults, and because this time most likely varies between 
HD models and among strains, the development of behavioral 
symptoms informed the timepoints chosen for mRNA 
collection. There were several reasons to justify this 
choice.  First, by the time of symptom onset, sufficient 
changes should have occurred within MSNs to be detectable 
by molecular assays.  Second, changes that are reflected by 
behavioral symptoms are likely to be relevant to human 
disease. Third, correlations with a behavioral phenotype 
would allow for future experiments to link candidate genes 
causatively to the phenotype. Thus, an mRNA collection 
timepoint before and after behavioral symptoms emerge were 
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chosen to reveal early, relevant pathological changes 
within these neurons. 
 Because we introduced a new transgene into the HD 
mouse models and changed the mouse strain background upon 
which they were characterized, we re-tested their behavior, 
in order to find the time of symptom onset in the mice.  
The R6-2 model exhibited a robust behavioral phenotype 
with an onset of approximately 9 weeks in the open field 
and 12 weeks on the rotarod.  The mice steadily declined in 
health, becoming moribund and cachetic by 5-6 months of age 
and dying soon after. This phenotype follows a similar 
course to the R6-2 on the B6/CBA background; it just takes 
approximately twice as long to develop.  Our results 
largely agree with those of Menalled who also characterized 
the R6-2 mice on the C57Bl/6 background; however, they 
found that females were slightly more susceptible to 
disease, with open field deficits at 6 weeks. In our 
colony, females typically showed a less severe phenotype 
and lived longer than males (data not shown).  
In agreement to the findings of other groups, we have 
found a constant expansion of the number of CAG repeats in 
our R6-2 colony over time.  Similar to the results in 
Dragatsis et al. and Morton et al, we have seen a 
paradoxical amelioration of the phenotype with this CAG 
expansion. Whereas R6-2 mice from early generations in the 
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colony would die at approximately 5-6 months of age, R6-2 
mice born 2 years later could live up to 1 year of age or 
longer (Morton, Glynn et al. 2009); (Dragatsis, Goldowitz 
et al. 2009).  As suggested by both of these groups, this 
delay in phenotype onset may result from a difference in 
the ability of mhtt with very long polyglutamine repeats to 
traffic to the nucleus, where it exerts some of its 
deleterious effects.  
The YAC128 model exhibits a late onset phenotype that 
exhibits more variability between individuals. We aged two 
cohorts of mice and found that, in the open field, the 
hypokinesis of the model only became statistically 
significant at 13 months and only in the D1 TRAP 
background. The YAC D2 TRAP mice did not exhibit 
hypokinesis even as late as 23 months (data not shown). On 
the rotarod, we observed a statistically significant 
constant deficit in the D1 TRAP background beginning at 15 
weeks of age: in the D2 TRAP line, a similar pattern was 
observed, but the repeated measures ANOVA test failed to 
reach significance (p=.08), perhaps owing to the premature 
death of three of the D2 TRAP mice prior to the completion 
of the study. The CAG repeats were stable in the YAC128 
line. 
Our results agree with the phenotype in the published 
literature with the exception of the subtle hyperkinesis 
published in Slow et al., although Menalled et al. also 
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failed to reproduce this result (Menalled, El-Khodor et al. 
2009). The variability of the behavior in these mice may be 
due to their hybrid background, but this complication was 
unavoidable, as the YAC128 phenotype on the C57Bl/6 
phenotype is almost completely silent (Van Raamsdonk, 
Metzler et al. 2007; Menalled, El-Khodor et al.).  The 
basis of these strain modifier effects would be interesting 
to unravel in future studies. 
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Section 2: RNA collection and Microarray Analysis 
 
Background 
Improvements to the TRAP Protocol  
Once the behavioral decline of the models had been 
mapped, we began harvesting RNA from both D1 and D2 TRAP 
animals. When this project began, we used the co-
immunoprecipitation protocol published in Heiman et al. 
2008. Using this version of the TRAP methodology, it was 
necessary to pool groups of 8 animals to achieve a 
sufficient yield for subsequent amplification and 
hybridization to microarrays. The large number of animals 
required for a single replicate made longitudinal aging 
studies very challenging, as the R6-2 model has very small 
litters and the YAC128 line, as mentioned previously, is 
prone to aggression and fighting. Many of these males 
needed to be single-housed with ovarectomized females, and 
the numbers of animals required for the study quickly 
became space and cost limiting. Additionally, due to the 
inherent variability of age-related phenotypes, pooling 
individuals risks diluting out otherwise statistically 
significant changes occurring at the individual level. 
Fortunately, during the course of this study, Dr. 
Myriam Heiman continued to make improvements to the TRAP 
technique. By substituting Protein L, an immunoglobulin-
binding protein produced by Peptostreptococcus, for the 
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Protein G that had been used in the original protocol, and 
introducing a blocking step with BSA, signal-to-noise ratio 
was greatly enhanced (see Figure 12). As a result, the 
immunoprecipitation reaction could occur for much longer, 
allowing for higher yields, and analysis of translational 
profiles for individual animals. The possibility of single-
animal analysis allowed for larger sample sizes, reducing 
noise in the array data, and for the inclusion of 
timepoints far later in the disease process than would 
otherwise have been possible.  
In selecting the timepoints for RNA harvest, we wanted 
to start as early in the disease process as possible, 
particularly for the R6-2 line, which has a rapid-onset 
phenotype. We chose to harvest from 3-4 week old mice, as 
we had not identified any behavioral deficits in the mice 
at this age. We also harvested animals at the post-
symptomatic timepoint of 12 weeks and at an intermediate 
timepoint of 8 weeks. For a complete list of harvested 
timepoints, with IP protocol used and downstream 
applications tested, see Table 3.   
 For the YAC128 mice, we harvested one cohort of mice 
at 13 weeks, the period during which we had initially 
observed hyperkinesis.  We also harvested mice at 13 
months, when the hypokinesis in the D1 TRAP line became 
significant. We aged the remaining mice and harvested them 
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at 23 months. For a full detailed listing of all cohorts 
harvested see Table 3. 
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 Figure 12. TRAP methodological 
improvements. A. Average RNA yield from 
D1-expressing MSNs, using our published 
and newly refined TRAP protocol (± 
S.D.). 13 mice were used in the previous 
protocol, compared to 1 mouse with the 
new protocol. B. The expression values 
of astrocyte-enriched genes (Cahoy, 
Emery et al. 2008) (red dots; should be 
background signal in our purifications) 
are compared in our new protocol TRAP D1 
samples (X-axis) versus our old protocol 
TRAP D1 samples (Y-axis). Middle line 
represents equal expression; lines to 
each side represent 1.5-fold enrichment. 
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Table 3: Summary of IP timepoints collected, with protocol 
and downstream application. CAG repeats are included when 
available.  
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Results:  
The RNA yield from striatopallidal neurons but not 
striatonigral neurons decreases over time in R6-2 model 
 One observation that we made prior to microarray 
analysis was that the relative amount of RNA that we could 
immunoprecipitate from individual mice declined with age in 
the R6-2 D2 TRAP line. While there was no significant 
difference in the amount of RNA collected from the 3-week-
old R6-2 cohort or age-matched controls, there was a six-
fold decrease in the amount of RNA harvested on average 
from 12-week-old striatopallidal cells (Student’s t-test, 
p=.003 see Figure 13).  This decline was not observed in 
the R6-2 D1 TRAP line or in the YAC model (data not shown). 
 To investigate the mechanism of this decline, we 
verified that there were no changes in copy number of the 
TRAP transgene at the DNA level using qPCR (data not 
shown). Because Drd2 expression is known to decrease in the 
R6-2 model and because the D2 TRAP promoter is driven by 
the Drd2 promoter, we next measured changes in the 
expression of the transgene at the RNA level, using qPCR 
from the amplified mRNAs that had been immunoprecipitated.  
At the RNA level, we saw differences of slightly more than 
two-fold at 14 weeks in D2 cells.  This effect was age-
dependent, as no difference was observed at 4 weeks (qPCR 
from pooled sample; see summary table). Finally, at the 
protein level, we found a dramatic decrease—a near absence 
of transgene expresed—in the amount of GFP detected in the 
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striatum by Western blot in a 6-month-old end-stage R6-2 D2 
TRAP animal (data not shown). This decrease in Drd2 
expression could reflect a general loss of D2 cell identity 
or a specific downregulation of dopamine signaling pathways 
in this cell type. 
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Figure 13: RNA yield decreases in R6-2 D2 TRAP mice over 
time. RNA was co-immunoprecipitated from single R6-2 D2 
TRAP mice and D2 TRAP littermate controls. At 12 weeks, RNA 
yield in the R6-2 striatum was significantly decreased 
compared to controls (Student’s Two-tailed t-test, p=.003). 
Yield was measured using Invitrogen Quant-It Ribogreen 
reagent. 
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Array results recapitulate known changes from the 
literature 
In order to confirm that we had indeed harvested cell-
type specific messages from our animals, all groups were 
first analyzed for the expression of known markers for 
striatonigral and striatopallidal MSNs. In all cases, D1 
and D2 samples cluster separately upon Principal Components 
Analysis (PCA) (data not shown). We then examined the 
expression of known D1 and D2 markers in the wild-type 
samples (HD groups were excluded from this analysis, as 
these markers are known to decrease at later stages of the 
disease). WT D2 samples were enriched for known 
striatopallidal markers: Drd2 (63-116 fold), Gpr6 (25-50-
fold), Adora2a (41-fold), and Penk (7.2-fold); WT D1 
samples were enriched for Drd1a (11 fold); Pdyn (15-fold), 
and Eya1 (50-fold).  These values are consistent with 
previous studies performed by other members of the 
laboratory (Heiman, Schaefer et al. 2008). 
 We next wanted to see whether our data from the HD 
models recapitulated any known changes from the literature. 
Phosphodiesterase10a (Pde10a) has been shown to decrease by 
~3 fold in late-stage R6-2 mice (Hu, McCaw et al. 2004); 
(Hebb, Robertson et al. 2004).  In the R6-2 12 week 
timepoint, which is a symptomatic timepoint, Pde10a was 
decreased by ~6.5 in D2 cells and 1.75 in D1 MSNs.  
Preproenkephalin (Cahoy, Emery et al.), which has been 
found to be downregulated 2-fold in the R6-2 B6/CBA line 
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was downregulated by 1.7 fold in D2 cells and 1.5 fold in 
D1 cells at the 12 week timepoint.  
To address this question more comprehensively, cell-
type specific data sets were compared with microarray data 
files from whole striatum of 12 week-old R6-2 B6/CBA mice 
and controls from (Kuhn, Goldstein et al. 2007).  
Microarray .CEL files were downloaded from the Gene 
Expression Omnibus Database (www.ncbi.nlm.nih.gov/geo/) and 
were analyzed in parallel with R6-2 12 week C57Bl6/J D1 and 
D2 MSN changes.  There were 51 gene expression changes of 
fold change > 1.5 and p<.05 present in all three datasets. 
Of these, 96% changed in the same direction, indicating a 
high concordance with previous results. The two genes which 
were not concordant were Chdh and Abcc12. The former was 
found to be upregulated 1.8 fold in whole striatum in the 
Kuhn data set: in our data, it was 3 fold up-regulated in 
D2 cells and 1.7 fold down-regulated in D1 cells. It is 
possible that the average of the D1 and D2 fold changes 
would lead to an overall fold change of 1.8 up-regulation.  
For Abcc12, the down-regulation of 1.8-fold in whole 
striatum is not easily explained by a combination of 2-fold 
up in D1 cells and 1.6 fold down in D2 cells, but it is 
possible that changes in expression level of this protein 
in the glia could help explain the observed discrepancy.  
There were many genes that were found in the Kuhn et 
al. study that were not found in either of the D1 or D2 
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changes in our data sets. Pathway analysis of these changes 
using the Ingenuity Pathway Analysis algorithm yields 
highest significance in pathways of G-protein coupled 
receptor signaling, calcium signaling, and glutamate 
receptor signaling. These pathways are driven by the loss 
of several key genes, including known MSN markers Drd1 and 
Adora2a, as well as non-neuronal genes such as Slc1a2.  The 
discrepancies are due to differences in disease progression 
on the two strain backgrounds – 12 weeks on the B6/CBA 
background from the Kuhn study is far more advanced in 
disease progression that our mice on the C57B/6J 
background, as well as the inclusion of changes in non-
neuronal cell types in the whole striatum Kuhn study. 
 For the YAC128 mice, several gene changes from the 
literature were confirmed in the datasets. Three of the 
four changes confirmed by qPCR identified in Becanovic   at 
the 24 month time point—Wilms Tumor 1 (WT1), DNA-damage 
induced transcript 4-like (Ddit4l), Gsg1l—are changed in D1 
MSNs at 23 months. A similar GEO parallel analysis with 
datasets from Becanovic et al. for the YAC128 13 month 
timepoint showed less overlap: only 5 gene changes were 
present in all sets. But 100% of the gene changes 
identified in Becanovic et al. shared directional 
concordance with the data from our results. 
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Figure 14: Comparison of cell-type specific changes with 
microarray datasets downloaded from the Gene Omnibus 
Database.  .CEL files from total striatum of R6-2 12 week 
mice from Kuhn  et al., 2007 were downloaded from GEO and 
analyzed  together in Genespring with data from R6-2 12 
week D1 and D2 BACTRAP data. Overlapping gene changes are 
shown. 
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The magnitude of gene expression changes correlates with 
progressive behavioral phenotype 
In both the R6-2 and YAC128 models, the number of 
genes that are differentially translated increases with 
time. This change happens dramatically in D2 MSNs in the 
R6-2 model between 4 and 12 weeks of age when symptom-onset 
occurs. During this period, the number of gene changes 
increases from 156 probesets at 4 weeks to 5913 at 12 weeks 
(f.c.>1.5 and p<.05; see Figure 15 for scatter plots of the 
data).  In the YAC128 model, in D2 MSNs, there were 183 
gene changes at 13 months of age, and 538 changes by 23 
months. (For these comparisons, sample sizes were kept 
constant by randomly selecting 3 replicates from the YAC128 
13 month group; this adjustment was necessary as larger 
sample sizes reduce noise in the data, and this can lower 
the number of observed changes). 
Comparisons of D1 and D2 changes within any one 
timepoint revealed many more differences than similarities.  
At 3 weeks of age in the R6-2 mice, there were 584 gene 
changes in R6-2 D1 MSNs compared to WT D1 MSNs and 781 
changes in D2 MSNs at this stringency.  Surprisingly, only 
22 of these changes overlap (see Figure 16 for tables of 
changes with overlap).  Similarly, at 8 weeks of age, there 
were 572 gene changes in D1 cells, 716 changes in D2 cells, 
with 34 overlapping changes.  By the 12 week timepoint, 
many more changes have occurred in both cell types, with 
1423 changes in D1 cells and 4061 changes in D2 cells, with 
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238 overlapping changes (all listed results have f.c.>1.5 
and p<.05, without multiple testing corrections). These 
results indicate that the toxic effects of mhtt are 
progressive and differential between D1 and D2 subtypes, 
with the greater changes occurring in D2 MSNs.  
 While there were fewer translational changes observed 
in the YAC128 model at all times tested, the number of 
overlapping gene changes between D1 and D2 cells was 
similar.  At 13 months of age, there were 139 changes 
observed in D1 cells, 69 in D2 cells, and 22 overlapping 
changes. At 23 months, there were 590 changes in D1 cells, 
538 in D2 cells, and 25 overlapping gene changes (all lists 
f.c.>1.5; p<.05).  Thus, the striking differences observed 
in the R6-2 model are borne out in miniature in the milder 
YAC128 model.  However, on the single gene level, there are 
few overlapping changes between models at the time points 
tested and notably more changes in D1 cells at early 
timepoints. 
 An important caveat regarding these numbers is that 
they do not factor in correction for multiple testing. 
Microarrays allow the parallel interrogation of thousands 
of probesets at one time.  While this powerful tool can 
provide a snapshot of all genes expressed at a given time, 
the large number of statistical tests asked at one time 
raises the likelihood of false-positive tests.  In the most 
stringent analyses of microarray data, the p-values for 
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each statistically significant gene need to be adjusted by 
the number of comparisons made. There are several different 
methods for making this correction – the results from 
Benjamini-Hochberg FDR, one of the more commonly used 
multiple testing corrections, is shown in Table 4.  For 
most of the comparisons made, no genes were found to be 
statistically significant after multiple testing 
correction. This result is most likely due to the small 
sample sizes – in the YAC 13 month timepoint, which had the 
largest sample sizes (see Table 3), there are several genes 
that remain statistically significant after multiple 
testing corrections.  Because so few genes came through 
with multiple testing corrections in the other experiments, 
however, the remainder of the analysis was performed 
without the correction. The risk of false positive results 
increases without the correction, but as the microarrays 
were being used a screening tool to find candidates for 
further analysis, the less stringent filtering was used. 
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Experimental Comparison # genes with 
fold change 
>1.5, p<.05 
without 
multiple 
testing 
correction 
# genes with 
fold change 
>1.5, p<.05 
WITH Benjamini-
Hochberg 
correction 
3 weeks R6-2 D1 vs. D1 WT 594 0 
3 weeks R6-2 D2 vs. D2 WT 781 0 
8 weeks R6-2 D1 vs. D1 WT 572 0 
8 weeks R6-2 D2 vs. D2 WT 716 0 
12 weeks R6-2 D1 vs. D1 WT 1423 0 
12 weeks R6-2 D2 vs. D2 WT 4061 637 
13 month YAC D1 vs. D1 WT 139 120 
13 month YAC D2 vs. D2 WT 69 32 
23 month YAC D1 vs. D1 WT 590 1 
23 month YAC D2 vs. D2 WT 538 0 
Table 4: Number of genes that remain statistically 
significant after Benjamini-Hochberg FDR multiple testing 
correction, using fold change > 1.5 and p-value < .05. 
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Figure 15: Gene expression scatter plots 
for R6-2 striatopallidal neurons (Top 
Panel) Normalized expression values from 
Affymetrix Mouse Genome 430 2.0 arrays 
are plotted for 4-week old R6-2 D2 TRAP 
mice (y-axis) and 4-week-old D2 TRAP 
littermate controls (x-axis). The middle 
diagonal line represents probe sets with 
equal expression in both groups, and the 
outer diagonal lines delineate probe 
sets with 1.5 fold difference in either 
group. Total number of probesets with 
greater or less than 1.5 fold difference 
between groups is indicated. (Bottom 
Panel) Same as in above for 13-week old 
mice. 	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3 week R6-2 D1 vs D1 WT 
gene changes fold change 
>1.5, p<.05 
3 week R6-2 D2 vs D2 WT 
gene changes fold change 
>1.5, p<.05 Overlap 
594 781 22 
 
8 week R6-2 D1 vs D1 WT 
gene changes fold change 
>1.5, p<.05 
8 week R6-2 D2 vs D2 WT 
gene changes fold change 
>1.5, p<.05 Overlap 
572 716 34 
 
12 week R6-2 D1 vs D1 WT 
gene changes fold change 
>1.5, p<.05 
12 week R6-2 D2 vs D2 WT 
gene changes fold change 
>1.5, p<.05 Overlap 
1423 4061 238 
 
13 month YAC D1 vs D1 WT 
gene changes fold change 
>1.5, p<.05 
13 month YAC D2 vs D2 WT 
gene changes fold change 
>1.5, p<.05 Overlap 
139 69 22 
 
23 month YAC D1 vs D1 WT 
gene changes fold change 
>1.5, p<.05 
23 month YAC D2 vs D2 WT 
gene changes fold change 
>1.5, p<.05 Overlap 
590 538 25 
 
Figure 16: Comparison of single-gene changes shared between 
cell-types at different time points in the R6-2 and YAC128 
models. All data represent lists generated at fold change 
>1.5, p<.05, with no multiple testing corrections.
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Pathway analysis reveals recurring patterns of cellular 
dysfunction  
In order to gain a better functional understanding of 
the gene changes observed across different models, cell 
types, and time-points, we grouped the observed changes by 
Gene Ontology Analysis and analyzed the data using 
Ingenuity Pathway Analysis. Gene Ontology analysis groups 
genes according to known molecular function, biological 
process, and subcellular localization. In the R6-2 3 week 
time point, we found enrichment in GO pathways only in D2 
MSNs.  The analysis revealed that the changes were enriched 
in the cellular compartment of the nucleus (p=.005), where 
mhtt is known to exert toxic effects, and the biological 
pathways  enriched for RNA processing, metabolism, and rRNA 
transcription (p=.01, .01, and .07 respectively).  This 
last pathway is intriguing given a very recent paper 
showing that the overexpression of rRNA processing genes 
can suppress mhtt toxicity in yeast (Tauber, Miller-Fleming 
et al.), implicating broader dysfunction in translation 
very early in the pathology. At the R6-2 D2 12 week 
timepoint, there are many more GO terms represented, with 
the most stringently enriched pathways occurring in various 
forms of carbohydrate metabolism (see Appendix).  There is 
a long literature regarding changes of metabolism and 
mitochondrial function in HD, beginning with the 3-
nitropropionic acid pharmacological model of the disease, 
but it is unclear whether these changes are specific to the 
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toxic insult of mhtt or are more general indicators of cell 
stress. In the YAC model, many fewer GO changes were 
observed. There was no representation of GO terms in D2 
cells at either the 13 or 23 month timepoints, and only 3 
in the D1 YAC 13 month timepoint. These changes pertained 
to G-protein signaling, driven by increases in the 
expression of the G-proteins Gng4 and Gng5 in the D1 MSNs 
at both these times, but very little is known about the 
function of these genes.  
To examine whether we could find any biological 
pathways that had a statistically significant enrichment in 
the datasets, we analyzed the gene changes using Ingenuity 
Pathway Analysis (IPA). IPA works by mapping gene changes 
to a library of canonical pathways obtained from reports of 
gene interactions in the literature.  The ratio of the 
number of changes in a pathway to the total number of genes 
contained in a pathway is used to rank an order of the most 
to least enriched pathways in a dataset. A Fisher’s exact 
t-test is then used to determine the likelihood that the 
pattern of enrichment in each pathway could be due to 
chance alone.   
Several pathways emerged consistently at different 
timepoints in the analysis, and some pathways appeared in 
both models. A summary table with the most commonly 
represented pathways is listed in Table 4.  Some of these 
pathways, such as PPAR activation (appearing 6 times), IGF-
 81 
1 signaling (5 times), and DNA damage pathways (4 times, 
combining p53 and ATM signaling) have been previously 
implicated in HD. We took this enrichment of previously 
described changes as a further validation of our approach. 
In addition to these known pathways, our analysis uncovered 
several pathways previously unpublished with respect to 
Huntington’s Disease.  
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Ingenuity Canonical Pathways Appearances 
Axonal Guidance Signaling 6 
*PPAR
€ 
α/RXR
€ 
α Activation 6 
*IGF-1 Signaling 5 
*Role of NFAT in Cardiac Hypertrophy 4 
RANK Signaling in Osteoclasts 4 
*Molecular Mechanisms of Cancer 4 
*Inositol Phosphate Metabolism 3 
Relaxin Signaling 3 
Thrombin Signaling 3 
CXCR4 Signaling 3 
4-1BB Signaling in T Lymphocytes 3 
*Protein Kinase A Signaling 3 
*NRF2-mediated Oxidative Stress Response 3 
Integrin Signaling 3 
Breast Cancer Regulation by Stathmin1 2 
*Nicotinate and Nicotinamide Metabolism 2 
Ephrin Receptor Signaling 2 
*Androgen Signaling 2 
Sphingosine-1-phosphate Signaling 2 
*Endoplasmic Reticulum Stress Pathway 2 
*Type I Diabetes Mellitus Signaling 2 
*ATM Signaling 2 
*p53 Signaling 2 
*Purine Metabolism 2 
Chronic Myeloid Leukemia Signaling 2 
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*IL-1 Signaling 2 
*cAMP-mediated Signaling 2 
Small Cell Lung Cancer Signaling 2 
CD27 Signaling in Lymphocytes 2 
Cardiac Hypertrophy Signaling 2 
*14-3-3-mediated Signaling 2 
Semaphorin Signaling in Neurons 2 
Germ Cell-Sertoli Cell Junction Signaling 2 
Wnt/
€ 
β-catenin Signaling 2 
*Calcium Signaling 2 
*Synaptic Long Term Potentiation 2 
Glioma Signaling 2 
RAR Activation 2 
*Huntington's Disease Signaling 2 
Leukocyte Extravasation Signaling 2 
Notch Signaling 2 
Aryl Hydrocarbon Receptor Signaling 2 
Phospholipase C Signaling 2 
LPS/IL-1 Mediated Inhibition of RXR Function 2 
*GABA Receptor Signaling 2 
Table 4: Pathway with multiple appearances in Top 15 
pathways at different time-points  
Gene lists (f.c.>1.5, p<.05) from all time points for both 
R6-2 and YAC128 models were analyzed with the Ingenuity 
Pathway Analysis algorithm. This program lists molecular 
pathways enriched in the datasets by testing how many genes 
in a pathway would be expected to change by chance alone. 
Pathways with multiple appearances in different models or 
at different times are listed in the table. Pathways that 
return hits when included in a PubMed search with 
“Huntington’s Disease” are marked with an asterisk.
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Novel Pathway Changes from Cell-Type Specific Data 
 In analyzing the many pathway changes, we established 
a set of priorities for thinking about the data. First, 
because we were interested in cell-type specific changes, 
we looked for any pathways that contained changes in genes 
with known differences between D1 and D2 MSNs.   Second, we 
looked for pathways that changed early in the time course 
of the disease—these changes could worsen with time, but 
they should be present before large number of secondary 
pathological effects. Third, we prioritized pathways that 
were shared at some point between models, as any model can 
have individual artifacts. Lastly, because D2 MSNs are more 
vulnerable than D1 MSNs, we preferred changes that occurred 
first in D2 cells and then later in D1 cells. These 
criteria were not meant as strict filters, but rather as 
guidelines for analyzing the data. 
 One pathway that fits many of these criteria is 
endoplasmic-reticulum (ER) stress signaling. ER stress is 
the top-ranked pathway in D2 MSNs in the R6-2 model. It is 
also enriched in YAC D1 MSNs at 14 weeks (p=.005). In the 
R6-2 3-week time point this enrichment is due to an 
increase in Eif2ak3 (f.c. 2.8, probeset 1449278_at), also 
known as PERK; where as in the YAC128 D1 gene set, it is 
driven by an increase in Hspa5 (f.c. 1.6; probeset 
1427264_at).  Both of these genes play critical roles in 
the regulation of this pathway (for review, see (Rutkowski 
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and Hegde)). These changes happen early in the pathological 
progression of the disease, before aggregates of mhtt are 
typically seen (typically 3 weeks in the cortex, 4-6 weeks 
in the striatum in the B6/CBA background).  It is not 
immediately clear why mhtt, a cytosolic protein that 
aggregates both in the cytosol and in the nucleus would 
disrupts protein folding in the ER, but one possibility is 
that MSNs benefit from the chaperones induced by the 
unfolded protein response initiated by ER-stress. Another 
possibility is that misregulation of sphingolipid 
synthesis, (to be discussed in Section 3) which takes place 
in the ER, is causing this activation of ER stress. The 
yeast mutants Orm1 and Orm2, two proteins which regulate 
membrane biogenesis in yeast, exhibit abnormal sphingolipid 
profiles and constitutively upregulate the UPR (Han, Lone 
et al.). 
 Another pathway that is highly enriched in both 
models, which exhibits increasing enrichment with 
progression of phenotype is axonal guidance signaling. 
Axonal guidance signaling is the ninth top-ranked pathway 
in R6-2 D1 cells at 3 weeks, and the 16th pathway in D2 
cells; by 12 weeks, it is the second most enriched pathway 
in both D1 and D2 cells. This pathway also makes several 
appearances in the YAC128 model, in D1 cells at 13 months 
and 23 months, where is the second-most enriched pathway.  
At many of these timepoints, various isoforms of 
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semaphorins, ephins, netrins, and slit proteins are 
changed.  These proteins play canonical roles in the 
regulation of axonal growth cone guidance during 
development, but they have also recently been implicated 
through genome-wide association studies to Parkinson’s 
Disease (for review, see (Lin, Lesnick et al. 2009)). It is 
not known whether this association is due to developmental 
abnormalities that occur many years before the degenerative 
disease is seen (i.e. mis-wiring patterns), or if there are 
synaptic remodeling events occurring in adulthood that use 
developmental pathway in different ways.   
Another possible reason for observing the prevalence 
of axonal guidance signaling enrichment in our datasets is 
the loss of BDNF that occurs in HD mouse models.  In HD, 
MSNs lose the trophic support of BDNF secreted from the 
cortex (Zuccato, Ciammola et al. 2001). BDNF exerts many 
roles on neurons, including the promotion of axon-branching 
(Cohen-Cory and Fraser 1995), which is mediated in cortical 
neurons by MKP-1 (Jeanneteau et al., 2010). MKP-1 is 
downregulated in D2 MSNs at the R6-2 12 week time point. 
The loss of BDNF-induced signaling might disturb axon 
guidance signaling pathways in the MSNs as a compensatory 
response, although a complete absence of BDNF seems to have 
a greater role to play in dendritic structure (Rauskolb, 
Zagrebelsky et al. 2010). 
 87 
A third novel pathway is inositol phosphate 
metabolism.  Inositol phosphate metabolism was ranked first 
in R6-2 D1 MSNs at 3 weeks and second in R6-2 D2 MSNs at 
the same time point. It is significantly enriched in D2 
MSNs at the 8 week time point (p=.01), and it remains 
enriched in both cell types at 12 weeks. It is selectively 
enriched in D2 MSNs in the YAC128 model at 14 weeks.  This 
pathway is intriguing given the important role that 
inositol 1,4,5 triphosphate plays as a second messenger in 
glutamatergic signaling, and the hypothesis that 
glutamatergic excitotoxicity might play an important role 
in HD pathology. One gene in this pathway that is 
oppositely regulated in D1 and D2 cells at this early 
timepoint is Ipmk (1.8 up in D1; 1.5 down in D2). Ipmk has 
been shown to play critical roles in nervous system 
development, as constitutive knockouts of this gene are 
embryonic lethal, displaying abnormal neural tube closure 
(Frederick, Mattiske et al. 2005). This gene is thought to 
participate in the generation of complex inositol second 
messengers. 
Besides inositol metabolism, another lipid signaling 
pathway altered in the models was sphingolipid metabolism. 
S1P metabolism will be discussed in detail in Section 3.  A 
comprehensive list of pathways found from the IPA analysis 
can be found in the Appendix. 
Quantitative PCR confirms many cell-type specific changes 
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 Microarrays allow for massively parallel 
interrogations of amplified cRNA. The large number of 
probes contained on each array, however, increases the 
probability of false positive results due to noise in probe 
hybridization, plate reading, or other experimental 
handling. As a result, it is standard practice to confirm 
gene changes of biological interest with another, 
independent methodology. We attempted to use 
immunohistochemistry (IHC) to detect differential cell-type 
specific changes at the protein level. However, due to 
limitations in the availability of commercial antibodies 
compatible with IHC, we could only test a small subset of 
targets and in all cases any cell-type specific change was 
obscured by high background signals in the tissue. We 
therefore turned instead to qPCR.  
We chose to use Taqman Expression real-time PCR assays 
from Applied Biosystems for their wide availability and 
ease of use.  In the R6-2 model, because so many genes 
change their expression at various points in the disease, 
several of the housekeeping genes typically used to 
normalize qPCR results, such as beta-actin or 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), cannot be 
used for normalization because their level of expression 
changes in late stage disease.  Benn et al. characterized 
12 candidate housekeeping genes from whole striatum in R6-2 
at 15 weeks, a late timepoint in disease. In the striatum, 
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they found the least variation in Eif4a2 and Atp5b.  We 
have used Eif4a2 as the reference gene for most of the 
studies, in both models. 
We confirmed a range of genes at both low and high 
levels of expression from the arrays, and also focused upon 
particular genes and pathways of interest. Changes were 
confirmed with independent amplifications of mRNA, using a 
different amplification kit. In some instances when samples 
were available, changes were confirmed with independent 
biological replicates. A subset of confirmed changes is 
shown for the YAC 13 month timepoint (Figure 17), and a 
full list of confirmed and unconfirmed gene changes is 
available in the Appendix.  
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Figure 17: Confirmation of selected genes from YAC128 13 
month time point by qPCR. Some of the most robust changes 
at the YAC128 13 month time point are compared by their 
expression on microarray (box-whisker graphs) and by qPCR 
(bar graphs). Experiments were performed using independent 
amplification methods on same biological samples, n=3-4 
mice per group.
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Discussion 
 For the first time, we have collected cell-type 
specific gene expression changes from vulnerable cell types 
in HD mouse models. Previous studies have attempted to 
track gene expression changes in HD models in whole tissue, 
which can obscure relevant gene expression changes in noise 
from interneurons, glia, and other cell types. By excluding 
messages from these other cell types, the TRAP technique 
allows for increased sensitivity in detecting cell-specific 
gene changes.  Our results both confirm changes in pathways 
previously reported as implicated in HD pathogenesis, such 
as PPAR activation, IGF-1 signaling, and the p53 pathway, 
while also revealing changes in novel pathways, such as 
sphingosine-1-phosphate signaling, ER stress response, 
axonal guidance, and inositol phosphate metabolism, which 
may contribute to MSN vulnerability and warrant further 
investigation. Even within previously identified pathways, 
our analysis implicates novel genes, and the full 
publication of our microarray results in the Gene 
Expression Omnibus Database will serve as a resource for 
the HD community. 
 Our early observation that RNA yields from D2 MSNs 
decreased over time in the R6-2 model may reflect the 
selective vulnerability of this cell type in the model. Our 
data suggest that the downregulation of the D2 TRAP 
construct occurs at the transcriptional, and possibly, 
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post-transcriptional levels. It is known that 
transcription of the Drd2 gene is altered in the R6-2 
model, so it is unsurprising that the D2 TRAP construct, 
which is under control of the Drd2 promoter would also be 
affected. At the timepoints we harvested, we did not see 
any reduction in the RNA yields from the D1 MSNs. Drd2 
expression has been shown to be either mildly reduced (Xie, 
Hayden et al. 2010) or unchanged (Benn, Slow et al. 2007) 
in the YAC128 line.  In agreement with these results, we 
did not see a loss in RNA yield in the YAC128 mice.   
 Our analysis of the microarray results indicates that 
the number of translational changes in striatonigral and 
striatopallidal cells increased with age in both models. 
This result fits with the model that mhtt exerts primary 
insults in cells which are further amplified by secondary 
compensatory changes as cells struggle to maintain 
homeostasis.  For this reason, we chose to focus our 
analysis on gene expression changes from earlier time 
points in the disease process, as these changes are more 
likely to represent primary toxic insults of mhtt. 
 It is somewhat surprising that the number of changes 
common to D1 and D2 MSNs is as low as it is.  At baseline, 
the two groups of neurons share 80% of their genes in 
common, but a very small percentage of total changes are 
shared between cell types at any one timepoint. The 
apparent discrepancy could be due to either biological 
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interference with genes that determine MSN identity, or to 
mathematical noise in the data.  To test the latter 
hypothesis, we filtered all of the data sets with 
Benjamini-Hochberg multiple testing corrections. With this 
highest stringency filtering, only the YAC128 13-month 
cohort still had detectable changes, most likely because of 
its very large sample size (n=9 in the smallest group 
compared with an average of n=4 for the other time points).  
Without applying the highest stringency filter, 13% of the 
total changes overlap between the two cell types; with the 
stringency filter applied, that number remains 13%. This 
result suggests that the differences between the two cell 
types are unlikely to be an artifact of low stringency 
filters.  
We used several tools to gain deeper biological 
insight into the function of the observed changes. Our 
pathway analysis returned many pathways previously 
implicated in HD pathogenesis. One of the two most commonly 
represented pathways, PPAR/RXR signaling (6 appearances), 
has received considerable attention in the HD community.  
One major regulator of this pathway, PPARGC1alpha, has been 
shown to be downregulated in HD knock-in mice, and 
overexpression of this protein can rescue some toxicity in 
an in vitro system (Cui, Jeong et al. 2006). Moreover, 
subsequent genetic analysis has identified the same gene as 
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modifier of age of onset in human patients (Weydt, Soyal et 
al. 2009). 
A number of groups have also studied the role of the 
IGF-1 signaling pathway in HD.  Humbert et al. have shown 
in vitro that activation of the IGF-1 pathway leads to an 
AKT-mediated reduction in nuclear inclusions (Humbert, 
Bryson et al. 2002). Pouladi has shown that the large 
weight gain present in the YAC128 model, which we have also 
observed, correlates to circulating plasma levels of IGF-1 
and that perturbation of IGF-1 levels leads to a weight-
decrease (Pouladi, Xie et al. 2010). We have seen in the 
arrays and confirmed by qPCR a downregulation in Igfbp4 in 
the YAC128 model, one of the most robust changes present in 
all timepoints tested. Interestingly, Gatchel et al. 
identified Igfbp5 as a misregulated gene in a screen to 
identify polyglutamine-induced changes between two 
spinocerebellar ataxias in the cerebellum (Gatchel and 
Zoghbi 2005). This downregulation of Igfbp4 that we have 
observed could be a striatal response to polyglutamine 
expression. 
Thirdly, the high number of cancer and DNA-damage 
pathways fits with other studies in the HD field. One very 
recent study has shown that mhtt increases the number of 
double-strand breaks in DNA in the R6-2 striatum and also 
interferes with Ku70-mediated DNA repair (Enokido, Tamura 
et al.). Other groups have shown that mhtt binds to DNA 
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directly, changing its confirmation (Benn, Slow et al. 
2007).  Still other groups have demonstrated a major 
relationship between mhtt and p53 signaling.  Mutant htt 
binds to p53, and more importantly, knockdown of p53 
improves longevity in several HD mouse models (Bae, Xu et 
al. 2005).  
Because of the greater likelihood of identifying 
primary pathogenic insults, we chose to focus our attention 
on the changes that occurred very early in the disease 
process. One pathway in particular, sphingolipid 
metabolism, caught our attention, and became the subject of 
further study, to be described in the next section.  
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Section 3: Sphingolipid Metabolism 
Background 
In preliminary studies, one of the most altered 
pathways in R6-2 mice at the presymptomatic timepoint was 
sphingolipid metabolism. This result was intriguing for 
several reasons. First, several groups, including ours, 
have recently described GPR6, a sphingosine-1-phosphate 
(S1P) receptor, as a highly specific marker for 
striatopallidal neurons (Lobo et. al, 2007; (Heiman, 
Schaefer et al. 2008). Second, in gene expression studies 
from human HD pathological specimens, GPR6 was found to be 
the third most significantly downregulated gene in human 
striatum, although it is not yet clear whether this loss of 
GPR6 is due to downregulation of GPR6 in striatopallidal 
neurons or death of GPR6-expressing striatopallidal neurons 
overall (Hodges, Strand et al. 2006). Third, S1P has 
recently been appreciated as an important signaling 
molecule in the nervous system, for neurite extension and 
retraction, neuronal survival, and neurotransmitter release 
(for review, see (Milstien, Gude et al. 2007); (Okada, 
Kajimoto et al. 2009)). Fourth, S1P has recently been 
implicated in neurodegenerative disease: in an Alzheimer’s 
Disease study, GPR3, an S1P receptor, was found in an RNAi 
screen to increase the amounts of toxic ABeta produced in 
cell culture (Thathiah, Spittaels et al. 2009).  
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S1P is a bioactive lipid with diverse cellular 
functions both within and outside of the central nervous 
system. It has been implicated in numerous cellular 
processes, including proliferation, migration, and 
survival. S1P’s functions have historically been understood 
in terms of signaling through a series of G-protein coupled 
receptors (GPCRs) S1PRs 1-5, although more recently, S1P 
has been suggested to exert direct intracellular effects in 
diverse processes including chromatin remodeling, 
mitochondrial function, and ubiquitination (Strub, 2010;) 
(Hait, Allegood et al. 2009); (Alvarez, Harikumar et al. 
2010).  In the nervous system, S1P is thought to regulate 
glutamatergic neurotransmission, and injection of S1P 
directly into the brain leads to catalepsy, suggesting 
possible direct modulation of striatopallidal signaling 
(Sim-Selley, Goforth et al. 2009).  S1P is made from 
sphingosine by two different kinases, sphingosine kinase 1 
(Sphk1) and sphingosine kinase 2 (Sphk2). It can be 
dephosphorylated by sphingosine-1-phosphate phosphatase 
(Sgpp1) or irreversibly cleaved to phosphoethanolamine by 
sphingosine-1-phosphate lyase (Sgpl1) (Maceyka, Milstien et 
al. 2007).  
Together with ceramide, S1P is thought to regulate a 
cell-survival “rheostat,” in which S1P exerts pro-survival 
effects and ceramide stimulates apoptosis (Hannun and 
Obeid). S1P, sphingosine, and ceramide can also be 
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converted to wide range of other more complex sphingolipid 
species (see Figure 18). There are a great diversity of 
complex sphingolipid species, but much is unknown about 
their individual biological functions.  Some of these 
molecules, like S1P and ceramide, can influence protein-
signaling pathways by binding to receptors or second 
messengers. Others may signal through still-unknown 
mechanisms.  But these bioactive molecules also serve as 
building blocks for two classes of lipids that are known to 
play fundamental roles in the nervous system—sphingomyelin, 
a major component of the myelin sheath around neurons, and 
gangliosides, lipids for which defects in metabolism lead 
to a series of severe neurological disorders, including 
Tay-Sachs and Gaucher’s Disease. 
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Figure 18 (Fuller et al 2010). Schematic representation of 
metabolic relationships between sphingolipid bases. 
Sphingosine can be created de novo from serine and 
palmitoyl CoA, or it can be made by cleavage of ceramide by 
ceramidase. Sphingosine can then in turn be phosphorylated 
by one of two sphingosine kinases to make sphingosine-1-
phosphate (S1P). S1P can be reversibly dephosphorylated or 
it can be irreversibly metabolized by the enzyme Sgpl1.
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Quantification of S1P and sphingoid bases in HD mouse 
models and post-mortem tissue 
For all of the reasons above, the S1P pathway was 
chosen as a candidate pathway for further analysis. We 
attempted several different methods for measuring S1P in 
the R6-2 mice, including immunohistochemistry (Cosmo Bio), 
and ELISA (Echelon Biosciences).  However, both of these 
assays failed quality control experiments. The antibody 
from Cosmo Bio was found to cross-react with sphingomyelin 
in a dot-blot assay (data not shown), and the colorimetric 
assay used in the Echelon Biosciences ELISA kit was 
inhibited by a component of the recommended homogenization 
buffer (data not shown). Thus, the highly related nature of 
these sphingolipid species makes study of individual 
components in the pathway difficult, and many reagents are 
not specific enough to detect changes in single molecules. 
 We therefore attempted to quantify S1P by mass 
spectrometry, the gold standard for detection and 
quantification of complex lipids. For these experiments we 
collaborated with Dr. Jeff Moore of Avanti Polar Lipids, 
who was involved in the establishment of protocols for the 
use of mass spectrometry for complex sphingolipid analysis.  
We analyzed striatal homogenates, normalized to total 
amounts of protein, from R6-2 C57Bl6/J mice and WT controls 
at 3, 6, and 24 weeks (n=3-5 animals for each group), as 
well as 6-week-old R6-2 B6/CBA mice and WT controls from 
the Jackson Laboratory (to control for CAG repeat 
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expansion) (n=5). There were statistically significant 
decreases in several complex sphingolipid species in the 
striatum. Most sphingolipids in mammals are 18 or 20 carbon 
chains, with differing placement of double bonds along the 
chain. This property affects the classification and naming 
of the species: thus, there are two known forms of S1P 
detectable by mass spec, differing in length by two 
carbons, and they each have a double bond on the first 
carbon, hence they are named d18:1 and d20:1 S1P. We 
observed changes in d:20:1 S1P (significant at 6 weeks and 
24 weeks p<.05; p<.005 respectively). There were also 
statistically significant decreases in d18:1 sphingosine-1-
phosphate, d18:0 sphinganine, d20:1 sphingosine, d18:0 
sphinganine-1-phosphate, d20:0 sphinganine-1-phosphate and 
d20:1 sphinganine-1-phosphate, although at different time 
points. All statistically significant differences are 
displayed in Figure 19. There were no changes observed in 
any of the 25 ceramide species tested or in the other 
complex sphingolipids. There were no changes observed in 
the cerebellum from 6-week and 24-week-old R6-2 C57Bl6/J, 
with the exception of d:18:0 sphinganine, which was 
decreased by 40%, p=.03, and there were no changes observed 
from 6-month-old YAC128 mouse striatum or cerebellum. 
We next asked whether levels of S1P would be decreased 
in post-mortem tissue from human patients with Huntington’s 
Disease. We obtained one sample each of striatum and 
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cerebellum from an early stage HD case (Grade 2 on the 
Vonsattel neuropathological scale), a late stage HD case 
(Vonsattel Grade 4), and a control patient who had no known 
neurological history.  We observed very large fluctuations 
in several complex lipids between HD cases and control. 
There were undetectable levels of d18:1 S1P in Grade 2 HD 
striatum, and then a large increase in the level of d18:1 
S1P in Grade 4 HD post mortem tissue (Figure 20). This same 
pattern occurred with other lipid species, particularly 
with several of the ceramide moieties—sometimes with an 
order of magnitude difference (Figure 20).  However, given 
the small sample size, it is difficult to make any 
conclusions from these observations.  Future experiments 
will require larger sample sizes. 
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Figure 19: Summary of mass spectrometry quantification for 
complex sphingolipids in the R6-2 mouse striatum. Lipids 
are normalized to total protein in sample, as measured by 
BCA assay.  All R6-2 mice are on C57Bl/6 background except 
“JAX” mice, which are maintained on B6/CBA background (see 
Introduction for details). A. d20:1 Sphingosine-1-phosphate 
is decreased in R6-2 striatum at 6 weeks in B6/CBA 
background (Students t-test p=.03) and at 24 weeks on 
C57Bl/6J background (p=.005), n=3-5 per group. B. d18:1 
Sphinsogine-1-phosphate is decreased in R6-2 striatum on 
C57Bl/6 background at 6 weeks (Student’s t-test p=.03). C. 
Mass spectrometric quantification of d20:1 Sphingosine, 
which is decreased at 6 weeks on B6/CBA background and at 
24 weeks on C57Bl/6J (Students two-tailed t-test, p=.004 
and p=.03). D. d18:0 sphingosine is decreased at 6 weeks in 
B6/CBA background (p=.03). E. d18:1 sphinganine-1-phosphate 
is decreased at 6 weeks in B6/CBA background (p=.01). F. 
d20:1 sphinganine-1-phosphate is decreased at 6 weeks on 
B6/CBA background (p=.01).  
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Figure 20: Preliminary mass spectrometric quantification of 
complex sphingolipids in human caudate. A pilot experiment 
to compare levels of complex sphingolipids and ceramides 
was conducted in human caudate from a control, Grade 2, and 
Grade 4 HD patient (n=1 per group).  Levels of sphingosine-
1-phosphate were variable, but there were large increases 
in the amounts of some complex ceramide moieties-at times, 
almost an order of magnitude.
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Mechanism of Changes in S1P abundance 
 In the microarrays, Sgpl1 exhibited low, variable 
levels of expression, but it was increased at several 
timepoints in the R6-2 model and in both cell types.  It 
was increased 1.3 fold in the 4-week R6-2 D2 pooled 
animals, 1.4 fold (in one probe) in the R6-2 3-week D1 
cells, and 2-fold in R6-2 D1 cells at 12 weeks (data not 
shown).  In contrast, Sphk2 was expressed at intermediate 
levels and was downregulated by 1.4 fold in both R6-2 D1 
and D2 cells at 12 weeks compared to WT TRAP levels alone 
(data not shown). Sphk1 levels were very low and unchanged 
at all times and Sgpp1 did not change at any timepoint. 
Although these results were variable, we attempted to 
investigate the changes by qPCR.  At 3 weeks, in the R6-2 
line, Sgpl1 expression was too low in any of the WT 
animals, either D1 (n=4) or D2 (n=4) to be detected by 
qPCR; however, in the R6-2 mice, Sgpl1 was present in 3/5 
R6-2 D1 mice tested and 2/4 R6-2 D2 mice tested, at 
variable levels ranging from 7 cycles above Eif4a2 to 17 
cycles.  In the same animals, Sphk2 was decreased by 2-fold 
in D1 cells and 34-fold in D2 cells (Figure 21).  Sphk1 was 
not detected in two separate assays.  
Eight months later, however, in an independent cohort 
of R6-2 D2 TRAP 4.5 week animals, with a different number 
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of CAG repeats, expression levels of both Sgpl1 and Sphk2 
were highly variable (data in qPCR supplemental table). 
To settle this discrepancy, we attempted to 
investigate Sphk2 and Sgpl1 with in situ hybridization, an 
independent technique.  Although in situ hybridization is 
less sensitive and less quantitative than qPCR, we reasoned 
that if the large differences observed were present, they 
would be detectable by the technique. In addition, because 
of the instability of the CAG repeats in the R6-2 colony, 
we performed the in situ experiment in R6-2 animals on the 
B6/CBA background from the Jackson Laboratory colony, where 
CAG repeats are monitored and maintained at constant levels 
through periodic resuscitation of the line from frozen 
embryos. Unfortunately, preliminary results from this study 
were inconclusive, as sense and anti-sense probes for both 
genes gave similar low-level patterns of expression. 
While incomplete, these studies offer a preliminary 
hypothesis for the mechanism by which S1P levels might 
decrease in HD models, and possibly in HD patients, namely 
by transcriptional downregulation of the kinase that 
converts sphingosine to S1P and upregulation of the lyase 
that degrades S1P.  
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Figure 21: Sphk2 mRNA is downregulated in D2 MSNs in pre-
symptomatic R6-2 mice. Quantitative PCR was performed on 
amplified immunoprecipitated mRNA from D1 or D2 MSNs. Sphk2 
is statistically decreased in R6-2 D2 MSNs at 3 weeks of 
age. Data represents 4 technical replicates from n=3 
biological replicates. 
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S1P exerts a modest pro-survival effect in striatal cell 
culture lines  
 To gain insight into the function of S1P in MSNs in 
Huntington’s Disease, we turned to an in vitro model, the 
ST14A cell line (Cattaneo and Conti, 1998).  The ST14A line 
was established by transducing rat embryonic striatal cells 
with a temperature sensitive allele of the large T40 
antigen oncogene.  At the permissive temperature of 33°C, 
these cells grow indefinitely, but when shifted to 39°C in 
serum-deprived conditions, the non-permissive temperature, 
the activity of the T40 antigen is reduced, and the cells 
differentiate into neuronal-like cells (expressing NeuN, 
Map2, and low levels of DARPP-32), and then die due to loss 
of growth factor stimulation.  We received three lines of 
these cells: the parental ST14A line; the N548 line, which 
is stably transfected with the first 548 amino acids of 
mhtt with 128 CAG repeats; and the ST12.7 line, which 
places the same N548 transgene under the control of a Tet-
on promoter, allowing the doxycycline-inducible control of 
the mhtt transgene (Rigamonti, Bauer et al. 2000); 
(Sipione, Rigamonti et al. 2002).  
 We performed a dose-response experiment with S1P in 
the ST12.7 cell line, with or without doxycycline.  Cells 
were plated at high-density and grown for two days at 33°C 
days in serum-containing media in the presence or absence 
of doxycycline and with various concentrations of S1P. The 
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cells were then changed to serum-free media, to which the 
same concentrations of S1P were added, and then shifted to 
39°C. In the absence of S1P, after temperature shift, cells 
quickly begin to die, and by 24 hours after shifting, there 
is 46.8% cell toxicity, as measured by an LDH release 
assay. In the presence of S1P at 2.5 uM, the cell toxicity 
was 37.2% (Figure 22). The result was statistically 
significant (2-WAY ANOVA, Bonferroni post-test p<.001). 
This effect was specific, as an identical protocol 
substituting S1P treatment with BDNF, a neurotrophin that 
is thought to contribute to MSN survival, failed to produce 
any statistically significant effect on survival (Figure 
23).  Importantly, ST14A cells express low levels of TrkB 
at both 33˚C and 39˚C (Cattaneo et al, 1998). BDNF exerts 
its cell-survival effects by signaling through the TrkB 
receptor. Thus, we cannot exclude that the lack of effect 
on cell survival by increasing BDNF concentrations might 
reflect the low TrkB expression in the cell line. This 
experiment also shows that the induction of mhtt by 
doxycycline does not accelerate cell death in this line 
(p=.44). 
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Figure 22: S1P protects ST12.7 cells from cell death after 
serum deprivation and temperature shift. Cell death was 
measured using LDH-release assay 24 hours after temperature 
shift, without mhtt induction using doxycline. Data 
represent replicates from n=16 separate wells. One-Way 
ANOVA with Tukey’s post-hoc comparison, p<.001 for each 
concentration of S1P as compared to control condition. 
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Figure 23: BDNF exerts no cell-survival effect on ST12.7 
cell line.  Cell death was measured with an LDH-release 
assay, without mhtt induction using doxycline. Data 
represent n=16 well replicates. Statistical analysis was 
performed using a one-way ANOVA test. 
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Because the doxycycline-induced mhtt in the ST12.7 
cell line has no effect on cell death, we could not 
determine the effects of S1P upon mhtt toxicity in this 
model. Instead, we turned to the constitutively-expressing 
N548 line to investigate the effect of S1P on mhtt-induced 
cell death. Rigamonti et al. show a strong acceleration of 
cell death at 39°C with serum deprivation in the N548 line 
using an MTT assay. We have subsequently acquired the N548 
line from the Cattaneo lab and have reproduced the 
accelerated cell death phenotype due to mhtt using Trypan 
Blue staining (see Figure 24).  We will next use this cell 
line to test S1P’s ability to mitigate against mhtt 
toxicity in this line. At this time, however, we do not yet 
have results for the effects of S1P treatment of the N548 
line. 
We also tested the effect of a dose response of S1P 
with or without BDNF in primary culture from wild-type 
animals on the expression of DARRP-32.  We found a variable 
trend toward an increase of DARPP-32 expression in primary 
culture at 2.5 uM S1P treatment that failed to reach 
statistical significance (Figure 25 n=5 separate 
experiments, p=.1) 
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Figure 24: Stably transfected N548 cell line (ST14A 
transfected with mhtt with 128 repeats) has an accelerated 
cell death phenotype at 24 hours when measured with Trypan 
Blue staining. Cells were stained with Trypan blue and 
counted with a hemocytometer. Results represent 3 
independent biological replicates each counted four times. 
Students Two-tailed t-test, p<.0001.
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Figure 25: S1P may promote differentiation in striatal 
primary culture.  Primary culture started from striata of 
E15-E17 C57Bl/6 embryos and treated with S1P for 7 days. 
Protein lysates from cells were run on a Western blot and 
detected with rabbit anti-DARPP32. Quantification of blots 
was performed with ImageJ software.  Data are not 
statistically significant (One-Way ANOVA p=0.25), n=5 
independent experiments with 3 well replicates in each 
experiment.
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Production of S1P Modifying Viruses 
 In order to assess the effects of altering S1P levels 
on the HD phenotype in vivo, we produced Adeno-associated 
viruses (AAV) to overexpress Sphk2 and Sphk1, and an shRNA 
virus to knockdown expression levels of Sphk2.  Plasmids 
for over-expression and shRNA were tested prior to 
packaging by transfection into HEK293T cells. We saw robust 
expression of Sphk2 by Western blot, and we were then able 
to knockdown this overexpressed protein by ~80%, using the 
viral plasmid encoding for the shRNA against Sphk2 (Figure 
26).  Viruses were then packaged by Vector Biolabs. In 
future work, viruses will be injected into the striatum of 
R6-2 mice using stereotactic guidance (see Figure 27 
picture of dye injection). 
 
In Vitro Functional Screen of Additional Candidates 
 The genes and pathways identified from the 
interrogation of microarrays in Section 2 might play a role 
in HD pathogenesis.  In order to identify candidates within 
these gene changes that have functional relevance, we 
performed a preliminary in vitro functional screen by over-
expressing candidates in N548 cells and assaying their 
ability to protect against serum-deprivation death at 39°C.  
A list of gene candidates was chosen for their robust 
differences at early time-points. Of the 16 candidates 
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tested, 4 have shown modest protection of ~3-5% with Trypan 
Blue counting. These candidates, Sox11, Pea15a, Bcl11a, and 
Mrpl22, await further confirmation (see Figure 28).  None 
of the other candidates, except Anxa5, which worsened cell 
death, showed any effect (data not shown). 
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Figure 26: Knockdown of Sphk2 with shRNA. Sphk2 
overexpression virus plasmid and Sphk2 shRNA plasmids were 
co-transfected into HEK293T cells.  Protein lysates were 
analyzed by Western blot and quantified with LiCor Odyssey 
Imaging System. Results represent mean of 3 independent 
biological replicates.
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Figure 27: Dye injection into 
striatum. 2 ul of Nile Blue dye (10%) 
was injected stereotactically with a 
Hamilton syringe and microinjecting 
pump. The same method will be used to 
deliver AAV viruses to the dorsal 
striatum. 
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Figure 28: Candidates from preliminary screen in N548 cells 
for rescue of cell death. Gene candidates found from 
microarrays were transfected into N548 cells and then 
shifted to 39˚C in serum-deprived conditions. Trypan blue 
staining was used to count live cells remaining after 48 
hours. Data represent average of 3 independent wells, each 
counted 4 times. Statistical analysis performed using one-
way ANOVA (p=.0002 overall difference due to chance. * 
represents Tukey post-hoc test which shows Pea15a compared 
to Mock p<.001.)
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Discussion 
 We have conducted preliminary investigations into 
alterations in the sphingosine-1-phosphate signaling 
pathway in HD mouse models, human post mortem tissue, and 
in vitro systems.   We focused our interest on this pathway 
because of the strong D2 enrichment (~50 fold) of GPR6, a 
putative S1P receptor, alterations in sphingolipid 
metabolism at the pre-symptomatic timepoint in the R6-2 
model, and because of S1P’s role in cell-survival 
signaling. We have shown that S1P and other complex 
sphingolipid levels are altered at an early symptomatic 
timepoint in the R6-2 model and that S1P can exert a modest 
pro-survival effect on the striatally-derived ST12.7 line 
in vitro.  
 As mentioned previously, S1P is a powerful signaling 
molecule that exerts effects through both extracellular 
signal transduction cascades through GPCRs as well as 
intracellular pathways by binding to a series of protein 
partners. S1P levels are maintained at low levels in the 
tissue and are tightly regulated by both sphingosine 
kinases, lipid phosphatase Sgpp1, as well as Sgpl1, which 
irreversibly cleaves S1P into phosphoethanolamine. 
Sphingolipid signaling is remarkably complex, involving 
many categories of distinct, biologically active signaling 
lipids, such as ceramides, ceramide-phosphates, and complex 
glycosphingolipids.  In their review of sphingolipid 
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signaling, Hannun   emphasize the interconnectivity of 
these lipid species and suggest that alterations of any one 
enzyme in the pathway may result in more widespread changes 
than simple changes of the sphingolipid immediately 
downstream of the effect. 
 For this reason, we cast a wide net when analyzing 
mouse striatum samples by mass spectrometry to look at the 
levels of many complex sphingolipids.  We found many 
changes in different sphingoid base species in the R6-2 
mouse striatum, including two forms of S1P, d:18:1 and 
d:20:1 S1P, which differ by two carbon atoms. There has 
been some evidence to suggest that d:20 sphingoid bases are 
more CNS specific (Sonnino and Chigorno 2000), but there is 
not very much information in the literature about 
differences in biological activity between these two 
molecules. We observed many other changes in these complex 
lipids, but the changes were specific to the sphingolipids—
the closely related ceramide species, which can send potent 
apoptotic signals themselves, were unchanged. These changes 
were also specific to the striatum: in the cerebellum, with 
the exception of a decrease in d18:0 sphinganine, we 
observed no changes in any of the sphingolipids tested, at 
either 6 or 24 weeks of age.  
In the human samples, S1P levels varied between 
control and HD subjects—it was increased in Grade 2 and 
decreased in Grade 4 tissue.  There were also very large 
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changes—sometimes an order of magnitude—difference in the 
levels of several ceramide species between HD tissue and 
control tissue. It is too early to make any conclusions 
about these trends, because of the small sample size, but 
these promising data warrant further study with larger 
cohorts. 
 One of the challenges in this investigation was the 
variability of Sgpl1 and Sphk2 levels as measured by qPCR. 
This variability was seen in both HD and WT animals at 
different ages, and was not attributable to technical 
variability, as the standard deviation of the technical 
replicates for each sample was within the range of 0.05-0.1 
cycles, which is within the typically acceptable range of 
<.1 cycles. Furthermore, other genes tested in parallel, 
from the same samples on the same plates, did not show this 
variability.  
There are some possible biological explanations to 
explain this variability. One possibility is that these 
genes are highly susceptible to environmental signals, such 
as stress. Sgpl1 might function as an immediate early gene 
in the striatum, subject to quick alterations in 
translation. There is some precedence for this in the 
literature: Sgpl1 was found in an unbiased screen for 
immediate early genes stimulated by PDGF (Chen, Delrow et 
al. 2004). If Sgpl1 levels are regulated in such a way as 
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to produce rapid changes in translation of the protein, it 
might vary widely between individual animals. 
 To gain insight into the functional consequences of 
these observed changes in sphingolipid levels and 
regulating enzymes, we took a parallel approach to study 
the effects of perturbations in S1P signaling in both in 
vivo and in vitro systems.  For our in vitro studies, we 
chose to use the ST14A cell line. The ST14A cell line 
established in Elena Cattaneo’s lab has been used by 
several groups in the HD community to investigate the role 
of BDNF in HD (Zuccato, Ciammola et al. 2001), to study 
cell death pathways in HD (Wang, Zhu et al. 2003), and for 
pharmacological screens of natural products to protect 
against HD-indued cell death (Varma, Cheng et al. 2007).  
We chose this cell line because it is derived from rat 
embryonic striatum and expresses markers of MSN identity, 
including Map2 and DARPP-32 (Ehrlich, Conti et al. 2001), 
and because it has a measurable acceleration of cell death 
pathways when stably transfected with mhtt (Rigamonti, 
Bauer et al. 2000).  
 We were originally sent a version of this cell line, 
the ST12.7 line, in which mhtt expression is controlled by 
a Tet/on promoter. When exposed to doxycycline, the ST12.7 
cells are induced to express a truncated mhtt construct 
with exon 1 of the gene and 128 CAG repeats.  We performed 
S1P dose response experiments with this line and saw a 
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consistent, modest rescue of ~10% upon temperature shift 
and serum deprivation without doxycycline. This result was 
consistent with many studies that have shown S1P to have 
pro-survival effects in many cell lines (Edsall, Pirianov 
et al. 1997; Olivera, Kohama et al. 1999 2000, Karliner et 
al, 2001).   
 Because the transformation process of immortalized 
cell lines can introduce artifacts in cell behavior, we 
complemented our studies in the ST14A system with a primary 
culture model. The induction of DARPP-32 upon S1P 
stimulation suggests that S1P may promote MSN 
differentiation. Taken together, like many neurotrophic 
factors, such as BDNF, S1P may play a role in MSN survival 
and differentiation. 
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Conclusions and Future Directions 
The brain is composed of hundreds of different 
neuronal cell types, possessing distinct morphologies, gene 
expression profiles, connectivity, and functions. This 
heterogeneity allows for the manifestation of the vast 
array of behaviors of which the brain is capable, but it 
also produces complex disease syndromes when particular 
parts in the machine become damaged. Given the 
extraordinary diversity of cell types in the brain and the 
highly specialized, divergent functions each type has been 
evolutionarily selected to carry out, it is unsurprising 
that these cell types might respond differently to disease.  
Indeed, one of the unifying properties of the many 
neurological disorders that affect the brain is their 
specificity: Parkinson’s Disease affects the substantia 
nigra; ALS damages motor neurons, Alzheimer’s Disease first 
affects the entorhinal cortex.  Indeed, the classical 
definitions of these neurological diseases are based on 
their differing clinical symptoms, which are themselves a 
result of damage to distinct neuronal populations.  
The polyglutamine disorders in general and 
Huntington’s Disease in particular offer an opportunity to 
investigate the molecular mechanisms responsible for 
selective vulnerability in genetically defined systems. HD 
is a monogenic disease of known cause with a well-
characterized and highly specific pattern of neuronal 
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pathology. It is a disease that has been modeled in a wide 
range of systems, from single-celled organisms to primates. 
The mouse models of HD, although imperfect, reproduce many 
of the behavioral aspects of the human disease and 
recapitulate features of human selective vulnerability. 
Until recently, however, the question of selective 
vulnerability of striatopallidal MSNs in HD was severely 
limited by technological constraints.  The complexity and 
heterogeneity of cell types in the brain, which facilitates 
the brain’s rich complement of behaviors and make it 
fascinating to study, obscure changes in one cell type 
within noise from the messages present in surrounding 
types.  Even in the striatum, which is a relatively 
homogeneous brain structure, there are glia, endothelial 
cells, and interneurons, in addition to the presence of the 
two major classes of MSNs, which prevented whole tissue 
studies from identifying many gene changes that could 
specifically be assigned to one cell type or another.  A 
recent study using microarray profiling from whole striatal 
tissues in the YAC128 model was able to identify only a 
handful of changes at the tissue level, and these changes 
could not be attributed to any particular cell type 
(Becanovic, Pouladi et al. 2010).   
The development of the BACTRAP technique allows this 
question of selective vulnerability to be addressed for the 
first time. Among the techniques that allow study of cell-
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type specific messages, such as laser-capture 
microdissection (LCM) and fluorescence-activated cell 
sorting (FACS), TRAP provides the highest sensitivity and 
most faithful reflection of endogenous messages by avoiding 
loss of tissue-intrinsic signals and loss of messages from 
within neurites.  
We have taken the previously characterized D1 and D2 
TRAP lines (Heiman, Schaefer et al. 2008) and applied this 
system to the problem of selective vulnerability in HD.  We 
chose to study HD because it affects MSN function generally 
and striatopallidal MSN biology specifically.  We 
hypothesized that differences in the gene expression 
patterns that characterize these two cell types would 
contribute to their selective vulnerability and that by 
following changes in the translational profiles of these 
cell types over time, we might learn something about the 
underlying basis of their susceptibility. 
To address this question, we chose two HD mouse models 
to study, the R6-2 and YAC128 models.  We chose these 
models because they reflect complementary properties of 
human HD: whereas the R6-2 mouse phenotype is rapid, 
robust, but less specific, the YAC128 phenotype is 
specific, but more protracted. The YAC128 model is often 
thought be the better model of HD, because one of the 
defining characteristics of human HD is its late onset: 
even though mhtt is expressed in development, the nervous 
 129 
system of HD patients seems to develop normally. The 
reasons for the late onset of the disease are not entirely 
known but are thought to relate to the slow build-up over 
time of post-translational modifications to mhtt, including 
phosphorylations, sumoylations, and cleavages that enhance 
or diminish the toxicity of the protein.  These modified 
pieces of mhtt aggregate, which may protect or hurt the 
cell. The end result of this long process may be the 
gradual accumulation of insults that become too much for 
the cell to handle.  The R6-2 transgene, which truncates 
the mhtt protein, may not undergo any of these protective 
modifications.  
Because this experiment introduced a novel transgene 
into the models and because we wished to account for 
differences due to mouse strain and variability between 
laboratories, we re-characterized the behavior of the HD 
TRAP mice.  The R6-2 model exhibited a robust behavioral 
phenotype in both the open field and on the rotarod.  The 
YAC128 model exhibited a variable behavioral phenotype, 
which reached significance at only a very late age.  The 
more variable, milder YAC128 phenotype fits with the model 
that the processing of full-length mhtt is subject to more 
stochastic biochemical modifications, and hence leads to 
more varied disease presentation. It is somewhat surprising 
that deficits in the R6-2 appeared earlier in the open 
field, while the YAC128 model showed earlier deficits on 
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the rotarod.  It is difficult to provide a satisfying 
answer to this question without more careful studies 
mapping the neural circuits required for the rotarod task, 
which might then allow investigation into the differential 
vulnerability of these cell types.  The TRAP technique 
gives us access to cell-type specific translational 
information, but there are very few known behavioral 
outputs that respond to deficits in one particular cell 
type in the mouse: hyperlocomotion in the open field would 
have been one such example, but we did not observe it in 
our experiments. 
We harvested mRNAs separately from both cell types 
first using the original published TRAP protocol and then, 
when it became available, an improved TRAP co-
immunoprecipitation methodology that allowed single-animal 
analysis.  Our results both confirmed pathways, such as 
PPAR signaling and DNA damage responses, which had 
previously been implicated in HD pathology, as well as 
uncovered new pathways and genes, such as sphingosine-1-
phosphate signaling, which may provide new avenues for 
research.  At the pathway level, we did not observe a great 
deal of cell-type specificity: most of the pathways seemed 
specific to the model, rather than the cell-type. However, 
we do observe the preferential loss of D2 MSN markers—at 
the 12 week time point in the R6-2, Drd2, Penk, and Gpr6 
are all decreased by ~2-fold, whereas D1 MSN markers Drd1a 
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and Pdyn are changed only slightly (~1.2 fold down). One 
possible explanation for the loss of D2 markers is that 
mhtt is interfering with the action of a transcription 
factor responsible for coordinating levels of these genes.   
There are a few major conclusions one can make about 
the data.  We began these experiments with the hypothesis 
that gene expression changes opposite in direction in D1 
and D2 MSNs were being lost in studies of transcriptional 
changes in whole striatal tissue.  Our data show that this 
hypothesis was incorrect: the most statistically 
significant gene changes are shared in D1 and D2 MSNs. We 
did, however, identify some gene changes of high 
statistical significance and low magnitude, like Igfbp4, 
that were previously unreported in the literature.  These 
changes may have been obscured by noise from other cell 
types besides MSNs in the tissue.  Future studies might use 
TRAP to profile glia in the striatum, to see whether the 
changes found in this study but not whole tissue are 
reflected by opposing changes in non-neuronal cell types. 
Second, we hypothesized that differences in D1 and D2 MSNs 
could explain the variability observed in most previous 
studies. However, our cell-type specific data also showed 
high variability and gene changes of low magnitude. The 
high variability seems to be a problem intrinsic to the HD 
models themselves. We are in discussions with a 
biostatistician from Yale about trying to account for some 
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of this variability in our data sets by breaking the mice 
into phenotypic sub-groups. 
Interestingly, biochemically, the R6-2 model seems 
better able to recapitulate the differential vulnerability 
of D1 and D2 MSNs.  In this model, the loss of D2 markers 
Gpr6, Adora2a, and Penk all occur before loss of D1 
markers. We also saw this result reflected in the fact that 
at all timepoints tested in the R6-2 model, there were more 
changes in D2 MSNs than D1 MSNs.  Furthermore, in this 
model, we saw the loss of the TRAP transgene selectively in 
D2 MSNs, which was another indication we had that there 
were differential responses of these two cell populations 
to mhtt. Despite these biochemical indications of D2 MSN 
vulnerability, however, we have seen no phenotypic 
hyperkinesis in the R6-2 model that would reflect this 
preferential D2 vulnerability.   
In contrast, the YAC128 model, which we expected to 
have a more cell-specific phenotype given its inclusion of 
mhtt’s full regulatory elements, had fewer changes in D2 
cells compared to D1 cells. In this model we also did not 
see hyperkinesis, but we did eventually see a hypokinesis.  
This result raises the question of whether it is true that 
D2 MSNs are more vulnerable in the YAC128 model.  We 
performed a very thorough behavioral characterization of 
these mice, so it is unlikely that we missed a hyperkinetic 
phenotype, so it may be that these mice are a better model 
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for D1 MSN dysfunction than D2 vulnerability. Thus, we saw 
the opposite pattern from what we expected: the R6-2 model, 
with a less specific transgene, gave a better 
recapitulation of D2 MSN vulnerability than the YAC128 
model.  
There is an ongoing debate in the HD community about 
which of the models best recapitulates human disease.  As 
many others have found as well, we show than neither model 
is perfect.  The R6-2 model has a more robust behavioral 
phenotype, and it displays features of D2 MSN 
vulnerability, but it suffers from a very rapid phenotypic 
progression and a steady expansion of CAG repeats that 
modifies the phenotype in successive generations.  The 
YAC128 model has a more variable behavioral phenotype, but 
it offers a long enough time window to see early 
pathological changes. 
We have performed the most detailed follow-up on a 
significant difference observed in the arrays for the S1P 
pathway. We saw statistically significant decreases in 
striatal S1P levels at early timepoints in the R6-2 model 
by mass spectrometry, and we have some indication that 
levels of sphingolipids are variable in human HD as well. 
We have shown that this decrease in S1P may be caused by 
increases in Sgpl1 expression and decreases in Sphk2 
expression, but these differences were variable. Finally, 
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we have shown that S1P can exert pro-survival effects on a 
striatally-derived cell culture line in vitro.   
We do not know why the levels of Sphk2 and Sgpl1 are 
so variable in MSNs, but one possibility is that the 
observed changes in sphingolipids are being caused by 
changes in expression of these enzymes in coordination with 
other cell types. Endothelial cells are known to express 
high levels of S1P regulating enzymes, so the changes we 
observe in sphingolipids in the striatum may be due to 
regulation by other cell types in the striatum (Lucke and 
Levkau, 2010).  This uncertainty reflects a larger question 
in the sphingosine-1-phosphate field about whether S1P’s 
signaling is primarily autocrine or paracrine in nature. 
Future studies will require TRAP lines in other striatal 
cell types to provide the necessary resolution to parse 
where the changes in sphingolipids are coming from. 
Future Directions 
Short-term 
 There are a number of experiments which will be done 
in the immediate short-term to clarify points of 
uncertainty in the data for publication.  First, the in 
situ hybridization experiments will be repeated with tissue 
that is already available using lower hybridization 
temperatures and lower stringency washes in order to 
amplify signal-to-noise ratios in the assay.  Second, S1P 
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dose-response experiments will be performed in the N548 
cell lines to observe the effect of S1P on rescuing cell 
death in a model where there is a clear acceleration of 
cell-death caused by mhtt. Third, viral injections to 
overexpress and knockdown levels of Sphk2 will be initiated 
in R6-2 mice.  These experiments will be performed with 
Ruth Kulicke, a technician in the laboratory, who is 
proficient in all of the techniques needed to perform these 
experiments. These mice will be analyzed for behavioral 
phenotypes, development of nuclear inclusions, DARPP-32 
expression, and other markers of D1 and D2 MSN identity.  
We will expand our mass spectrometry studies of human 
samples, if we can procure more post-mortem tissue: we are 
currently requesting more tissue.  We will complete our 
more sophisticated microarray analysis, and we will expand 
our preliminary screen of robust gene changes in N548 cells 
to include some of the changes seen in pathway analysis. 
Longer-term 
 Taking the long view of the experiments presented 
here, there are a number of possible directions to take 
future work.   
Development of a cell-type specific in vitro system 
 One of the challenges posed by the exciting wealth of 
data afforded by the BACTRAP technique is how to 
investigate the functional relevance of the gene candidates 
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identified by the screen.  The establishment of 
immortalized in vitro systems that reflected D1 or D2 MSN 
properties would allow for high-throughput functional 
analysis of the gene changes observed in vivo. Stephen 
Finkbeiner’s group at UCSF has had success in developing in 
vitro primary cultures from D1 and D2 BAC GFP mice (Miller 
et al., 2010), but these cultures are not immortalized, and 
therefore cannot be used for high throughput studies.  
 A potential approach toward solving this problem would 
be to find a protocol to differentiate embryonic stem cells 
into D1 or D2 MSNs. Currently, the transcription factors 
needed to create D1 or D2 MSN identity are unknown; 
however, these genes are most likely those that are 
differentially expressed at high levels in these two cell 
populations. In fact, a number of the genes that are most 
divergent in their expression patterns between these two 
cell types are transcription factors: we could employ an 
approach like the one used by Shinya Yamanaka to identify 
factors to restore pluripotency to determine which 
transcription factors are necessary and sufficient to 
confer D1 and/or D2 identity. We could then use this model 
system to screen the gene changes from the TRAP analysis 
for survival and the expression of cell-specific identity 
traits. 
Mapping loci of modifier genetic mouse strain differences  
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 There is a very clear effect of mouse strain on 
phenotype in both of these models. In particular, the 
C57Bl/6 background seems to afford protection against 
pathology in both models.  One possible future project 
would be to attempt to map genetic loci that could explain 
these differences in strain background.  One could then 
take these candidate loci and compare them to modifier 
effects of age of onset from human HD patients.  These 
studies could also be complemented with more careful 
clinical analysis of patients to see whether any of the 
effects could be correlated with specificity of disease 
presentation. 
Development of techniques to investigate cell-type specific 
post-translational modifications 
 There is considerable evidence that mhtt exerts many 
toxic cellular effects at the post-translational level and 
that mhtt itself can be post-translationally modified in 
ways that affect its toxicity (Morfini, Burns et al. 2009; 
Subramaniam, Sixt et al. 2009; Thompson, Aiken et al. 
2009). One of the limitations of the BACTRAP approach is 
that it cannot help identify these post-translational 
effects.  While there are approaches for studying the cell-
type specific post-translational modifications of 
particular proteins, such as the work of Helen Bateup, a 
former graduate student in the Greengard Lab who pioneered 
an approach for studying the phosphorylation state of 
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DARRP-32 selectively in D1 or D2 MSNs, current methods for 
analyzing all post-translational modifications in an 
unbiased fashion do not provide cell-type specific 
information. 
 To begin to address this question, one could use the 
protocol developed in Kriaucionis et al. to sort nuclei 
from HD/BACTRAP animals and perform mass spectrometry upon 
proteins found in the nuclei of D1 and D2 MSNs (Kriaucionis 
et al, 2009).  This study would allow a comprehensive 
analysis of post-translational modifications that occur in 
nuclear proteins. It would also allow the identification of 
any differences in the composition of nuclear inclusions 
that may exist between these two cell populations. This 
study is immediately feasible, as members of our laboratory 
and the Heintz laboratory are currently using this 
technique to identify baseline differences in DARPP-32 
phosphorylation in D1 and D2 MSNs and changes in response 
to psychostimulants.  
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Materials and Methods 
All procedures involving animals were performed in 
accordance with the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals and were approved by 
The Rockefeller University Institutional Animal Care and 
Use Committee. 
Behavioral Analysis 
Open Field Test 
 Mice were brought into the behavioral testing room at 
least 30 minutes before beginning of the test. Open field 
testing was conducted using the AccuScan activity 
monitoring system (AccuScan Instruments; Columbus, Ohio). 
The arenas were each 40 cm x 40 cm x 30 cm and made from 
clear Plexiglass. Light in the room was measured with a 
luminometer and maintained between 100 and 200 Lux, tested 
in 5 points in each arena so that light was evenly 
distributed across arenas +/- 10 Lux. Before each round of 
testing, arenas were disinfected with Clidox for 5 minutes 
and washed twice with distilled water.  
 The mice were tested in groups of 8 in identical home 
cage environments. Each testing session lasted one hour, 
during which mouse activity was quantified through breaks 
in a grid of infrared beams. Activity was analyzed for 
total activity and grouped into 10 minute bins for analysis 
of habituation to the novel environment.  
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Rotarod Test 
 Mouse balance and motor function were tested with a 
standard accelerating rotarod test protocol in which the 
rotarod speeds from 4 rpm to 40 rpm over a period of 5 
minutes (Med Associates St. Albans, Vermont). Mice were 
trained on the machine on the first day with three 
successive trials, during which they were continually 
placed onto the rotarod if they fell off, until 100 seconds 
had passed. These three training runs were followed by a 
rest interval of at least 2 hours before the first day 
test.  Mice were tested on consecutive days with three 
trials of the accelerated protocol on each day. The time it 
took for the mouse to fall off the bar (latency to fall) 
was recorded in seconds. If a mouse clung passively to the 
rod for two consecutive rotations without moving, it was 
scored as a fall. 
CAG repeat analysis 
1 cm tail-clips of mice were immediately placed upon biopsy 
in 200 ul Direct Lysis reagent (Viagen Biotech) with a 1:50 
dilution of Proteinase K (Viagen Biotech). Tail samples 
were incubated overnight at 55 °C. Samples were vortexed 
thoroughly to ensure complete disgestion of the tissue and 
then centrifuged and heat-inactivated for 45 minutes at 85 
°C. 100 ul of the lysate were sent to Laragen Inc. for 
analysis. 
 141 
Immunoprecipitation of mRNA 
 For pooled-animal IPs, purifications were performed as 
described in Heiman et al., 2008. 
For single-animal IPs, mice were anesthetized with CO2, 
decapitated, and striata were quickly dissected. Tissue was 
immediately homogenized 12 times at 900 rpm in ice-cold 
polysome extraction buffer (10 mM HEPES [pH 7.4]. 150 mM 
KCl, 5 mM MgCl2, 0.5 mM dithiothreitol, 100 ug/mL 
cycloheximide, protease inhibitors, and recombinant RNase 
inhibitors) with a motor-driven Teflon glass homogenizer 
(Lab Stirrer LT-400, Yamato-USA, Santa Clara, CA). 
Homogenates were centrifuged for 10 minutes at 2000 x g, 4 
C to pellet large cell debris, and NP-40 (EMD Biosciences, 
San Diego, CA) and 1,2-Diheptanoyl-sn-Glycero-3-
Phosphocholine (DHPC, Avanti Polar Lipids, Alabaster, AL) 
were added to the supernatant at a final concentration of 
1% and 30 mM, respectively.  After incubation on ice for 5 
minutes, samples were centrifuged for 10 minutes at 20,000 
x g, 4 C. Supernatant was added to Streptavidin MyOne T1 
magnetic beads (Invitrogen, Carlsbad, CA), which were 
coupled to biotinylated Protein L (Pierce, Rockford, IL) 
and anti-GFP antibody (custom-made).  Beads were prepared 
as follows: beads were resuspended, aliquoted 300 ul per IP 
and washed once with PBS. Biotinylated Protein L (Pierce # 
29997) was resuspended to a concentration of 1 ug/ul in PBS 
and was added to beads, 120 ul per IP.  Tubes were 
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incubated for 35 minutes at room temperature with end-over-
end mixing.  Beads were collected on a magnetic rack and 
blocked by washing 5 times with 3% BSA (w/v; Jackson 
Immunoresearch, West Grove, PA). Beads were then 
resuspended in low salt wash buffer (20 mM HEPES, 150 mM 
KCl, 5 mM MgCl2, 1% NP-40) and incubated with mouse 
monoclonal anti-GFP antibody for 1 hour. After antibody-
binding, beads were washed three times with low-salt wash 
buffer, resuspended in 100 ul low-salt wash buffer per IP 
and then added to samples as described above.  
Beads and samples were incubated at 4 °C for 18 hours 
with end-over-end mixing. Tubes were centrifuged briefly to 
collect beads, and beads were washed 4 times with high-salt 
wash buffer, containing 350 mM KCl. Beads were resuspended 
in lysis buffer from the Absolutely RNA Nanoprep kit from 
Agilent (Santa Clara, CA), incubated for 5 minutes at room 
temperature, and then lysis buffer containing the eluted 
RNA was removed from beads. RNA was processed according to 
the Nanoprep kit protocol. RNA quantity was measured using 
Quant-it RiboGreen reagent (Invitrogen, Carlsbad, CA) and 
quality was measured with a Bioanalyzer (Agilent, Santa 
Clara, CA).  
 
Gene Expression Analysis 
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 Purified mRNAs were amplified with either the 
Affymetrix Two-Cycle cDNA synthesis kit (Affymetrix, Santa 
Clara, CA) or NuGen WT-Ovation Pico kit (NuGen, San Carlos, 
CA) according to the manufacturer’s instructions.  
Amplified cDNA was hybridized to Affymetrix Mouse Genome 
430 2.0 microarrays and scanned at The Rockefeller 
University Genomics Center. 
 Microarray .CEL files were imported into the 
GeneSpring GX software. RMA normalization was performed on 
the data and genes were normalized to that chips 50th 
percentile. Quality control analysis was performed by 
calculating Pearson correlation coefficients for replicate 
arrays and by performing Principal Components Analysis to 
scan for outlier gene chips. Data were filtered to select 
genes with expression levels above the 20th percentile.  
Genes were then filtered using a volcano plot analysis with 
a student’s unpaired t-test. Fold change value was set at 
1.5 and a significance level of p<.05 was selected.  For 
Venn diagram plots, data were reanalyzed with equal sample 
sizes. Gene ontology analysis was performed on these lists 
within GeneSpring.  Lists were also exported and analyzed 
using Ingenuity Pathway Analysis. 
Quantitative PCR 
 Quantitative PCR was performed using cDNA amplified 
from NuGen WT-Ovation kit. Reaction were performed with 20 
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ng of cDNA in triplicate or quadruplicate. The Taqman Gene 
Expression assays used included: Eif4a2 Mm01343573_gH, 
Sphk2 Mm00445020_m1,  Actb Mm00607939_s1, Sgpl1 
Mm01149898_m1, Sphk1 Mm00448841_g1, Mm01252544_m1, GPR6 
Mm01701705_s1, Tmem183a Mm00508045_m1, Pea15a 
Mm01293295_m1, Rprm Mm00469773_s1, B3gat1 Mm00661499_m1, 
Thtpa Mm00462068_m1, Agfg2 Mm00523929_m1, Igfbp4 
Mm00494922_m1, Sox11 Mm01281943_s1, Gpr56 Mm00457581_m1, 
Bcl11a Mm00479358_m1, Anxa5 Mm00477537_m1, Mrpl13 
Mm00452782_m1, Mrpl22 Mm00838506_g1, Hexb Mm00599880_m1, 
Spata5 Mm00502400_m1, Pcdh20 Mm00724499_m1, Mgst1 
Mm00498294_m1, Jun Mm00495062_s1, Phyh Mm00477734_m1, Pkp2 
Mm00503159_m1, WT1 Mm00460570_m1, Ppp1r9a Mm00725102_m1, 
Actn2 Mm00473657_m1, Mapkbp1 Mm00522025_m1, Lsm10 
Mm00522588_m1, trnamt6 Mm01278146_m1, tbc1d24 
Mm00557451_m1, Ntrk3 Mm00456222_m1, Fxc1 Mm00727252_s1, 
Igfbp5 Mm00516037_m1, Mtap1a Mm01330378_m1 
Immunohistochemistry and immunofluorescence 
 IHC and IF were performed as described in (Heiman, 
Schaefer et al. 2008) with the following antibodies: Abcam 
Chicken anti-GFP (ab13970) 1:1000, Abcam Rabbit anti Map2 
ab32454 1:200; Cell Signaling Rabbit anti-DARPP-32 1:1000; 
Abcam Rabbit anti PPARalpha ab8934 1:1000; Cosmo Bio Mouse 
anti-S1P 1:100; Santa Cruz Goat anti IGFBP4 1:100; Abcam 
Sheep anti-prealbumin (transthyretin) ab9015 1:1000; Abcam 
mouse anti-desmoplakin ab16434 1:100; Novozymes Rabbit anti 
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Igfbp4 1:250; Santa Cruz goat anti Sph2 1:100; Abcam rabbit 
anti-Sphk2 ab37978 1:100; Millipore anti-NeuN; Millipore 
anti-htt EM48 ; Abcam Rabbit anti-Sox11 1:1000; Abcam anti-
WT1 ab96792 1:200; Origene rabbit anti-Actn2 1:100  
Mass Spectrometric Analysis 
 Mice were stunned with CO2 and immediately decapitated. 
Striata or cerebella were quickly dissected and placed into 
cell lysis buffer ((10 mM HEPES [pH 7.4]. 150 mM KCl, 5 mM 
MgCl2). Tissue was homogenized as above and then sonicated 
with 2 x 15 sec pulses.  A 50 ul aliquot of homogenate was 
saved for BCA analysis, which was performed with Pierce BCA 
detection kit.  Samples were immediately frozen in liquid 
nitrogen and stored at -80 C, until they were shipped on 
dry ice to Avanti Polar Lipids. Samples were coded so that 
analysis was performed in a blind fashion. Extraction and 
LC/MS/MS analysis were performed according to protocol in 
Merrill et al.  2005, with optimization by Dr. Jeff Moore. 
 Human samples were provided by the New York Brain 
Bank, and the study was approved as being exempt from IRB 
regulation. 
Cell Culture  
 ST12.7, ST14A, and N548 were provided by the Cattaneo 
lab. Cells were grown in DMEM + 10% FBS (Sigma-Aldrich, 
heat inactivated), and 1X penicillin/streptomycin/glutamine 
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and split every 2-3 days.  For S1P experiments, cells were 
plated at density of 30,000 cells/well in a 24 well dish. 
They were left to grow overnight, and then washed two times 
in serum-free media (DMEM + F12 supplement +N2 supplement) 
and then left in serum-free media with S1P diluted at test 
concentrations. Fatty-acid free BSA (4 mg/mL), which is 
used as a carrier to dilute S1P, was used as control. Cells 
were transferred to 39 °C, where they were allowed to grow 
for 24 hours. Media was then harvested for Promega lactate 
dehydrogenase (LDH) assay. Fresh media was added to the 
cells, which were then lysed at -80 °C for at least 30 
minutes and used for LDH kit to control for total cell 
numbers.  Cell toxicity represents fraction of released LDH 
over total LDH in the sample. 
Primary Culture 
 Pregnant C57Bl/6 females were ordered from Charles 
River. At embryonic day E15-E17, a dam was sacrificed, the 
uterus was removed, and embryos quickly dissected into PBS 
+ 0.6% glucose (filtered sterilized). Striata from embryos 
were dissected and treated with trypsin for 30 minutes.  
Trypsin was inactivated by adding Neurobasal medium + 10% 
FBS and DNase was added. Cells were triturated using a 
P1000 pipette tip until no tissue clumps remained.  Cells 
were pelleted and resuspended in DMEM +10% FBS, + 
penicillin-streptomycin-glutamine and counted.  Cells were 
then plated on wells at density of 500,000 cells/well in a 
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24-well-dish with coverslips that had been coated with 
polyornithine.  Cells were grown at 37 C +10% CO2 for 2 
hours. After attaching, cells were washed 2 x with 
neurobasal media and fresh neurobasal medium with S1P and 
BDNF were applied. Cells were grown for 7 days in vitro, 
changing media every other day.  On final day, NuPage 
sample buffer was applied directly to wells. 
Western Blots 
 Protein lysates were prepared in 1X NuPage Sample 
Buffer with 100 mM DTT. Samples were heated to 70 C for 5 
minutes and then centrifuged at maximum speed for 1 minute 
to pellet debris. Samples were loaded onto NuPage 4-12% 
Bis-Tris gels and run at 120 mV for 1.5 hours.  Proteins 
were transferred for 2 hours at 30 mV onto PVDF membranes 
that had been activated with 1 methanol wash for 30 
seconds, followed by 3 washes with PBS, and a 5 minute 
incubation in 1X NuPage Transfer Buffer. After transfer, 
membranes were allowed to dry completely and then were re-
activated with a 30 second methanol wash, followed by 3 x 5 
min PBS washes.  Membranes were blocked with 10% non-fat 
evaporated milk dissolved in PBS-T, and then incubated 
overnight at 4 °C with rabbit anti-DARPP-32 antibody (Cell 
Signaling) dissolved in blocking buffer 1:1000.  Membranes 
were washed 3 x 10 minutes with PBS-T and then incubated in 
HRP-coupled secondary antibody for 1 hour.  Membranes were 
washed 3 x in PBS-T, then once in PBS and developed using 
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Western Lightning Detection method. Membranes were exposed 
to film, and bands were quantified using Image J software. 
In situ Hybridization 
 6-week-old R6-2 mice and WT littermates from Jackson 
laboratory were stunned with CO2 and decapitated. Brains 
were rapidly dissected and placed on dry ice for 30 
minutes, before storing at -80°C. Brains were cut on a 
cryostat in 12 uM sagittal sections.  Slides were fixed for 
15 minutes in 4% paraformaldehyde at 4 °C.  Slices on slides 
were washed 1 min in 1XPBS, then for 1 min in 0.1 M 
triethanolamine (TEA). Sections were aceylated for 15 
minutes in 0.1M TEA + .25% acetic anhydride. Sections were 
washed 2 X 2 min in 2X SSC, then washed in 30%, 75%, and 
100% ethanol, each for 2 minutes. Sections were air-dried 
for 20 minutes and then incubated 1 hour in 
prehybridization buffer (50% formamide/5XSSC/5X Denhart’s 
solution/250 ug/mL yeast RNA/500 u/mL sonicated DNA).  The 
hybridization solution was heated 15 minutes at 80 °C, RNA 
probes were added, and the mixture was then heated an 
additional 5 minutes at 80°C. Hybridization buffer with 
probes was applied to sections and slides were incubated 
overnight at 58 °C Slides were washed in 5X SSC for 30 
minutes at 65 °C and then washed twice for 20 minutes each 
in 2X SSC/50% formamide. Slides were washed in 2XSSC, 0.2X 
SSC, and 0.1X SSC and then 2 times in PBS. Slides were then 
incubated 30 minutes in 0.2% H202. Slides were washed 2 x 10 
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minutes in PBS, 1 x 10 min in PBS-T and blocked for 1 hour 
in PBS-T + 2% heat-inactivated donkey serum + 0.1% fish 
gelatin.  Slides were incubated at 4 C overnight with Roche 
mouse-anti-DIG at 1:250. Slides were washed 3 x 10 minutes 
in PBST and then incubated with mouse Superpicture reagent 
(Invitrogen) for 2 hours at room temperature. Slides were 
washed 3 x in PBS-T for 10 minutes and then incubated with 
Tyramide –AlexaFluor 546 for 10 minutes (Invitrogen). 
Slides were washed 3 x 10 minutes in PBST and mounted with 
ProLong Gold Anti-fade. 
 
 
 
Appendix	  I:	  GO	  analysis	  R6-­2	  3	  wk	  D2	  
GO Term Ontology p value 
Adjusted 
p value 
Total 
genes in 
GO 
class Genes present 
RNA 
metabolic 
process BP 3.13E-06 0.011 647 
Sart3, Cpeb1, Trdmt1, LOC639633 /// Npm3 /// Npm3-ps1, Ddx41, 
Cugbp1, LOC433064 /// Ppih, Hnrpdl, Cpsf4, Tcof1, Cugbp1, Trp53, 
Dicer1, Prpf39, Elac2, Aqr, Aqr, Bxdc5, Exosc10, Adarb1, Tfb1m, Sfrs7, 
Trmt1, Eif4g1, Plrg1, Hars2, Smad3, Gemin8, Nova1, Rbm22, Sf3a2, 
Tardbp, Exosc8, Smg1, Trmt6, Gemin5, Mettl1, Tdrd3, Lcor, Sf3a1, Hif3a, 
Mettl1, Elac1, Zfc3h1, Zhx2, Utp23, Dgcr8, Ppwd1 
RNA 
processing BP 3.98E-06 0.012 466 
Sart3, Cpeb1, Trdmt1, LOC639633 /// Npm3 /// Npm3-ps1, Ddx41, 
Cugbp1, LOC433064 /// Ppih, Cpsf4, Cugbp1, Dicer1, Prpf39, Elac2, Aqr, 
Aqr, Bxdc5, Exosc10, Adarb1, Tfb1m, Sfrs7, Trmt1, Plrg1, Gemin8, Nova1, 
Rbm22, Sf3a2, Tardbp, Exosc8, Trmt6, Gemin5, Mettl1, Tdrd3, Sf3a1, 
Mettl1, Elac1, Zfc3h1, Utp23, Dgcr8, Ppwd1 
biopolymer 
metabolic 
process BP 8.97E-07 0.006 2988 
Mcm5, Aurkaip1, Mcm6, Ptprn, Ube3a, Gys1, Tyk2, Sart3, Cpeb1, Ufd1l, 
Csnk1d, Acvr2b, Stk39, Trdmt1, Cul2, Suz12, Gbe1, B3gnt2, Traf6, Wsb2, 
Nr3c1, Pdgfra, Mapk11, Uty, Xpc, Stk17b, Riok2, LOC639633 /// Npm3 /// 
Npm3-ps1, Ddx41, Cugbp1, Suv420h2, LOC433064 /// Ppih, Hnrpdl, 
Cpsf4, Tcof1, Hemk1, Ube3a, Polb, Mark1, Nmnat1, Hltf, Mlh3, Park2, Ryk, 
Cugbp1, Trp53, Ptprz1, Mdm2, EG665955, LOC100045866 /// Tceb1, 
Dicer1, Prpf39, Elac2, Cand1, Fbxo45, Otud7b, Aqr, Aqr, Agk, Uba3, 
Bxdc5, Exosc10, Mul1, Tbl1x, Adarb1, Parp1, LOC100048362 /// Rimklb, 
Tfb1m, Sfrs7, Trmt1, Mcm7, Eif4g1, Mcm7, Rlim, Plrg1, Irak1, Ube2j1, 
Afg3l1, Eif2ak3 /// LOC100047634, Hars2, Grk5, Suz12, Ptprt, Lnx1, 
Smad3, C1galt1, Kat2b, Prkx, Pomt2, Gemin8, Setdb1, Nova1, 
0610007P08Rik, Kdm5d, Zdhhc2, Rbm22, Cad, 2810408M09Rik, Vrk2, 
BC057552, Dusp11, Sf3a2, Tardbp, Nsmce1, Pxn, Ndst1, Irak1, Exosc8, 
B3galt5, Smg1, Senp5, Fem1c, Ttll4, Senp7, Cdyl2, Trmt6, Stk32b, Cbx7, 
Mapk4, Ccdc88a, Gemin5, Rtel1, Bmpr1b, Rrm2b, Ntrk2, Ipmk, Mettl1, 
Map3k5, March1, Med12l, Socs2, Tdrd3, Ercc1, B230120H23Rik, Tbl1xr1, 
Lcor, Rad51l3, Pak6, Sf3a1, Hif3a, Mettl1, Spop, Usp15, Fbxl20, Cdc2l5, 
Elac1, Ep400, Zfc3h1, Zhx2, Utp23, Dgcr8, Zdhhc17, Cdkl3, Ssh2, Ppwd1, 
LOC100046241 /// Tlk1, Tnks, Ttll10 
intracellular 
membrane-
bound 
organelle CC 1.26E-05 0.031 7500 
Mcm5, Klf10, Sec61a1, Aurkaip1, Mcm6, Ap3m1, Mrpl4, Eif3a, Ube3a, 
Sigmar1, Cpt2, Tia1, Cisd1, Bet1, Nt5c, Plekha2, Sorbs1, S100a1, Sart3, 
Sfxn1, Sdc4, Zfp35, Ndst2, Hmgxb3, Ufd1l, Lhx2, Wdr33, Mtx1, Etv3, 
Rfxap, Bcl10, Invs, Stk39, Tmem9, Trdmt1, Hdgf, Suz12, Myh9, Phf7, 
B3gnt2, Hccs, Mef2c, Vps25, Zbtb33, Myo7a, Zfp318, Tmem49, Acer2, 
Txnrd1, Sytl2, Nr3c1, Elk1, Mrpl19, LOC100045442 /// Stag1, Ccdc123, 
Pex5, Khdrbs2, Uty, Chrac1, Ccnf, Xpc, Yy1, Dgat2, Gyk, Sypl, Sfmbt1, 
Sc4mol, Tomm20, Npc1, Gnpnat1, Pole4, Plbd2, Stk17b, LOC100048299 
/// Max, LOC639633 /// Npm3 /// Npm3-ps1, Ddx41, Cugbp1, Suv420h2, 
LOC433064 /// Ppih, Hnrpdl, Pet112l, Gart, Cpsf4, Tmem70, Tcof1, Cux1, 
Tmed10, Zkscan5, Sox10, Zfp472, Ddx19a /// Ddx19b, Ube3a, Mllt6, Polb, 
Nmnat1, B4galt4, Hltf, Mlh3, Park2, Scmh1, B4galt7, Far1, Cugbp1, 
Tmem43, Trp53, Me2, Acbd3, Apbb2, Rpap1, Mtmr7, Smo, Ascc2, Ryr1, 
Mdm2, LOC100045866 /// Tceb1, Dicer1, Pcgf1, Prpf39, Elac2, Mrpl41, 
Cand1, Cytsb, Mapre1, Otud7b, Klf3 /// LOC100046855, Aqr, Aqr, Mbtps1, 
Ica1, Agk, 9030409G11Rik, Bxdc5, Exosc10, Rab3c, Nup54, Fubp1, Mul1, 
Zfp574, Tbl2, Agpat5, Crebzf, Tbl1x, Sema5a, Adarb1, Pip5k1a, Tom1, 
Id2, Baz2b, Parp1, Bcl2l11, 2310008H09Rik, Tfb1m, Mrpl13, Mrpl22, 
Sfrs7, Rab2b, Lpp, Serinc1, Cux1, Mcm7, Timm17b, Son, Mcm7, Bach1, 
Plrg1, Tpp1, Timm22, Cox4nb, Mcm3ap, Ciz1, Ube2j1, Afg3l1, Zfp148, 
Eif2ak3 /// LOC100047634, Eps15l1, Hars2, Zfx, Suz12, Commd5, Nkx3-1, 
Ngfr, Tef, Kif5a /// Kif5c, Lnx1, Smad3, Chst11, Surf1, Smpd3, Kat2b, 
Synpo2, Gadd45b, Oxa1l, Zscan12, Vps36, Ergic2, Pex26, Pomt2, Gemin8, 
Nop16, Zfp451, Setdb1, Agfg1, Nova1, Phf20, Med26, 0610007P08Rik, 
Kdm5d, Rab2b, Rbm22, Cad, 2810408M09Rik, 0610038F07Rik, Vrk2, 
Nr2c2, Wasf2, LOC100047324 /// Sesn1, Dusp11, AU021838, Sf3a2, 
Tardbp, Unc45a, Nsmce1, Fuca1, Agxt2l2, Syn2, Ppp4c, Tm9sf2, Mrpl13, 
Ccdc117, Ndst1, Ap2a1, Ing4, Exosc8, Ip6k2, B3galt5, Smg1, Senp5, Ttll4, 
Hexim2 /// LOC100044959, Cdyl2, Trmt6, Rabl2a, Cbx7, Zfp367, Hspa13, 
Pknox2, Gtpbp10, Epm2aip1, Csrnp1, Bbs4, Zfp715, Ebf4, Arl4a, Taf5, 
Mrps5, Ikbkg, Optn, Pphln1, 5730455O13Rik, Ccdc88a, Nfkbid, Pcyt1b, 
Nmnat2, Gemin5, Rtel1, Mbtps2, Mex3b, Rrm2b, 5430432N15Rik, Ipmk, 
Zfp799, Npas3, Ddx11, Mllt10, Sept10, Mettl1, Zfp827, Zfp708, Klf12, 
4933407N01Rik, Atxn3, Rora, Med12l, Zfp39, Tdrd3, Ercc1, 
B230120H23Rik, Tbl1xr1, Mga, Zfp827, BC031441, Lcor, Dgkd, Rad51l3, 
2700050L05Rik, Yipf5, Pdia3, Sf3a1, Hif3a, Mettl1, Ripply2, Spop, Spred1, 
Elac1, Ep400, 5730507C01Rik, Rabgap1l, Ccnt2, Cgrrf1, 1110020G09Rik, 
2810002N01Rik, Gmeb2, Zfc3h1, Zhx2, Utp23, Dgcr8, Zdhhc17, Cdkl3, 
Adamts5 /// LOC100048332, LOC100046241 /// Tlk1, Tmem38b, Rbm12, 
Tia1, 4930422I07Rik, Mtdh, Tmed5, Nup54, Tnks, Zfp592 
kinase 
activity MF 1.70E-05 0.036 830 
Aurkaip1, Tyk2, Csnk1d, Mpp3, Acvr2b, Stk39, Pdgfra, Mapk11, Gyk, 
Stk17b, Riok2, Rbks, Mark1, Crk, Ryk, Fastkd1, Dscaml1, Pip5kl1, Agk, 
Etnk1, Pip5k1a, 2010111I01Rik, Irak1, Nrp1, Akap2, Eif2ak3 /// 
LOC100047634, Grk5, Pip5k1c, Prkx, Cad, 2810408M09Rik, Vrk2, 
AU021838, Ppp4c, Irak1, Ip6k2, Smg1, Stk32b, Mapk4, Ikbkg, Kcnh1, 
Bmpr1b, Ntrk2, Ipmk, Dgke, Map3k5, Med12l, B230120H23Rik, Dgkd, 
Pak6, Cdc2l5, 1110020G09Rik, Sephs1, Cdkl3, LOC100046241 /// Tlk1 
membrane-
bound 
organelle CC 1.31E-05 0.031 7503 
Mcm5, Klf10, Sec61a1, Aurkaip1, Mcm6, Ap3m1, Mrpl4, Eif3a, Ube3a, 
Sigmar1, Cpt2, Tia1, Cisd1, Bet1, Nt5c, Plekha2, Sorbs1, S100a1, Sart3, 
Sfxn1, Sdc4, Zfp35, Ndst2, Hmgxb3, Ufd1l, Lhx2, Wdr33, Mtx1, Etv3, 
Rfxap, Bcl10, Invs, Stk39, Tmem9, Trdmt1, Hdgf, Suz12, Myh9, Phf7, 
B3gnt2, Hccs, Mef2c, Vps25, Zbtb33, Myo7a, Zfp318, Tmem49, Acer2, 
Txnrd1, Sytl2, Nr3c1, Elk1, Mrpl19, LOC100045442 /// Stag1, Ccdc123, 
Pex5, Khdrbs2, Uty, Chrac1, Ccnf, Xpc, Yy1, Dgat2, Gyk, Sypl, Sfmbt1, 
Sc4mol, Tomm20, Npc1, Gnpnat1, Pole4, Plbd2, Stk17b, LOC100048299 
/// Max, LOC639633 /// Npm3 /// Npm3-ps1, Ddx41, Cugbp1, Suv420h2, 
LOC433064 /// Ppih, Hnrpdl, Pet112l, Gart, Cpsf4, Tmem70, Tcof1, Cux1, 
Tmed10, Zkscan5, Sox10, Zfp472, Ddx19a /// Ddx19b, Ube3a, Mllt6, Polb, 
Nmnat1, B4galt4, Hltf, Mlh3, Park2, Scmh1, B4galt7, Far1, Cugbp1, 
Tmem43, Trp53, Me2, Acbd3, Apbb2, Rpap1, Mtmr7, Smo, Ascc2, Ryr1, 
Mdm2, LOC100045866 /// Tceb1, Dicer1, Pcgf1, Prpf39, Elac2, Mrpl41, 
Cand1, Cytsb, Mapre1, Otud7b, Klf3 /// LOC100046855, Aqr, Aqr, Mbtps1, 
Ica1, Agk, 9030409G11Rik, Bxdc5, Exosc10, Rab3c, Nup54, Fubp1, Mul1, 
Zfp574, Tbl2, Agpat5, Crebzf, Tbl1x, Sema5a, Adarb1, Pip5k1a, Tom1, 
Id2, Baz2b, Parp1, Bcl2l11, 2310008H09Rik, Tfb1m, Mrpl13, Mrpl22, 
Sfrs7, Rab2b, Lpp, Serinc1, Cux1, Mcm7, Timm17b, Son, Mcm7, Bach1, 
Plrg1, Tpp1, Timm22, Cox4nb, Mcm3ap, Ciz1, Ube2j1, Afg3l1, Zfp148, 
Eif2ak3 /// LOC100047634, Eps15l1, Hars2, Zfx, Suz12, Commd5, Nkx3-1, 
Ngfr, Tef, Kif5a /// Kif5c, Lnx1, Smad3, Chst11, Surf1, Smpd3, Kat2b, 
Synpo2, Gadd45b, Oxa1l, Zscan12, Vps36, Ergic2, Pex26, Pomt2, Gemin8, 
Nop16, Zfp451, Setdb1, Agfg1, Nova1, Phf20, Med26, 0610007P08Rik, 
Kdm5d, Rab2b, Rbm22, Cad, 2810408M09Rik, 0610038F07Rik, Vrk2, 
Nr2c2, Wasf2, LOC100047324 /// Sesn1, Dusp11, AU021838, Sf3a2, 
Tardbp, Unc45a, Nsmce1, Fuca1, Agxt2l2, Syn2, Ppp4c, Tm9sf2, Mrpl13, 
Ccdc117, Ndst1, Ap2a1, Ing4, Exosc8, Ip6k2, B3galt5, Smg1, Senp5, Ttll4, 
Hexim2 /// LOC100044959, Cdyl2, Trmt6, Rabl2a, Cbx7, Zfp367, Hspa13, 
Pknox2, Gtpbp10, Epm2aip1, Csrnp1, Bbs4, Zfp715, Ebf4, Arl4a, Taf5, 
Mrps5, Ikbkg, Optn, Pphln1, 5730455O13Rik, Ccdc88a, Nfkbid, Pcyt1b, 
Nmnat2, Gemin5, Rtel1, Mbtps2, Mex3b, Rrm2b, 5430432N15Rik, Ipmk, 
Zfp799, Npas3, Ddx11, Mllt10, Sept10, Mettl1, Zfp827, Zfp708, Klf12, 
4933407N01Rik, Atxn3, Rora, Med12l, Zfp39, Tdrd3, Ercc1, 
B230120H23Rik, Tbl1xr1, Mga, Zfp827, BC031441, Lcor, Dgkd, Rad51l3, 
2700050L05Rik, Yipf5, Pdia3, Sf3a1, Hif3a, Mettl1, Ripply2, Spop, Spred1, 
Elac1, Ep400, 5730507C01Rik, Rabgap1l, Ccnt2, Cgrrf1, 1110020G09Rik, 
2810002N01Rik, Gmeb2, Zfc3h1, Zhx2, Utp23, Dgcr8, Zdhhc17, Cdkl3, 
Adamts5 /// LOC100048332, LOC100046241 /// Tlk1, Tmem38b, Rbm12, 
Tia1, 4930422I07Rik, Mtdh, Tmed5, Nup54, Tnks, Zfp592 
nucleobase, 
nucleoside, 
nucleotide 
and nucleic 
acid 
metabolic 
process CC 1.64E-06 0.007 3089 
Impdh2, Mcm5, Klf10, Mcm6, Atp6v0e, Nt5c, Sart3, Zfp35, Cpeb1, Lhx2, 
Etv3, Trdmt1, Hdgf, Suz12, Mef2c, Vps25, Zbtb33, Zfp318, Nr3c1, Elk1, 
Khdrbs2, Uty, Xpc, Yy1, Gnpnat1, LOC100048299 /// Max, LOC639633 /// 
Npm3 /// Npm3-ps1, Ddx41, Cugbp1, Suv420h2, LOC433064 /// Ppih, 
Hnrpdl, Gart, Cpsf4, Tcof1, Cux1, Zkscan5, Sox10, Zfp472, Polb, Nmnat1, 
Hltf, Mlh3, Scmh1, Cugbp1, Trp53, Rpap1, Ascc2, Dscaml1, EG665955, 
LOC100045866 /// Tceb1, Dicer1, Pcgf1, Prpf39, St5, Elac2, Cand1, Klf3 
/// LOC100046855, Aqr, Aqr, Bxdc5, Exosc10, Fubp1, Zfp574, Crebzf, 
Tbl1x, Adarb1, Parp1, Tfb1m, Sfrs7, Trmt1, Cux1, Mcm7, Eif4g1, Mcm7, 
Rlim, Bach1, Plrg1, Zfp148, Hars2, Zfx, Suz12, Nkx3-1, Tef, Smad3, 
Kat2b, Zscan12, Vps36, Gemin8, Zfp451, Setdb1, Nova1, Phf20, Med26, 
0610007P08Rik, Kdm5d, Rbm22, Cad, Nr2c2, AU021838, Sf3a2, Tardbp, 
Nsmce1, Exosc8, Smg1, Hexim2 /// LOC100044959, Fpgt, Cdyl2, Trmt6, 
Cbx7, Zfp367, Csrnp1, Zfp715, Ebf4, Taf5, Ikbkg, Ccdc88a, Nmnat2, 
Gemin5, Rtel1, Mbtps2, Rrm2b, 5430432N15Rik, Zfp799, Npas3, Ddx11, 
Mettl1, Zfp827, Zfp708, Klf12, Atxn3, Rora, Med12l, Zfp39, Tdrd3, Ercc1, 
Tbl1xr1, Mga, Zfp827, BC031441, Lcor, Rad51l3, 2700050L05Rik, Sf3a1, 
Hif3a, Mettl1, Elac1, Ep400, 5730507C01Rik, Gmeb2, Zfc3h1, Gmps, 
Zhx2, Utp23, Dgcr8, Ppwd1, LOC100046241 /// Tlk1, 4930422I07Rik, 
Zfp592 
nucleus CC 4.45E-07 0.005 4706 
Mcm5, Klf10, Aurkaip1, Mcm6, Eif3a, Ube3a, Sigmar1, Tia1, Nt5c, Plekha2, 
Sorbs1, Sart3, Zfp35, Hmgxb3, Ufd1l, Lhx2, Wdr33, Etv3, Rfxap, Bcl10, 
Invs, Stk39, Trdmt1, Hdgf, Suz12, Myh9, Phf7, Mef2c, Vps25, Zbtb33, 
Zfp318, Txnrd1, Nr3c1, Elk1, Mrpl19, LOC100045442 /// Stag1, Khdrbs2, 
Uty, Chrac1, Ccnf, Xpc, Yy1, Sfmbt1, Pole4, Stk17b, LOC100048299 /// 
Max, LOC639633 /// Npm3 /// Npm3-ps1, Ddx41, Cugbp1, Suv420h2, 
LOC433064 /// Ppih, Hnrpdl, Gart, Cpsf4, Tcof1, Cux1, Zkscan5, Sox10, 
Zfp472, Ddx19a /// Ddx19b, Ube3a, Polb, Nmnat1, Hltf, Mlh3, Park2, 
Scmh1, Cugbp1, Tmem43, Trp53, Apbb2, Rpap1, Mtmr7, Ascc2, Mdm2, 
LOC100045866 /// Tceb1, Dicer1, Pcgf1, Prpf39, Elac2, Cand1, Cytsb, 
Otud7b, Klf3 /// LOC100046855, Aqr, Aqr, Mbtps1, 9030409G11Rik, 
Bxdc5, Exosc10, Nup54, Fubp1, Zfp574, Crebzf, Tbl1x, Adarb1, Id2, 
Baz2b, Parp1, 2310008H09Rik, Sfrs7, Lpp, Cux1, Mcm7, Son, Mcm7, 
Bach1, Plrg1, Mcm3ap, Ciz1, Zfp148, Eps15l1, Zfx, Suz12, Commd5, 
Nkx3-1, Ngfr, Tef, Kif5a /// Kif5c, Lnx1, Smad3, Kat2b, Synpo2, Gadd45b, 
Zscan12, Vps36, Ergic2, Gemin8, Nop16, Zfp451, Setdb1, Agfg1, Nova1, 
Phf20, Med26, 0610007P08Rik, Kdm5d, Rbm22, Cad, 2810408M09Rik, 
Nr2c2, LOC100047324 /// Sesn1, Dusp11, AU021838, Sf3a2, Tardbp, 
Unc45a, Nsmce1, Ppp4c, Ccdc117, Ing4, Exosc8, Ip6k2, Smg1, Senp5, 
Hexim2 /// LOC100044959, Cdyl2, Trmt6, Rabl2a, Cbx7, Zfp367, Pknox2, 
Gtpbp10, Csrnp1, Zfp715, Ebf4, Arl4a, Taf5, Ikbkg, Pphln1, 
5730455O13Rik, Nfkbid, Gemin5, Rtel1, Mbtps2, Mex3b, Rrm2b, 
5430432N15Rik, Ipmk, Zfp799, Npas3, Ddx11, Mllt10, Sept10, Mettl1, 
Zfp827, Zfp708, Klf12, Atxn3, Rora, Med12l, Zfp39, Tdrd3, Ercc1, 
B230120H23Rik, Tbl1xr1, Mga, Zfp827, BC031441, Lcor, Rad51l3, 
2700050L05Rik, Sf3a1, Hif3a, Mettl1, Ripply2, Spop, Spred1, Elac1, 
Ep400, 5730507C01Rik, Rabgap1l, Ccnt2, Cgrrf1, Gmeb2, Zfc3h1, Zhx2, 
Utp23, Dgcr8, Cdkl3, Adamts5 /// LOC100048332, LOC100046241 /// 
Tlk1, Rbm12, Tia1, 4930422I07Rik, Mtdh, Nup54, Tnks, Zfp592 
phosphotrans
ferase 
activity, 
alcohol group 
as acceptor MF 2.33E-05 0.044 678 
Tyk2, Csnk1d, Acvr2b, Stk39, Pdgfra, Mapk11, Gyk, Stk17b, Riok2, Rbks, 
Mark1, Ryk, Fastkd1, Pip5kl1, Agk, Etnk1, Pip5k1a, 2010111I01Rik, Irak1, 
Nrp1, Eif2ak3 /// LOC100047634, Grk5, Pip5k1c, Prkx, Cad, 
2810408M09Rik, Vrk2, Ppp4c, Irak1, Ip6k2, Smg1, Stk32b, Mapk4, Kcnh1, 
Bmpr1b, Ntrk2, Ipmk, Dgke, Map3k5, Med12l, B230120H23Rik, Dgkd, 
Pak6, Cdc2l5, 1110020G09Rik, Cdkl3, LOC100046241 /// Tlk1 
rRNA 
transcription BP 4.22E-05 0.074 12 LOC639633 /// Npm3 /// Npm3-ps1, Tcof1, Trp53 
transferase 
activity, 
transferring 
phosphorus-
containing 
groups MF 1.73E-06 0.007 967 
Aurkaip1, Tyk2, Csnk1d, Mpp3, Acvr2b, Stk39, Pdgfra, Mapk11, Chrac1, 
Gyk, Pole4, Stk17b, Riok2, Rbks, Polb, Mark1, Nmnat1, Crk, Ryk, Rpap1, 
Fastkd1, Dscaml1, EG665955, Pip5kl1, Agk, Etnk1, Ugp2, Pip5k1a, 
2010111I01Rik, Irak1, Nrp1, Akap2, Eif2ak3 /// LOC100047634, Grk5, 
Pip5k1c, Prkx, Ugp2, Cad, 2810408M09Rik, Vrk2, AU021838, Ppp4c, 
Irak1, Ip6k2, Smg1, Fpgt, Stk32b, Mapk4, Ikbkg, Kcnh1, Pcyt1b, Nmnat2, 
Bmpr1b, Ntrk2, Ipmk, Dgke, Map3k5, Med12l, B230120H23Rik, Dgkd, 
Pak6, Cdc2l5, 1110020G09Rik, Sephs1, Cdkl3, LOC100046241 /// Tlk1 	  
R6-­2	  8	  weeks	  D1	  GO	  analysis	  
GO Term Ontology p value 
Adjusted p 
value Genes present 
integrase 
activity MF 7.64E-14 1.88E-09 
100039204 /// 100039345 /// 100040790 /// 100041175 /// 100041416 
/// 100042151 /// 100042787 /// 100043211 /// 100043258 /// 
100043316 /// 434166 /// Bzw2 /// OTTMUSG00000017752 
	  
R6-­2	  8	  weeks	  D2	  GO	  analysis	  
GO Term Ontology p value 
Adjusted p 
value Genes present 
interleukin-11 
binding MF 5.62E-06 0.074 100038993 /// Il11ra1 /// Il11ra2 /// OTTMUSG00000011351 
interleukin-11 
receptor 
activity MF 5.62E-06 0.074 100038993 /// Il11ra1 /// Il11ra2 /// OTTMUSG00000011351 
	  
R6-­2	  12	  weeks	  D1	  GO	  analysis	  
GO 
Term Ontology p value 
Adjusted 
p value 
Total 
genes 
in GO 
class Genes present 
protein 
binding MF 
1.43E-
06 0.034 6998 
Fryl, Creg1, LOC100048726 /// Sec23b, Efr3a, Olig1, Vcl, Sec61a1, Crk, Il2rg, 
Shcbp1, Wwox, Ap3m1, Dpf2, Ezh2, Ptprn, Acvr1, C1d, Tsn, Psme1, Gipc2, Ppm1a, 
Il16, Nap1l5, Arid1a, Cap1, Ctnnbip1, Thumpd3, Cplx1, Ccna2, Pak3, Ncapg2, 
Apoa2, Tnfrsf1b, Hey2, Ezh1, Kif5b, Stx7, Yes1, Cenpo, Sf3b1, Limk2, Avpr1a, 
Kcnj1, Rgs9, Fech, Ccl25, F10, Nagk, Vsx2, Efnb2, Trp53rk, Asgr2, Cul2, Arap3, 
Nfkbia, Sntb2, Pcdhb19, Pglyrp2, Ccdc50, Sgce, Dach1, Ppp3cc, Ccndbp1, Pcdha1 /// 
Pcdha10 /// Pcdha11 /// Pcdha12 /// Pcdha2 /// Pcdha3 /// Pcdha4 /// Pcdha5 /// 
Pcdha6 /// Pcdha7 /// Pcdha8 /// Pcdha9 /// Pcdhac1 /// Pcdhac2, Hdac7, Ywhag, 
Ywhaq, Itga9, Tgfbr1, Cnot4, 2610028A01Rik, Itsn1, Chrna4, Rnf144a, Irf9, Csf2rb, 
Mynn, Gria4, Trim34, Adrb3, Tnfrsf8, Cacna1e, Eya1, Nr5a1, Stag2, Tcf12, Faah, 
Eif4e2, Strn, Ntn3, Khdrbs2, LOC100047606 /// Ntrk3, Hist1h1e, Krt1, Cpox, Cask, 
Rprm, Yy1, Exoc4, Ttyh1, Pmepa1, Inha, Mapre1, Fstl3, Prkcd, Ctbp2, Fgf3, Pcdhb6, 
Txndc17, Tmod3, Irs1, Shoc2, Sfrs5, Id4 /// LOC100045546, Nedd4l, Stmn2, Hyou1, 
Pnn, Ergic1, Orc4l, Wnt7a, Psmd9, Phip, Kptn, Rad54l2, LOC100048299 /// Max, 
Tagln, Cct6a, Tram1, Ddx41, Prpf6, Ppp5c, Gprin1, Nup93, Camkk2, Camkk2, 
Elmo1, Frag1, Cstf3, Rasgrf1, Zbtb1, Ric8, Ptbp1, Baiap2l1, Vrk1, Ephb2, Cdh10, 
Ace2, Epb4.1l5, Tcf7l2, Trim31, Polb, Parn, Il12a, H2-D1, Klc4, Edil3, Cep290, Lepr, 
Eps8 /// LOC632638, Recql, Csrp1, Hpca, Limk1, Nek6, Htt, Wt1, Rabggta, Trib3, 
Tor1aip1, Syt6, Kcnj9, Gipc3, Kitl, Shmt2, Gphn, Rasa1, Ckap4, Hipk3, Cln5, Crim1, 
Myh4, Zbed4, Zbtb3, Sfrs12, Hnrpll, Palld, Mll1, Ryr1, Dab1, Dapk1, Odc1, Mdm2, 
Ids, Myh1, Pold4, Mycbp, Hist1h4h, Synj2bp, Ptcd3, Ebf3, Cand1, Hopx, Zbtb46, 
2610524H06Rik, Csnk2a2, Styx, Clasp2, Myl6b, Slc9a3r2, Myo5a, Scara5, Gas7, 
Slc4a1, Il34, Stambp, Sh3kbp1, Cbx3, Cd80, Derl1, Cdc37l1, Sox4, S100pbp, 
Pla2g1b, Rcan3, Tle1, Kat2b, Ibtk, Adipor2, S100b, Ncoa1, Ero1lb, Coro2b, Iqgap3, 
Sec61a1, Pip5k1a, Limch1, Sod1, Pim1, Pacs1, Actr10, Itsn1, Atp1a1, Rab3gap2, 
Kazald1, Sptlc1, D0H4S114, Sh3bgrl, Usp39, Akap9, Rpa1, EG620521 /// Hnrnpr, 
Apex1, Pax6, Nupl1, Hexb, Bat1a, Eea1, Vim, Rbm39, Id4, Srr, Srr, Masp1, Foxp1, 
Nup54, Dtx2, Syt2, Bach1, Fgf3, Ankib1, Rnf2, Wwp2, Cul1, Fkbp5, Rdx, Lgals3bp, 
Myh6 /// Myh7, Ralbp1, Smc2, Eed, Arhgdig, Rpp25, Nfat5, Syn2, Crem, Mapk8ip2, 
Cdh2, B2m, Hsf2, Zfp53, Qpctl, Trps1, Coro1c, Map3k6, Ctnnb1, Pard6g, Itga9, 
Stat1, Gopc, H2-D1, Ngfr, Cbx5, Ccl24, Gli3, Ing3, Zfp191, Cbx1, Sgcd, D0H4S114, 
Wdr1, Rqcd1, Bcl2l2, LOC100047651 /// Zfpm1, Atp1a1, Cmtm6, Pias3, Edem1, 
Lamb1-1, Ppp5c, Ctsl, Spon1, Racgap1, Angptl7, Mtss1, Rhobtb2, H2-D1, H2-D1, 
Mib1, Setdb1, H2-L, Txnrd2, Trdn, Dyrk1a, Dlat, Actr1b, Rrp1b, Phf17, Ahnak, Fxr1, 
Shprh, Rnf20, Atp2a2, Coro2a, Mll1, Actn1, LOC100046932 /// Taf4a, H2-D1 /// H2-
T18 /// H2-T3 /// H2-T3-like /// H2-Tw3 /// LOC674370, Pcbd2, Tubb2b, Itgav, 
Ppfia4, Apaf1, Gna13, Serinc1, Ckap4, Pip5k1a, Vps18, Ccnd2, Itgb5, Trib3, Fgf17, 
Lasp1, Mat2a, Hexb, Phyh, Cmtm7, Dusp7, Brpf1, 100039786 /// 
OTTMUSG00000014597 /// Ywhaq, Ap2a1, Cltb /// LOC100046457, Pramef12, 
LOC676870 /// Pbx1, Tns1, Pfn4, Otud7b, Smurf2, Tln2, Nradd, Gapvd1, 
2310057M21Rik, Dab2, Cdc73, Fcnb, Klf5, Sdcbp, Cmtm5, Lrrc28, Rassf4, Dnajc8, 
2310061N02Rik, Mllt4, Dock8, Parp14, Pde3b, Gcn1l1, Ntf3, Irak3, Prmt8, Taf4b, 
Sarm1, Htr2c, Atl2, Nufip2, Klhl12, Ppm1l, Aph1b, Ppfia1, Lrrc15, Rnf24, Dock4, 
Metap2, Rgs7bp, Lsm6, Peli2, Zbtb7a, Pak3, Nedd4l, Plec1, Nek2, Lrrtm2, Tgfb2, 
Shc2, Parvb, Hnrnpr, Fras1, 627912 /// Mllt4 /// Zfp160, Klhl4, Zbtb16, Dnajb4, Hrk, 
Ank2, Dynll1, Rxfp1, Lrp8, Strn3, Wnt8b, Socs2, Kctd8, Kcnj5, Atp8b2, Zfp467, 
Fgf3, Lynx1, Zfp295, Usp4, Top2a, Lrch1, Pdzrn3, Atp2a2, Utf1, Ppp4r4, Tbc1d5, 
Agrn, Rgnef, Epb4.1, Thrsp, Cep135, Tm2d1, Adcy1, Chn1, Ostf1, Akap9, Cd84, 
Atox1, Dnajc17 /// EG621763, Tbc1d5, Snx6, Srrm1, Ripply2, Spop, Hist2h2be, 
Zbtb7a, Med13, Fam175a, Pdzd11, Mpp7, Fnbp1, Senp8, Mpp7, Mif, Cep97, Mapt, 
Phf16, Pak6, Frem1, Abl2, Vangl2, Ssh1, Ltbp3, Emx2, Ints10, Clspn, Pag1, Fbxo41, 
Paip1, Ppfia2, Garnl1, Snx19, Tcf4, Kdm2a, Vapb, Matr3, Ston2, Adam23, Nup54, 
Hecw1 
	  
R6-­2	  D2	  TRAP	  GO	  Analysis	  
GO Term 
Ontolog
y 
p 
value 
Adjuste
d p 
value 
Total 
genes 
in GO 
class Genes present 
cell 
morphogenesis BP 
3.51E-
13 5.21E-10 311 
Gja1, Stmn1, Tbr1, Cap1, Chl1, Gas7, Dcx, Dcx, Lhx2, Notch1, Atp7a, Drd2, 
Cnp, Pdpn, Rgnef, Rgnef, Ect2, Myh9, Myh9, Atp2b2, 100039963 /// Sema3a, 
Add1, Apc, Plxna3, Myo7a, Etv1, Shroom3, Isl1, Ift172, Dclk1, Dst, Slit2, Enah, 
Enah, Ndel1, Mapk8ip3, Hnrnpab, Slc1a3, Apbb2, Ptprz1, Sox6, Egr2, 
Pafah1b1, Apoe, Cdk5r1, Mycbp2, Sod1, Hmgb1, Atp7a, Cnp, Gja1, Gja1, 
100042515 /// EG545555 /// EG546331 /// EG665056 /// 
ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, EG623112 /// Stmn1, Hnrnpab, Hif1a, 
100039943 /// 100040234 /// 100041386 /// 100041667 /// 100042549 /// 
100043683 /// 4932431P20Rik /// EG432959 /// EG545506 /// EG545555 /// 
EG546331 /// EG666011 /// EG666969 /// Hmg1l1 /// Hmgb1 /// Hmgb1l /// 
LOC100045876 /// LOC637733 /// OTTMUSG00000007611 /// 
OTTMUSG00000015121, Ulk1, Pafah1b1, Dscam, Klf7, B3gnt2, Arx /// 
LOC100044440, Kif5a /// Kif5c, Onecut1, Isl1, Nr4a2, Dclk1, Tgfb2, Ephb3, 
Ptprz1, Hnrnpab, Ablim1, Ntn1, Gli2, Pafah1b1, Nrn1, Dync2h1, Pcnt, Kif5a, 
Nr2e1, Chl1, Apc, Dnaic2, Sema6a, Efna5, Bmpr1b, Sema5a, Prox1, Bcl11b, 
Slitrk3, Onecut2, Dcc, Evl /// LOC100047333, Dscam, Enah, Rgnef, Pcdh15, 
Onecut2, Sox6, Nr4a2, Col4a3bp, Ablim1, Mycbp2, Nr4a2, Onecut2 
cell projection 
organization BP 
1.10E-
15 2.77E-12 344 
Gja1, Stmn1, Cd24a, Rdx, Rdx, Tbr1, Vav3, Lpar1, Frap1, Chl1, Gas7, Dcx, 
Dcx, Lhx2, Notch1, Atp7a, Drd2, Cnp, Rgnef, Rgnef, Myh9, Myh9, Atp2b2, 
100039963 /// Sema3a, Apc, Plxna3, Myo7a, Itga6, Itga6, Lima1, Etv1, Isl1, 
Ift172, Ube2b, Dclk1, Rock1, Rock1, Dst, Fgfr1, Lamb1-1, Gprin1, Slit2, Enah, 
Enah, Ndel1, Klc3, Baiap2, Mapk8ip3, Cit, Lpin1, EG666036 /// EG666422 /// 
EG666875 /// EG668576 /// Phgdh, Apbb2, Wasl, Ptprz1, Egr2, Pafah1b1, 
Atg7, Atg7, Apoe, Cdk5r1, Myo6, Mtss1, Arf6, Mycbp2, Sod1, Myo6, Atp7a, 
Ccdc88a, Cnp, EG665516 /// EG666036 /// EG668771 /// Phgdh, Gja1, Gja1, 
EG623112 /// Stmn1, Rdx, Ulk1, Pafah1b1, Vav3, Lpar1, Nrtn, Dscam, Klf7, 
Prkg1, B3gnt2, Arx /// LOC100044440, Kif5a /// Kif5c, Onecut1, Lima1, Isl1, 
Nr4a2, Dclk1, Tgfb2, Rock1, Baiap2, Ephb3, Klf5, Gtrgeo22, Ptprz1, Wasf2, 
Ablim1, EG665516 /// EG666036 /// EG668771 /// Phgdh, Ntn1, EG385344 /// 
EG627427 /// EG665516 /// EG666036 /// EG666422 /// EG666875 /// 
EG668506 /// EG668576 /// EG668771 /// LOC630761 /// LOC630896 /// 
OTTMUSG00000011498 /// Phgdh, Gli2, Pafah1b1, Nrn1, Dync2h1, Pcnt, 
Mtap2, Alkbh1, Kif5a, Nr2e1, Chl1, Apc, Dnaic2, Cc2d2a, Sema6a, Grin3a, 
Efna5, Bmpr1b, Sema5a, Wasf2, Bcl11b, Grin3a, Slitrk3, Ube2b, Onecut2, Dcc, 
Mtap2, Evl /// LOC100047333, Akt1, Dscam, Enah, Rgnef, Pcdh15, Onecut2, 
Nck1, Nr4a2, Ablim1, Mycbp2, Nr4a2, Fgd4, Neurl1a, Ppp1r9a, Rasgrf1, 
Onecut2 
cellular 
component 
morphogenesis BP 
6.81E-
13 9.17E-10 339 
Gja1, Stmn1, Tbr1, Cap1, Chl1, Gas7, Dcx, Dcx, Lhx2, Notch1, Tnnt2, Atp7a, 
Drd2, Cnp, Pdpn, Rgnef, Rgnef, Ect2, Myh9, Myh9, Atp2b2, 100039963 /// 
Sema3a, Add1, Apc, Plxna3, Myo7a, Etv1, Shroom3, Isl1, Ift172, Ube2b, 
Dclk1, Dst, Slit2, Enah, Enah, Ndel1, Tnnt2, Mapk8ip3, Hnrnpab, Slc1a3, 
Apbb2, Ptprz1, Sox6, Egr2, Pafah1b1, Acta1, Apoe, Cdk5r1, Mycbp2, Sod1, 
Hmgb1, Atp7a, Cnp, Gja1, Gja1, 100042515 /// EG545555 /// EG546331 /// 
EG665056 /// ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// 
LOC100045972 /// LOC100046019 /// LOC637733, EG623112 /// Stmn1, 
Hnrnpab, Hif1a, 100039943 /// 100040234 /// 100041386 /// 100041667 /// 
100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// EG545506 /// 
EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 /// Hmgb1 
/// Hmgb1l /// LOC100045876 /// LOC637733 /// OTTMUSG00000007611 /// 
OTTMUSG00000015121, Ulk1, Pafah1b1, Dscam, Klf7, B3gnt2, Arx /// 
LOC100044440, Kif5a /// Kif5c, Onecut1, Isl1, Nr4a2, Dclk1, Tgfb2, Ephb3, 
Gtrgeo22, Agfg1, Ptprz1, Hnrnpab, Ablim1, Ntn1, Gli2, Pafah1b1, Nrn1, 
Dync2h1, Pcnt, Kif5a, Nr2e1, Chl1, Apc, Dnaic2, Sema6a, Efna5, Bmpr1b, 
Sema5a, Prox1, Bcl11b, Slitrk3, Ube2b, Onecut2, Dcc, Evl /// LOC100047333, 
Dscam, Enah, Rgnef, Pcdh15, Onecut2, Sox6, Nr4a2, Col4a3bp, Ablim1, 
Mycbp2, Nr4a2, Neurl1a, Onecut2 
cellular 
component 
organization BP 
6.08E-
13 8.37E-10 2110 
Atg5, Gja1, Gsn, Stmn1, Lcp1, Satb1, Cd24a, Flii, Ap1s1, Eif3d, Hist1h1c, 
100042266 /// EG434428 /// EG636070 /// LOC100044416 /// LOC100045728 
/// Tuba1a /// Tuba1b /// Tuba1c, Fbln5, Rdx, Rdx, Arpc1b, Cat, Dctpp1, Trrap, 
Ezh2, Acin1, Tbr1, H2afx, Trpm7, Nid1, Kpnb1, Bid, Vav3, Lpar1, Mlh1, 
Sertad1, Arid1a, Tacc3, Cap1, Hells, Timeless, Frap1, Limk1, Ankfy1, Unc13b, 
Chl1, Gas7, Vldlr, Dclre1a, Gng4, Ghr, Sh3glb1, Ndufs4, Dcx, Dcx, Lhx2, 
Phf21a, Kif5b, Kif5b, Kif5b, Nap1l3, Col11a1, Notch1, Tnnt2, LOC100046998 
/// Opa1, Atp7a, Epc1, Nek3, Drd2, Cnp, Rgs14, Abca7, Spnb2, Tns1, Pdpn, 
Hook2, l7Rn6, l7Rn6, Pclo, Rgnef, Rgnef, Immp2l, Ect2, Cd47, Pttg1, Sgcb, 
Myo5a, Scp2, Myh9, Myh9, Atp2b2, 100039963 /// Sema3a, 100043064 /// 
Nap1l1, Nap1l1, Cacng2, Ttf1, Cd2ap, Add1, Apc, Plxna3, Tro, Myo7a, Cdkn1a, 
Col19a1, Abca1, Gria2, Inhba, LOC100047606 /// Ntrk3, Hras1, Cdk4 /// 
LOC640611, Cdk4 /// LOC640611, Itga6, Itga6, Lima1, H2-DMa, Etv1, 
Shroom3, Ache, Isl1, Eps8 /// LOC632638, Eps8, Xrn2, Tfrc, Kat2a, Dnmt3a, 
Ift172, Npc1, Tmod3, Ube2b, Dclk1, Rala, Taf7, Pard6b, Itsn2, Ncor1, Cap2, 
Wnt7a, Rock1, Rock1, Myst4, Dst, Tubb2c, Ndufs8, Anapc4, Fgfr1, Lamb1-1, 
Hras1, Gprin1, Ccdc80, Elmo1, Msto1, Slit2, Rab5c, Mapt, Hip1, Enah, Enah, 
Nefh, Ndel1, Tnnt2, Slu7, Klc3, Anxa5, Baiap2, Tacc2, Olfm1, Sorbs1, 
Mapk8ip3, Cit, Hnrnpab, Slc1a3, LOC100048460 /// Lzts2, Rasa1, Lpin1, 
Trp53, Tesk2, Olfm1, Arhgap17, EG666036 /// EG666422 /// EG666875 /// 
EG668576 /// Phgdh, Apbb2, Cnn3 /// LOC100047856, Mfn1, Wasl, Smarca4, 
Uimc1, Ep400, Pbrm1, Ptprz1, Abi3bp, Mll3, Spg7, Mll5, Smc4, Bptf, Tubb2a, 
Zwint, Kdm6a, Sox6, Egr2, Pafah1b1, Acta1, Tubb2a, Spna2, Spna2, Rnf6, 
Dicer1, Caprin2, 2310043N10Rik, 2610039C10Rik, Atg7, Atg7, Mapre1, 
Hmg20a, Eny2, Dnajb6, Itsn2, Pdss1, Tekt1, Aplp2, Apoe, Cdk5r1, Anln, Nisch, 
Myo6, Mtss1, Arf6, Wdtc1, Ndufs8, Mycbp2, Mrpl15, Mrpl15, Mrpl15, Sod1, 
Kif11, Hmgb1, Fcgr2b, Myo6, Nde1, Hist3h2a, Itsn1, Fxc1, Ipo4, Kazald1, 
Atp7a, Gsn, Lats2, Gsn, Ccdc88a, Cnp, Rcor1, EG665516 /// EG666036 /// 
EG668771 /// Phgdh, Coro1c, Hexb, Gja1, Eea1, Chd4, Gja1, Fhdc1, Bptf, 
Cdc20, Incenp, Lats2, 100042515 /// EG545555 /// EG546331 /// EG665056 
/// ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, Chd7, EG623112 /// Stmn1, Hnrnpab, Hif1a, 
Flii, 100039943 /// 100040234 /// 100041386 /// 100041667 /// 100042549 
/// 100043683 /// 4932431P20Rik /// EG432959 /// EG545506 /// EG545555 
/// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 /// Hmgb1 /// Hmgb1l 
/// LOC100045876 /// LOC637733 /// OTTMUSG00000007611 /// 
OTTMUSG00000015121, Rdx, Hdac1, Ulk1, Eif3a, Pafah1b1, Vav3, Lpar1, 
Fcgr3, Smc2, Eed, Lrp1, Sept4, Hdac6, Blm, Cadps, Ino80, Ina /// 
LOC100047943, Ina /// LOC100047943, Rhou, Rhou, Akap2, Nrtn, Tns1, 
Dscam, Klf7, Mfn1, Casp3, Prkg1, Hsd17b12, Ccng1, B3gnt2, Arx /// 
LOC100044440, Fmn2 /// LOC100044570, Baz1b, Nolc1, Brdt, Fmnl1, Kif5a /// 
Kif5c, Onecut1, Nf2, Musk, Lima1, Isl1, Nr4a2, Cenpa, Stx6, Ezr, Dclk1, Tgfb2, 
Rock1, Baiap2, Brd8, Rerg, Mul1, Ephb3, Prkdc, Acvrl1, Ttl, Klf5, Atg12, Arid4b, 
Gtrgeo22, Taf11, Thrap3, Spnb2, Smc4, Agfg1, Ptprz1, Smarca2, Itsn1, Brd8, 
Suz12, Mll1, Hist1h2bc /// Hist1h2be /// Hist1h2bl /// Hist1h2bm /// Hist1h2bp 
/// LOC100046213 /// LOC665622 /// RP23-38E20.1, Tubb2b, Sfrs2ip, Gria2, 
2610039C10Rik, Fxc1, Hnrnpab, Usp21, Wasf2, Ablim1, EG665516 /// 
EG666036 /// EG668771 /// Phgdh, Rbbp4, Ntn1, Timm13, Ndufs8, Sept4, 
Notch2, Olfm1, Tgfbi, Pex6, Gsn, EG385344 /// EG627427 /// EG665516 /// 
EG666036 /// EG666422 /// EG666875 /// EG668506 /// EG668576 /// 
EG668771 /// LOC630761 /// LOC630896 /// OTTMUSG00000011498 /// 
Phgdh, Bptf, Gli2, Lasp1, Hexb, Pafah1b1, Epb4.9, Ppp4c, Arid4b, Tspyl1, 
Smarcc2, Nrn1, Chd3, Fmnl2, Cep192, Lrrcc1, Dync2h1, Aqp11, Tubgcp4, 
Gapvd1, 4921505C17Rik, Megf10, Cd47, Chd6, Srpk2, Nrxn1, Kank1, Als2cl, 
Fat1, Pcnt, Ablim3, Mll3, Mtap2, Alkbh1, Kif5a, Ep300, Iqcb1, Dok7, Tdrd3, 
Nr2e1, Atpaf1, Cenpe, Nsd1, Tubgcp6, Lrrcc1, Lrrcc1, Chl1, Rtn4, Taf4b, 
Epas1, Apc, Mpzl3, Phf21a, Ston2, Optn, Nrxn2, Dlc1, Cdc42bpg, Dnaic2, 
Cc2d2a, Sema6a, Grin3a, Ermn, Itsn1, H2afv, Efna5, Nav1, Ep400, Kdm5a, 
Nlgn1, Rrm2b, Bmpr1b, Sgol2, Sema5a, Nek2, Nek2, Chd7, Pacsin3, Dusp18, 
Prox1, Epb4.9, Cdc42bpa, Wasf2, Steap2, Bcl11b, Grin3a, Rps6ka5, Mll5, Mll5, 
Hook1, Slitrk3, Ube2b, Ipo9, Dot1l, Ston1, Anln, Rtn4, Onecut2, Rps6ka5, 
Kdm6b, Cbx4, Dcc, Chrna7, Mtap2, Lrp8, Evl /// LOC100047333, Ermn, Akt1, 
Parp4, Dscam, Phf21a, Atg4c, Mtap9, Enah, Lrp8, Steap2, Huwe1, Rgnef, 
Spnb2, Pcdh15, Phf21a, Onecut2, Tubb6, Gspt1, Elmo1, Hook3, Nck1, Cep164, 
Ep400, Taf1, Sox6, Gng4, Hist2h2be, Nr4a2, Jmjd1c, Col4a3bp, Igf1r, Ablim1, 
Gapvd1, Ube2i, Cttnbp2, Ehmt1, Mycbp2, Mapt, Nr4a2, Aifm2, Smarcc1, Fgd4, 
Gspt2, Kdm2a, Kdm6b, Htt, Neurl1a, Adamts20, Mll3, Dot1l, Ppp1r9a, Lmna, 
Dclre1c, Kdm3b, Daam1, Rasgrf1, Anapc11, Palm2, Hps1, Onecut2, Dlc1 
induction of 
positive 
chemotaxis BP 
9.00E-
14 1.63E-10 35 
Hmgb1, 100042515 /// EG545555 /// EG546331 /// EG665056 /// 
ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, 100039943 /// 100040234 /// 100041386 /// 
100041667 /// 100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// 
EG545506 /// EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 
/// Hmgb1 /// Hmgb1l /// LOC100045876 /// LOC637733 /// 
OTTMUSG00000007611 /// OTTMUSG00000015121, Scg2 
nervous system 
development BP 
1.42E-
21 8.20E-17 890 
Gja1, Scd2, Stmn1, Dpysl3, Cd24a, Smad1, Olig1, Nr2f2, Olig2, Glis2, Id3, 
Tbr1, Bcan, Sox2, Fzd6, Tacc3, Limk1, Cdkn1c, Chl1, Gas7, Neurod6, Ndufs4, 
Dcx, Dcx, LOC100046044 /// Nr2f1, Bhlhe22, Lhx2, Socs2, Notch1, Atp7a, En2, 
Drd2, Cnp, Rgnef, Rgnef, Mbp, Myo5a, Zbtb16, Atp2b2, 100039963 /// 
Sema3a, Mtpn, Vegfa, Atrx, Apc, Plxna3, Mef2c, Mef2c, Dab1, Nkx2-2, Atm, 
Myo7a, Fgfr3, LOC100045707 /// Pou3f1, Pou3f4, Slc5a3, LOC100047606 /// 
Ntrk3, Etv1, Shroom3, Isl1, Aldh1a2, Ift172, Dclk1, Src, Id4 /// 
LOC100045546, Wnt7a, Zic1, Sox5, Dst, Fgfr1, Lamb1-1, Gprin1, Rufy3, 
Rufy3, Slit2, Mapt, Enah, Enah, Ndel1, Lhx6, LOC676870 /// Pbx1, Tacc2, 
Map3k7, Dtx1, Psen2, Sema3e, Mapk8ip3, Cit, Ptprr, Slc1a3, Neurod1, Nrp2, 
Trp53, EG666036 /// EG666422 /// EG666875 /// EG668576 /// Phgdh, Apbb2, 
Smarca4, Ptprz1, Bptf, Nkx6-2, Zbtb16, Nfib, Egr2, Pafah1b1, Rnf6, Atg7, 
Atg7, Tcf7l2, Aplp2, Apoe, Cdk5r1, Tcf7, Myo6, Mtss1, Mycbp2, Sod1, Hmgb1, 
Rhoc, Myo6, Nde1, Hes6, Atp7a, Cnp, Mtpn, EG665516 /// EG666036 /// 
EG668771 /// Phgdh, Hexb, Gja1, Sema4a, Gja1, Bptf, Med1, 100042515 /// 
EG545555 /// EG546331 /// EG665056 /// ENSMUSG00000060128 /// Hmg1l1 
/// Hmgb1 /// LOC100045972 /// LOC100046019 /// LOC637733, Chd7, 
EG623112 /// Stmn1, Ndrg2, 100039943 /// 100040234 /// 100041386 /// 
100041667 /// 100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// 
EG545506 /// EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 
/// Hmgb1 /// Hmgb1l /// LOC100045876 /// LOC637733 /// 
OTTMUSG00000007611 /// OTTMUSG00000015121, Nfib, Ulk1, Mmp14, 
Pafah1b1, Sept4, Sema6b, Ncor2, Ina /// LOC100047943, Ina /// 
LOC100047943, Socs2, Sema4g, Nrtn, Dscam, Klf7, Prkg1, B3gnt2, Arx /// 
LOC100044440, Atrx, Kif5a /// Kif5c, Nf2, Isl1, Nr4a2, Fabp7, Dclk1, Src, 
Tgfb2, Ephb3, Prkdc, Ttl, Ptprz1, Elavl3, Fmr1, Med1, Dpysl3, Timp2, Ablim1, 
EG665516 /// EG666036 /// EG668771 /// Phgdh, Ntn1, Sept4, Gatad2a, Hes5, 
Mbp, Dner, EG385344 /// EG627427 /// EG665516 /// EG666036 /// EG666422 
/// EG666875 /// EG668506 /// EG668576 /// EG668771 /// LOC630761 /// 
LOC630896 /// OTTMUSG00000011498 /// Phgdh, Bptf, Gli2, LOC100045707 
/// Pou3f1, Hexb, Pafah1b1, Ndst1, Pcsk2, Nrn1, Kndc1, Gnaq, Sox11, 
Dync2h1, Sema3c, Sox11, Sema3d, Nrxn1, Jag1, Nfib, Nfib, Mtap2, Zeb2, Igf1, 
Alkbh1, Kif5a, Nr2e1, Cntn2, Chl1, Ntrk2, Plxnb1, Rtn4, Sox8, Apc, Nrxn2, 
Dlc1, Rora, Sema6a, Nr2f2, Grin3a, Efna5, Nav1, Rfx4, Nlgn1, Bmpr1b, Ednrb, 
Sema5a, Otx1, Chd7, Hhip, Hectd1, Fzd3, Slc1a2, Rgma, Sox1, Atrx, Bcl11b, 
Grin3a, Gfra1, Zbtb16, Slitrk3, Rtn4, Vegfc, Ppard, Rorb, Onecut2, Pbx1, Dcc, 
Mtap2, Sox5, Prdm16, Lrp8, Evl /// LOC100047333, Dscam, Plxna4, Bcan, 
Enah, Lrp8, Pofut1, Rgnef, Pcdh15, Onecut2, Gje1, Nr4a2, Pcsk2, Igf1r, Sox11, 
Sema6d, Ablim1, Plxna2, Cttnbp2, Nfib, Mycbp2, Mapt, Nr4a2, Hhip, Sox5, 
Rorb, Prdm8, Emx2, Htt, Eya1, Ppp1r9a, Rora, Dtx1, Rasgrf1, Smad1, 
Onecut2, Dlc1 
neurogenesis BP 
4.84E-
13 7.00E-10 556 
Gja1, Stmn1, Cd24a, Olig1, Nr2f2, Olig2, Id3, Tbr1, Sox2, Tacc3, Limk1, 
Cdkn1c, Chl1, Gas7, Dcx, Dcx, LOC100046044 /// Nr2f1, Bhlhe22, Lhx2, 
Socs2, Notch1, Atp7a, En2, Drd2, Cnp, Rgnef, Rgnef, Atp2b2, 100039963 /// 
Sema3a, Mtpn, Vegfa, Apc, Plxna3, Dab1, Nkx2-2, Myo7a, Fgfr3, 
LOC100045707 /// Pou3f1, Pou3f4, LOC100047606 /// Ntrk3, Etv1, Isl1, 
Aldh1a2, Dclk1, Id4 /// LOC100045546, Wnt7a, Sox5, Dst, Fgfr1, Lamb1-1, 
Gprin1, Slit2, Mapt, Enah, Enah, Ndel1, Lhx6, LOC676870 /// Pbx1, Tacc2, 
Dtx1, Mapk8ip3, Cit, Ptprr, Slc1a3, Trp53, EG666036 /// EG666422 /// 
EG666875 /// EG668576 /// Phgdh, Apbb2, Smarca4, Ptprz1, Nkx6-2, Egr2, 
Pafah1b1, Rnf6, Atg7, Atg7, Apoe, Cdk5r1, Myo6, Mycbp2, Sod1, Rhoc, Myo6, 
Nde1, Atp7a, Cnp, Mtpn, EG665516 /// EG666036 /// EG668771 /// Phgdh, 
Gja1, Gja1, EG623112 /// Stmn1, Ulk1, Mmp14, Pafah1b1, Socs2, Nrtn, 
Dscam, Klf7, Prkg1, B3gnt2, Arx /// LOC100044440, Kif5a /// Kif5c, Nf2, Isl1, 
Nr4a2, Fabp7, Dclk1, Tgfb2, Ephb3, Ttl, Ptprz1, Timp2, Ablim1, EG665516 /// 
EG666036 /// EG668771 /// Phgdh, Ntn1, Hes5, Dner, EG385344 /// 
EG627427 /// EG665516 /// EG666036 /// EG666422 /// EG666875 /// 
EG668506 /// EG668576 /// EG668771 /// LOC630761 /// LOC630896 /// 
OTTMUSG00000011498 /// Phgdh, Gli2, LOC100045707 /// Pou3f1, Pafah1b1, 
Nrn1, Kndc1, Gnaq, Jag1, Mtap2, Igf1, Alkbh1, Kif5a, Nr2e1, Cntn2, Chl1, 
Ntrk2, Plxnb1, Rtn4, Apc, Rora, Sema6a, Nr2f2, Grin3a, Efna5, Nav1, Nlgn1, 
Bmpr1b, Sema5a, Hhip, Sox1, Bcl11b, Grin3a, Slitrk3, Rtn4, Vegfc, Rorb, 
Onecut2, Pbx1, Dcc, Mtap2, Sox5, Prdm16, Evl /// LOC100047333, Dscam, 
Enah, Rgnef, Pcdh15, Onecut2, Nr4a2, Ablim1, Cttnbp2, Mycbp2, Mapt, Nr4a2, 
Hhip, Sox5, Rorb, Prdm8, Emx2, Htt, Eya1, Ppp1r9a, Rora, Dtx1, Rasgrf1, 
Onecut2 
positive 
regulation of 
carbohydrate 
metabolic 
process BP 
2.68E-
16 7.75E-13 37 
Sorbs1, Hmgb1, 100042515 /// EG545555 /// EG546331 /// EG665056 /// 
ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, 100039943 /// 100040234 /// 100041386 /// 
100041667 /// 100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// 
EG545506 /// EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 
/// Hmgb1 /// Hmgb1l /// LOC100045876 /// LOC637733 /// 
OTTMUSG00000007611 /// OTTMUSG00000015121, Dyrk2 /// LOC100044376, 
Igf1 
positive 
regulation of 
catabolic 
process BP 
9.91E-
14 1.74E-10 50 
Gja1, Apc, Gclc, Apoe, Hmgb1, Gja1, Gja1, 100042515 /// EG545555 /// 
EG546331 /// EG665056 /// ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// 
LOC100045972 /// LOC100046019 /// LOC637733, 100039943 /// 100040234 
/// 100041386 /// 100041667 /// 100042549 /// 100043683 /// 
4932431P20Rik /// EG432959 /// EG545506 /// EG545555 /// EG546331 /// 
EG666011 /// EG666969 /// Hmg1l1 /// Hmgb1 /// Hmgb1l /// LOC100045876 
/// LOC637733 /// OTTMUSG00000007611 /// OTTMUSG00000015121, Stub1, 
Igf1, Apc, Akt1 
positive 
regulation of 
cellular 
carbohydrate 
metabolic 
process BP 
2.68E-
16 7.75E-13 37 
Sorbs1, Hmgb1, 100042515 /// EG545555 /// EG546331 /// EG665056 /// 
ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, 100039943 /// 100040234 /// 100041386 /// 
100041667 /// 100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// 
EG545506 /// EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 
/// Hmgb1 /// Hmgb1l /// LOC100045876 /// LOC637733 /// 
OTTMUSG00000007611 /// OTTMUSG00000015121, Dyrk2 /// LOC100044376, 
Igf1 
positive 
regulation of 
cellular 
catabolic 
process BP 
1.41E-
17 5.83E-14 37 
Gclc, Apoe, Hmgb1, 100042515 /// EG545555 /// EG546331 /// EG665056 /// 
ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, 100039943 /// 100040234 /// 100041386 /// 
100041667 /// 100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// 
EG545506 /// EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 
/// Hmgb1 /// Hmgb1l /// LOC100045876 /// LOC637733 /// 
OTTMUSG00000007611 /// OTTMUSG00000015121, Stub1, Igf1, Akt1 
positive 
regulation of 
glucose 
metabolic 
process BP 
6.90E-
17 2.66E-13 36 
Sorbs1, Hmgb1, 100042515 /// EG545555 /// EG546331 /// EG665056 /// 
ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, 100039943 /// 100040234 /// 100041386 /// 
100041667 /// 100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// 
EG545506 /// EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 
/// Hmgb1 /// Hmgb1l /// LOC100045876 /// LOC637733 /// 
OTTMUSG00000007611 /// OTTMUSG00000015121, Dyrk2 /// LOC100044376, 
Igf1 
positive 
regulation of 
glycogen 
catabolic 
process BP 
8.04E-
19 4.23E-15 26 
Hmgb1, 100042515 /// EG545555 /// EG546331 /// EG665056 /// 
ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, 100039943 /// 100040234 /// 100041386 /// 
100041667 /// 100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// 
EG545506 /// EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 
/// Hmgb1 /// Hmgb1l /// LOC100045876 /// LOC637733 /// 
OTTMUSG00000007611 /// OTTMUSG00000015121 
positive 
regulation of 
glycogen 
metabolic 
process BP 
4.50E-
19 3.72E-15 31 
Sorbs1, Hmgb1, 100042515 /// EG545555 /// EG546331 /// EG665056 /// 
ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, 100039943 /// 100040234 /// 100041386 /// 
100041667 /// 100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// 
EG545506 /// EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 
/// Hmgb1 /// Hmgb1l /// LOC100045876 /// LOC637733 /// 
OTTMUSG00000007611 /// OTTMUSG00000015121, Dyrk2 /// LOC100044376 
positive 
regulation of 
mesenchymal 
cell 
proliferation BP 
1.17E-
13 1.99E-10 45 
Vegfa, Foxp1, Irs1, Fgfr1, Prrx1, Foxp1, Hmgb1, Foxp1, 100042515 /// 
EG545555 /// EG546331 /// EG665056 /// ENSMUSG00000060128 /// Hmg1l1 
/// Hmgb1 /// LOC100045972 /// LOC100046019 /// LOC637733, 100039943 
/// 100040234 /// 100041386 /// 100041667 /// 100042549 /// 100043683 /// 
4932431P20Rik /// EG432959 /// EG545506 /// EG545555 /// EG546331 /// 
EG666011 /// EG666969 /// Hmg1l1 /// Hmgb1 /// Hmgb1l /// LOC100045876 
/// LOC637733 /// OTTMUSG00000007611 /// OTTMUSG00000015121 
positive 
regulation of 
mitotic cell 
cycle BP 
1.27E-
13 2.10E-10 33 
Hmgb1, 100042515 /// EG545555 /// EG546331 /// EG665056 /// 
ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, 100039943 /// 100040234 /// 100041386 /// 
100041667 /// 100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// 
EG545506 /// EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 
/// Hmgb1 /// Hmgb1l /// LOC100045876 /// LOC637733 /// 
OTTMUSG00000007611 /// OTTMUSG00000015121 
positive 
regulation of 
myeloid cell 
differentiation BP 
2.54E-
14 4.89E-11 51 
Kitl, Acin1, Gnas, Inhba, Id2, Hmgb1, 100042515 /// EG545555 /// EG546331 
/// EG665056 /// ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// 
LOC100045972 /// LOC100046019 /// LOC637733, Kitl, Hif1a, 100039943 /// 
100040234 /// 100041386 /// 100041667 /// 100042549 /// 100043683 /// 
4932431P20Rik /// EG432959 /// EG545506 /// EG545555 /// EG546331 /// 
EG666011 /// EG666969 /// Hmg1l1 /// Hmgb1 /// Hmgb1l /// LOC100045876 
/// LOC637733 /// OTTMUSG00000007611 /// OTTMUSG00000015121, Gnas, 
Csf1, Jag1 
regulation of 
carbohydrate 
catabolic 
process BP 
8.35E-
17 2.68E-13 30 
Hmgb1, 100042515 /// EG545555 /// EG546331 /// EG665056 /// 
ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, 100039943 /// 100040234 /// 100041386 /// 
100041667 /// 100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// 
EG545506 /// EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 
/// Hmgb1 /// Hmgb1l /// LOC100045876 /// LOC637733 /// 
OTTMUSG00000007611 /// OTTMUSG00000015121, Igf1 
regulation of 
carbohydrate 
metabolic 
process BP 
9.49E-
15 1.96E-11 40 
Sorbs1, Hmgb1, 100042515 /// EG545555 /// EG546331 /// EG665056 /// 
ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, 100039943 /// 100040234 /// 100041386 /// 
100041667 /// 100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// 
EG545506 /// EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 
/// Hmgb1 /// Hmgb1l /// LOC100045876 /// LOC637733 /// 
OTTMUSG00000007611 /// OTTMUSG00000015121, Dyrk2 /// LOC100044376, 
Igf1 
regulation of 
cellular 
carbohydrate 
catabolic 
process BP 
8.35E-
17 2.68E-13 30 
Hmgb1, 100042515 /// EG545555 /// EG546331 /// EG665056 /// 
ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, 100039943 /// 100040234 /// 100041386 /// 
100041667 /// 100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// 
EG545506 /// EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 
/// Hmgb1 /// Hmgb1l /// LOC100045876 /// LOC637733 /// 
OTTMUSG00000007611 /// OTTMUSG00000015121, Igf1 
regulation of 
cellular 
carbohydrate 
metabolic 
process BP 
9.49E-
15 1.96E-11 40 
Sorbs1, Hmgb1, 100042515 /// EG545555 /// EG546331 /// EG665056 /// 
ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, 100039943 /// 100040234 /// 100041386 /// 
100041667 /// 100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// 
EG545506 /// EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 
/// Hmgb1 /// Hmgb1l /// LOC100045876 /// LOC637733 /// 
OTTMUSG00000007611 /// OTTMUSG00000015121, Dyrk2 /// LOC100044376, 
Igf1 
regulation of 
generation of 
precursor 
metabolites 
and energy BP 
6.30E-
19 4.23E-15 37 
Atp7a, Sorbs1, Hmgb1, Atp7a, 100042515 /// EG545555 /// EG546331 /// 
EG665056 /// ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// 
LOC100045972 /// LOC100046019 /// LOC637733, 100039943 /// 100040234 
/// 100041386 /// 100041667 /// 100042549 /// 100043683 /// 
4932431P20Rik /// EG432959 /// EG545506 /// EG545555 /// EG546331 /// 
EG666011 /// EG666969 /// Hmg1l1 /// Hmgb1 /// Hmgb1l /// LOC100045876 
/// LOC637733 /// OTTMUSG00000007611 /// OTTMUSG00000015121, Dyrk2 
/// LOC100044376, Igf1, Cisd1 
regulation of 
glucose 
metabolic 
process BP 
3.11E-
15 6.92E-12 39 
Sorbs1, Hmgb1, 100042515 /// EG545555 /// EG546331 /// EG665056 /// 
ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, 100039943 /// 100040234 /// 100041386 /// 
100041667 /// 100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// 
EG545506 /// EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 
/// Hmgb1 /// Hmgb1l /// LOC100045876 /// LOC637733 /// 
OTTMUSG00000007611 /// OTTMUSG00000015121, Dyrk2 /// LOC100044376, 
Igf1 
regulation of 
glycogen 
catabolic 
process BP 
8.04E-
19 4.23E-15 26 
Hmgb1, 100042515 /// EG545555 /// EG546331 /// EG665056 /// 
ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, 100039943 /// 100040234 /// 100041386 /// 
100041667 /// 100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// 
EG545506 /// EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 
/// Hmgb1 /// Hmgb1l /// LOC100045876 /// LOC637733 /// 
OTTMUSG00000007611 /// OTTMUSG00000015121 
regulation of 
glycogen 
metabolic 
process BP 
4.50E-
19 3.72E-15 31 
Sorbs1, Hmgb1, 100042515 /// EG545555 /// EG546331 /// EG665056 /// 
ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, 100039943 /// 100040234 /// 100041386 /// 
100041667 /// 100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// 
EG545506 /// EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 
/// Hmgb1 /// Hmgb1l /// LOC100045876 /// LOC637733 /// 
OTTMUSG00000007611 /// OTTMUSG00000015121, Dyrk2 /// LOC100044376 
regulation of 
mesenchymal 
cell 
proliferation BP 
2.82E-
13 4.29E-10 46 
Vegfa, Foxp1, Irs1, Fgfr1, Prrx1, Foxp1, Hmgb1, Foxp1, 100042515 /// 
EG545555 /// EG546331 /// EG665056 /// ENSMUSG00000060128 /// Hmg1l1 
/// Hmgb1 /// LOC100045972 /// LOC100046019 /// LOC637733, 100039943 
/// 100040234 /// 100041386 /// 100041667 /// 100042549 /// 100043683 /// 
4932431P20Rik /// EG432959 /// EG545506 /// EG545555 /// EG546331 /// 
EG666011 /// EG666969 /// Hmg1l1 /// Hmgb1 /// Hmgb1l /// LOC100045876 
/// LOC637733 /// OTTMUSG00000007611 /// OTTMUSG00000015121 
regulation of 
polysaccharide 
metabolic 
process BP 
4.50E-
19 3.72E-15 31 
Sorbs1, Hmgb1, 100042515 /// EG545555 /// EG546331 /// EG665056 /// 
ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// LOC100045972 /// 
LOC100046019 /// LOC637733, 100039943 /// 100040234 /// 100041386 /// 
100041667 /// 100042549 /// 100043683 /// 4932431P20Rik /// EG432959 /// 
EG545506 /// EG545555 /// EG546331 /// EG666011 /// EG666969 /// Hmg1l1 
/// Hmgb1 /// Hmgb1l /// LOC100045876 /// LOC637733 /// 
OTTMUSG00000007611 /// OTTMUSG00000015121, Dyrk2 /// LOC100044376 
response to 
corticosteroid 
stimulus BP 
5.82E-
16 1.53E-12 57 
Src, Ugt1a1 /// Ugt1a10 /// Ugt1a2 /// Ugt1a5 /// Ugt1a6a /// Ugt1a6b /// 
Ugt1a7c /// Ugt1a9, Ugt1a1 /// Ugt1a10 /// Ugt1a2 /// Ugt1a5 /// Ugt1a6a /// 
Ugt1a6b /// Ugt1a7c /// Ugt1a9, Hmgb1, 100042515 /// EG545555 /// 
EG546331 /// EG665056 /// ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// 
LOC100045972 /// LOC100046019 /// LOC637733, 100039943 /// 100040234 
/// 100041386 /// 100041667 /// 100042549 /// 100043683 /// 
4932431P20Rik /// EG432959 /// EG545506 /// EG545555 /// EG546331 /// 
EG666011 /// EG666969 /// Hmg1l1 /// Hmgb1 /// Hmgb1l /// LOC100045876 
/// LOC637733 /// OTTMUSG00000007611 /// OTTMUSG00000015121, Asl, 
Abcb4, Src, Gpr83 
response to 
glucocorticoid 
stimulus BP 
4.00E-
16 1.10E-12 54 
Ugt1a1 /// Ugt1a10 /// Ugt1a2 /// Ugt1a5 /// Ugt1a6a /// Ugt1a6b /// Ugt1a7c 
/// Ugt1a9, Ugt1a1 /// Ugt1a10 /// Ugt1a2 /// Ugt1a5 /// Ugt1a6a /// Ugt1a6b 
/// Ugt1a7c /// Ugt1a9, Hmgb1, 100042515 /// EG545555 /// EG546331 /// 
EG665056 /// ENSMUSG00000060128 /// Hmg1l1 /// Hmgb1 /// 
LOC100045972 /// LOC100046019 /// LOC637733, 100039943 /// 100040234 
/// 100041386 /// 100041667 /// 100042549 /// 100043683 /// 
4932431P20Rik /// EG432959 /// EG545506 /// EG545555 /// EG546331 /// 
EG666011 /// EG666969 /// Hmg1l1 /// Hmgb1 /// Hmgb1l /// LOC100045876 
/// LOC637733 /// OTTMUSG00000007611 /// OTTMUSG00000015121, Asl, 
Abcb4, Gpr83 
	  
YAC	  13	  months	  D1	  GO	  Analysis	  
GO Term Ontology 
p 
value 
Adjusted 
p value 
Total 
genes 
in GO 
class Genes present 
extrinsic to 
membrane CC 
9.38E-
07 0.003 87 
Sytl2, Gng5, 100041120 /// Gng5 /// LOC100044719 /// 
OTTMUSG00000011511 /// OTTMUSG00000026148, Gng4 
extrinsic to plasma 
membrane CC 
6.29E-
08 5.12E-04 59 
Sytl2, Gng5, 100041120 /// Gng5 /// LOC100044719 /// 
OTTMUSG00000011511 /// OTTMUSG00000026148, Gng4 
heterotrimeric G-
protein complex CC 
9.89E-
08 5.12E-04 38 
Gng5, 100041120 /// Gng5 /// LOC100044719 /// 
OTTMUSG00000011511 /// OTTMUSG00000026148, Gng4 
	  
YAC	  23	  months	  D2	  GO	  Analysis	  
GO Term Ontology 
p 
value 
Adjusted 
p value 
Total 
genes 
in GO 
class Genes present 
heterotrimeric G-
protein complex CC 
4.27E-
07 0.011 38 
Gng4, Gnb4, 100041120 /// Gng5 /// LOC100044719 /// 
OTTMUSG00000011511 /// OTTMUSG00000026148, Gna13, 
Gnao1, Gng4 
	  
Appendix	  II:	  IPA	  Analysis	  –	  pathways	  with	  Ratio	  p<.05	  
R6-­2	  3	  weeks	  D1	  IPA	  Analysis	  
Ingenuity Canonical 
Pathways 
 -log(p-
value) Ratio Molecules 
Inositol Phosphate 
Metabolism 4.77E+00 7.95E-02 
PIK3C2A,CDK7,MTMR1,GRK5,PIP5K1B,BRAF,SYNJ2,PLCB4,IPMK,PIM1,PIK3CG,PRPF4B,
GRK6,PRKAA2 
Breast Cancer Regulation 
by Stathmin1 2.85E+00 6.53E-02 
ARHGEF4,PIK3C2A,PPP1R14A,E2F3,GNG5,ROCK1,GNAI2,PLCB4,PPP1R10,PIK3CG,GNA1
3,PPP2R1B,GNG4 
Nicotinate and 
Nicotinamide Metabolism 2.82E+00 6.62E-02 BRAF,NNT,PIM1,PRPF4B,CDK7,NT5M,PRKAA2,GRK6,GRK5 
IL-8 Signaling 2.27E+00 5.91E-02 ROCK1,GNAI2,BRAF,HMOX1,CCND3,PIK3C2A,MYL12B,PIK3CG,GNA13,GNG5,GNG4 
Ephrin Receptor Signaling 2.17E+00 5.61E-02 ROCK1,GNAI2,GRIN1,ITSN1,EPHB2,PIK3CG,EPHA4,GNA13,GNG5,GNG4,FGF1 
Relaxin Signaling 2.17E+00 6.04E-02 GNAI2,BRAF,PDE7A,PIK3C2A,PIK3CG,GNA13,GNG5,GNG4,PDE1C 
AMPK Signaling 2.04E+00 5.45E-02 CPT1A,PIK3C2A,PIK3CG,TSC2,PRKAA2,RPTOR,AK2,PPP2R1B,HLTF 
Clathrin-mediated 
Endocytosis Signaling 2.03E+00 5.99E-02 
MYO6,SH3BP4,CD2AP,SNX9 (includes 
EG:51429),PIK3C2A,EPHB2,PIK3CG,TFRC,HIP1,FGF1 
Axonal Guidance Signaling 1.98E+00 4.47E-02 
RND1,PLXNC1,PIK3C2A,ITSN1,EPHB2,EPHA4,SLIT2,GNG5,ROCK1,GNAI2,NTNG1,PLCB4
,PLXNA1,MYL12B,PIK3CG,GNA13,SEMA3B,GNG4 
Androgen Signaling 1.96E+00 5.56E-02 GNAI2,AR,GTF2H4,CDK7,TBP,GNA13,GNG5,GNG4 
Thrombin Signaling 1.88E+00 5.39E-02 ROCK1,GNAI2,PLCB4,ARHGEF4,PIK3C2A,MYL12B,PIK3CG,TBP,GNA13,GNG5,GNG4 
Sphingosine-1-phosphate 
Signaling 1.71E+00 6.25E-02 GNAI2,PLCB4,S1PR5,PIK3C2A,PIK3CG,GNA13,SMPD3 
CXCR4 Signaling 1.67E+00 5.39E-02 ROCK1,GNAI2,PLCB4,PIK3C2A,MYL12B,PIK3CG,GNA13,GNG5,GNG4 
Insulin Receptor Signaling 1.61E+00 5.71E-02 PPP1R10,PIK3C2A,PIK3CG,TSC2,RPTOR,PPP1R14A,PTPRF,GRB10 
CCR3 Signaling in 
Eosinophils 1.57E+00 5.83E-02 ROCK1,GNAI2,PLCB4,PIK3C2A,PIK3CG,GNG5,GNG4 
Aryl Hydrocarbon Receptor 
Signaling 1.54E+00 5.19E-02 ALDH1B1,TRIP11,CCND3,MED1,NQO2,NFIA,APAF1,GSTO1 
Protein Kinase A Signaling 1.53E+00 4.44E-02 
TGFBR1,PDE7A,ANAPC10,PPP1R14A,GNG5,PDE1C,BRAF,ROCK1,GNAI2,PLCB4,PPP1R10,
MYL12B,GNA13,GNG4 
Type II Diabetes Mellitus 
Signaling 1.48E+00 4.43E-02 ACSL3,PIK3C2A,PIK3CG,SOCS6,SOCS2,PRKAA2,SMPD3 
Androgen and Estrogen 
Metabolism 1.46E+00 4.23E-02 CYP7B1,METTL2B,HSD17B7,B3GAT1,METTL6,SULF2 
Prolactin Signaling 1.44E+00 6.67E-02 PIK3C2A,PIK3CG,SOCS6,SOCS2,PDK1 
G Beta Gamma Signaling 1.44E+00 5.04E-02 GNAI2,PIK3CG,KCNJ3,GNA13,GNG5,GNG4 
Huntington's Disease 
Signaling 1.44E+00 4.58E-02 
PLCB4,PIK3C2A,PIK3CG,APAF1,TBP,TCERG1,HDAC9 (includes 
EG:9734),HIP1,GNG5,GNG4,ZDHHC17 
Antiproliferative Role of 
Somatostatin Receptor 2 1.39E+00 6.41E-02 BRAF,PIK3C2A,PIK3CG,GNG5,GNG4 
Cardiac Œ≤-adrenergic 
Signaling 1.36E+00 4.93E-02 PPP1R10,PDE7A,PPP1R14A,PPP2R1B,GNG5,GNG4,PDE1C 
Acute Myeloid Leukemia 
Signaling 1.33E+00 6.41E-02 BRAF,PIK3C2A,CSF2RA (includes EG:1438),PIM1,PIK3CG 
IL-9 Signaling 1.30E+00 8.11E-02 PIK3C2A,PIK3CG,SOCS2 
Histidine Metabolism 1.27E+00 3.33E-02 ALDH1B1,CYP7B1,METTL2B,METTL6 
G Protein Signaling 
Mediated by Tubby 1.23E+00 7.32E-02 PLCB4,GNG5,GNG4 
Ceramide Signaling 1.23E+00 5.75E-02 S1PR5,PIK3C2A,PIK3CG,PPP2R1B,SMPD3 
	  
R6-­2	  3	  wks	  D2	  IPA	  	  
Ingenuity Canonical 
Pathways 
 -log(p-
value) Ratio Molecules 
Endoplasmic Reticulum 
Stress Pathway 2.49E+00 2.22E-01 MBTPS1,MAP3K5 (includes EG:4217),EIF2AK3,MBTPS2 
Inositol Phosphate 
Metabolism 2.05E+00 6.25E-02 PIP5K1A,PRKX,IPMK,PIP5K1C,PDIA3,CSNK1D,PIP5KL1,GRK5,IP6K2,PLCL1,IRAK1 
Glutamate Metabolism 1.97E+00 6.41E-02 GNPNAT1,GMPS,CAD,GCLM,GPT2 
Keratan Sulfate 
Biosynthesis 1.96E+00 1.09E-01 B4GALT4,B4GALT7,HS6ST1,B3GNT2,CHST11,NDST1 
Type I Diabetes Mellitus 
Signaling 1.93E+00 7.83E-02 TRAF6,IKBKG,ICA1,NGFR,SOCS2,MAP3K5 (includes EG:4217),MAPK11,PTPRN,IRAK1 
Aminophosphonate 
Metabolism 1.59E+00 6.15E-02 PCYT1B,METTL1,METTL6,MEPCE 
Toll-like Receptor Signaling 1.56E+00 9.26E-02 TRAF6,IKBKG,ELK1,MAPK11,IRAK1 
ATM Signaling 1.46E+00 9.43E-02 TP53,GADD45B,TLK1,MDM2,MAPK11 
p53 Signaling 1.38E+00 7.61E-02 TP53,KAT2B,GADD45B,STAG1,RRM2B,CSNK1D,MDM2 
April Mediated Signaling 1.38E+00 9.52E-02 TRAF6,IKBKG,ELK1,MAPK11 
B Cell Activating Factor 
Signaling 1.31E+00 9.09E-02 TRAF6,IKBKG,ELK1,MAPK11 
Selenoamino Acid 
Metabolism 1.31E+00 5.19E-02 METTL1,SEPHS1,METTL6,MEPCE 
Purine Metabolism 1.27E+00 3.87E-02 
POLE4,AFG3L1,RRM2B,IDE,ADARB1,POLB,GART,NT5C,IMPDH2,MPP3,GMPS,PDE7B,CH
RAC1,MYH9,HLTF,ATP6V0E1,IFNAR1 
p38 MAPK Signaling 1.24E+00 7.22E-02 TRAF6,MAX,MEF2C,MAP3K5 (includes EG:4217),ELK1,MAPK11,IRAK1 
IL-10 Signaling 1.21E+00 7.14E-02 TRAF6,IKBKG,TYK2,ELK1,MAPK11 
Axonal Guidance Signaling 1.20E+00 4.71E-02 
SEMA3E,RAP1B,PXN,PLXNC1,PAK6,ADAM15,SHANK2,SEMA5A,CRKL,WNT2B,CRK,NTR
K2,NGFR,ADAM19,SMO,MYL4,SRGAP2,SEMA4B,NRP1 
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Chronic Myeloid Leukemia 
Signaling 3.14E+00 8.57E-02 IKBKB,E2F6,E2F4,TGFBR1,PA2G4,PIK3C2A,CRKL,CHUK,SIN3A 
IL-1 Signaling 2.61E+00 7.55E-02 ADCY9,IKBKB,JUN,PRKAR2A,CHUK,GNA13,GNG2,GNG4 
Relaxin Signaling 2.28E+00 6.04E-02 ADCY9,JUN,PDE7A,PIK3C2A,PRKAR2A,GNA13,GNG2,GNG4,PDE1C 
cAMP-mediated Signaling 2.15E+00 6.21E-02 ADCY9,CREM,PDE7A,OPRM1,PKIB,HTR7,RGS7,PRKAR2A,ADORA2A,PDE1C 
Role of CHK Proteins in Cell 
Cycle Checkpoint Control 2.00E+00 1.14E-01 E2F6,E2F4,HUS1,RAD50 
Small Cell Lung Cancer 
Signaling 2.00E+00 6.74E-02 IKBKB,PA2G4,PIK3C2A,CHUK,RXRA,SIN3A 
G-Protein Coupled 
Receptor Signaling 1.78E+00 5.00E-02 
ADCY9,IKBKB,PDE7A,PIK3C2A,OPRM1,HTR7,RGS7,PRKAR2A,CHUK,ADORA2A,P
DE1C 
Pancreatic Adenocarcinoma 
Signaling 1.76E+00 6.03E-02 RAD51,E2F6,E2F4,TGFBR1,PA2G4,PIK3C2A,SIN3A 
Androgen Signaling 1.58E+00 4.86E-02 JUN,PRKAR2A,POLR2B,GNA13,GNG2,GTF2A1,GNG4 
p53 Signaling 1.53E+00 6.52E-02 JUN,GADD45B,PIK3C2A,SNAI2,C12ORF5,RPRM 
Purine Metabolism 1.49E+00 3.19E-02 
ADCY9,RSF1,ABCA2,PDE7A,PKLR,RRM2,POLR2B,POLD4,ADARB1,ATIC,PDE1C,S
KIV2L,RAD51,POLR3K 
Cardiac Œ≤-adrenergic 
Signaling 1.44E+00 4.93E-02 ADCY9,PDE7A,PKIB,PRKAR2A,GNG2,GNG4,PDE1C 
4-1BB Signaling in T 
Lymphocytes 1.42E+00 8.82E-02 IKBKB,JUN,CHUK 
CD27 Signaling in 
Lymphocytes 1.37E+00 7.02E-02 IKBKB,SIVA1,JUN,CHUK 
ATM Signaling 1.37E+00 7.55E-02 RAD51,JUN,GADD45B,RAD50 
Ovarian Cancer Signaling 1.36E+00 5.19E-02 RAD51,PA2G4,PIK3C2A,FZD3,PRKAR2A,PMS2,SIN3A 
Breast Cancer Regulation 
by Stathmin1 1.31E+00 4.52E-02 ADCY9,E2F6,E2F4,PIK3C2A,PRKAR2A,TRPC5,GNA13,GNG2,GNG4 
Hepatic Cholestasis 1.27E+00 4.19E-02 ADCY9,IKBKB,JUN,PRKAR2A,CHUK,RXRA,HSD3B7 
Role of BRCA1 in DNA 
Damage Response 1.25E+00 6.56E-02 RAD51,E2F6,E2F4,RAD50 
Cell Cycle: G1/S 
Checkpoint Regulation 1.25E+00 6.78E-02 E2F6,E2F4,PA2G4,SIN3A 
Glutamate Receptor 
Signaling 1.20E+00 5.71E-02 SLC1A4,GRIK3,GNG2,HOMER1 
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LPS-stimulated MAPK 
Signaling 4.26E+00 1.28E-01 RAF1,IKBKG,NFKBIA,PIK3C2A,MAP3K7,PIK3C3,CREB1,MAPK8,PIK3CD,PRKCA 
Role of NFAT in Cardiac 
Hypertrophy 3.74E+00 7.73E-02 
ADCY9,RAF1,HDAC4,PIK3C2A,MAPK8,PPP3CC,PLCH2,GNG5,CABIN1,MAP3K7,PIK3C3,TG
FB3,IGF1R,PIK3CD,PLCL1,PRKCA 
Prostate Cancer Signaling 3.05E+00 9.38E-02 TP53,RAF1,NFKBIA,FOXO1,PA2G4,PIK3C2A,PIK3C3,CREB1,PIK3CD 
VEGF Signaling 2.86E+00 9.28E-02 RAF1,EIF2S2,FOXO1,PIK3C2A,PIK3C3,PIK3CD,ACTN1,PRKCA,ARNT 
IL-3 Signaling 2.86E+00 1.11E-01 STAT6,RAF1,FOXO1,PIK3C2A,PIK3C3,PIK3CD,PPP3CC,PRKCA 
Cardiac Hypertrophy 
Signaling 2.77E+00 6.58E-02 
ADCY9,RAF1,PIK3C2A,MYL2,GNA12,MAPK8,PPP3CC,PLCH2,GNG5,MAP3K7,PIK3C3,CRE
B1,IGF1R,TGFB3,PIK3CD,PLCL1 
RANK Signaling in 
Osteoclasts 2.76E+00 9.38E-02 RAF1,IKBKG,NFKBIA,PIK3C2A,MAP3K7,PIK3C3,MAPK8,PIK3CD,PPP3CC 
Molecular Mechanisms of 
Cancer 2.70E+00 5.65E-02 
TP53,ADCY9,RAF1,TCF4,PIK3C2A,PA2G4,GNA12,MAPK8,ARHGEF17,AURKA,NFKBIA,FOX
O1,MAP3K7,SUFU,BMPR1A,PIK3C3,FZD3,TGFB3,PIK3CD,FZD2,PRKCA 
EGF Signaling 2.67E+00 1.22E-01 RAF1,PIK3C2A,PIK3C3,MAPK8,PIK3CD,PRKCA 
14-3-3-mediated Signaling 2.62E+00 8.77E-02 RAF1,FOXO1,PIK3C2A,PIK3C3,MAPK8,VIM,PIK3CD,PLCH2,PLCL1,PRKCA 
IL-9 Signaling 2.59E+00 1.35E-01 PIK3C2A,PIK3C3,CISH,SOCS2,PIK3CD 
CD40 Signaling 2.58E+00 1.04E-01 IKBKG,NFKBIA,PIK3C2A,MAP3K7,PIK3C3,MAPK8,PIK3CD 
Chronic Myeloid Leukemia 
Signaling 2.56E+00 8.57E-02 TP53,RAF1,IKBKG,HDAC4,PA2G4,PIK3C2A,PIK3C3,TGFB3,PIK3CD 
JAK/Stat Signaling 2.54E+00 1.09E-01 STAT6,RAF1,PIK3C2A,PIK3C3,CISH,SOCS2,PIK3CD 
GŒ±12/13 Signaling 2.45E+00 8.00E-02 
RAF1,IKBKG,CDH4 (includes 
EG:1002),NFKBIA,MYL2,PIK3C2A,GNA12,PIK3C3,MAPK8,PIK3CD 
Non-Small Cell Lung 
Cancer Signaling 2.38E+00 8.86E-02 TP53,RAF1,PA2G4,PIK3C2A,PIK3C3,PIK3CD,PRKCA 
Neurotrophin/TRK 
Signaling 2.31E+00 9.33E-02 RAF1,PIK3C2A,PIK3C3,CREB1,MAPK8,SORCS1,PIK3CD 
ATM Signaling 2.29E+00 1.13E-01 TP53,NFKBIA,CREB1,MAPK8,MRE11A,SMC1A 
Prolactin Signaling 2.27E+00 9.33E-02 RAF1,PIK3C2A,PIK3C3,SOCS2,PIK3CD,PDK1,PRKCA 
PDGF Signaling 2.27E+00 9.21E-02 RAF1,PIK3C2A,PIK3C3,ACP1,MAPK8,PIK3CD,PRKCA 
Ovarian Cancer Signaling 2.22E+00 7.41E-02 TP53,RAF1,GJA1,MSH2,PA2G4,PIK3C2A,PIK3C3,FZD3,PIK3CD,FZD2 
Glioblastoma Multiforme 
Signaling 2.22E+00 6.75E-02 TP53,RAF1,FOXO1,PIK3C2A,PIK3C3,IGF1R,FZD3,PIK3CD,PLCH2,PLCL1,FZD2 
Small Cell Lung Cancer 
Signaling 2.17E+00 7.87E-02 TP53,IKBKG,NFKBIA,PA2G4,PIK3C2A,PIK3C3,PIK3CD 
NF-Œ∫B Activation by 
Viruses 2.13E+00 8.64E-02 RAF1,IKBKG,NFKBIA,PIK3C2A,PIK3C3,PIK3CD,PRKCA 
Role of NANOG in 
Mammalian Embryonic 
Stem Cell Pluripotency 2.13E+00 7.89E-02 TP53,RAF1,PIK3C2A,BMPR1A,PIK3C3,FZD3,PIK3CD,FZD2,IL11RA 
SAPK/JNK Signaling 2.11E+00 8.16E-02 TP53,PIK3C2A,MAP3K7,GNA12,PIK3C3,MAPK8,PIK3CD,GNG5 
Leptin Signaling in Obesity 2.10E+00 8.54E-02 ADCY9,FOXO1,PIK3C2A,PIK3C3,PIK3CD,PLCH2,PLCL1 
IL-12 Signaling and 
Production in Macrophages 2.08E+00 6.72E-02 STAT6,IKBKG,PIK3C2A,PIK3C3,MAF,MAPK8,TGFB3,PIK3CD,PRKCA 
IGF-1 Signaling 2.08E+00 8.00E-02 RAF1,FOXO1,PIK3C2A,PIK3C3,IGF1R,MAPK8,IGFBP5,PIK3CD 
HER-2 Signaling in Breast 
Cancer 2.04E+00 8.86E-02 TP53,FOXO1,PIK3C2A,PIK3C3,PIK3CD,PARD3,PRKCA 
Type II Diabetes Mellitus 
Signaling 2.03E+00 5.70E-02 IKBKG,NFKBIA,PIK3C2A,MAP3K7,PIK3C3,SOCS2,MAPK8,PIK3CD,PRKCA 
Melanoma Signaling 2.01E+00 1.09E-01 TP53,RAF1,PIK3C2A,PIK3C3,PIK3CD 
Neuropathic Pain Signaling 
In Dorsal Horn Neurons 2.00E+00 7.77E-02 PIK3C2A,GRIN2D,PIK3C3,CREB1,PIK3CD,PLCH2,PLCL1,PRKCA 
Glioma Signaling 2.00E+00 7.14E-02 TP53,RAF1,PA2G4,PIK3C2A,PIK3C3,IGF1R,PIK3CD,PRKCA 
T Cell Receptor Signaling 2.00E+00 7.48E-02 RAF1,IKBKG,NFKBIA,PIK3C2A,PIK3C3,MAPK8,PIK3CD,PPP3CC 
Inositol Phosphate 
Metabolism 1.99E+00 5.68E-02 SYNJ2,PIK3C2A,PIK3C3,SEC16A,CDK7,GRK6,MAPK8,PIK3CD,PLCH2,PLCL1 
Aldosterone Signaling in 
Epithelial Cells 1.95E+00 7.37E-02 RAF1,PIK3C2A,PIK3C3,PIK3CD,PLCH2,PLCL1,PRKCA 
Myc Mediated Apoptosis 
Signaling 1.92E+00 9.52E-02 TP53,PIK3C2A,PIK3C3,IGF1R,MAPK8,PIK3CD 
GM-CSF Signaling 1.89E+00 8.96E-02 RAF1,PIK3C2A,PIK3C3,CISH,PIK3CD,PPP3CC 
Factors Promoting 
Cardiogenesis in 
Vertebrates 1.87E+00 7.87E-02 MYL2,BMPR1A,MAP3K7,FZD3,TGFB3,FZD2,PRKCA 
Growth Hormone Signaling 1.85E+00 8.57E-02 PIK3C2A,PIK3C3,SOCS2,IGF1R,PIK3CD,PRKCA 
Sphingosine-1-phosphate 
Signaling 1.85E+00 7.14E-02 ADCY9,PIK3C2A,GNA12,PIK3C3,PIK3CD,PLCH2,PLCL1,ASAH2 
B Cell Receptor Signaling 1.85E+00 6.49E-02 RAF1,IKBKG,NFKBIA,PIK3C2A,MAP3K7,PIK3C3,CREB1,MAPK8,PIK3CD,PPP3CC 
FGF Signaling 1.84E+00 7.95E-02 RAF1,PIK3C2A,PIK3C3,CREB1,MAPK8,PIK3CD,PRKCA 
Thrombin Signaling 1.80E+00 5.88E-02 ADCY9,RAF1,MYL2,PIK3C2A,GNA12,PIK3C3,CREB1,PIK3CD,PLCH2,PLCL1,GNG5,PRKCA 
Pancreatic Adenocarcinoma 1.80E+00 6.90E-02 TP53,RAF1,PA2G4,PIK3C2A,PIK3C3,MAPK8,TGFB3,PIK3CD 
Signaling 
CREB Signaling in Neurons 1.80E+00 5.61E-02 ADCY9,RAF1,PIK3C2A,GNA12,PIK3C3,CREB1,PIK3CD,PLCH2,PLCL1,GNG5,PRKCA 
Erythropoietin Signaling 1.79E+00 7.89E-02 RAF1,NFKBIA,PIK3C2A,PIK3C3,PIK3CD,PRKCA 
Angiopoietin Signaling 1.79E+00 8.11E-02 IKBKG,NFKBIA,FOXO1,PIK3C2A,PIK3C3,PIK3CD 
Apoptosis Signaling 1.79E+00 7.78E-02 ACIN1,TP53,RAF1,IKBKG,NFKBIA,MAPK8,PRKCA 
Relaxin Signaling 1.77E+00 6.04E-02 ADCY9,NFKBIA,PIK3C2A,GNA12,PIK3C3,CREB1,PIK3CD,GNG5,NPR2 
fMLP Signaling in 
Neutrophils 1.76E+00 6.40E-02 RAF1,NFKBIA,PIK3C2A,PIK3C3,PIK3CD,PPP3CC,GNG5,PRKCA 
Cardiomyocyte 
Differentiation via BMP 
Receptors 1.75E+00 1.50E-01 MYL2,BMPR1A,MAP3K7 
NRF2-mediated Oxidative 
Stress Response 1.71E+00 6.01E-02 
DNAJC21,RAF1,DNAJC17,PIK3C2A,MAP3K7,PIK3C3,MAF,MAPK8,SLC35A2,PIK3CD,PRKC
A 
Renal Cell Carcinoma 
Signaling 1.70E+00 8.33E-02 RAF1,PIK3C2A,PIK3C3,PIK3CD,FH,ARNT 
CXCR4 Signaling 1.68E+00 5.99E-02 ADCY9,RAF1,MYL2,PIK3C2A,GNA12,PIK3C3,MAPK8,PIK3CD,GNG5,PRKCA 
Hypoxia Signaling in the 
Cardiovascular System 1.68E+00 8.57E-02 TP53,NFKBIA,CREB1,UBE2V2,UBE2E3,ARNT 
Thrombopoietin Signaling 1.67E+00 8.47E-02 RAF1,PIK3C2A,PIK3C3,PIK3CD,PRKCA 
Antiproliferative Role of 
Somatostatin Receptor 2 1.65E+00 7.69E-02 ADCY9,PIK3C2A,PIK3C3,PIK3CD,GNG5,NPR2 
p53 Signaling 1.64E+00 7.61E-02 TP53,PIK3C2A,JMY,PIK3C3,MAPK8,C12ORF5,PIK3CD 
Endometrial Cancer 
Signaling 1.63E+00 8.77E-02 TP53,RAF1,PIK3C2A,PIK3C3,PIK3CD 
Role of Pattern Recognition 
Receptors in Recognition of 
Bacteria and Viruses 1.62E+00 7.50E-02 PIK3C2A,PIK3C3,DDX58,CREB1,PIK3CD,IRF3 
IL-1 Signaling 1.61E+00 6.60E-02 ADCY9,IKBKG,NFKBIA,MAP3K7,GNA12,MAPK8,GNG5 
IL-2 Signaling 1.60E+00 8.62E-02 RAF1,PIK3C2A,PIK3C3,MAPK8,PIK3CD 
FLT3 Signaling in 
Hematopoietic Progenitor 
Cells 1.59E+00 8.11E-02 STAT6,RAF1,PIK3C2A,PIK3C3,CREB1,PIK3CD 
Aryl Hydrocarbon Receptor 
Signaling 1.59E+00 5.84E-02 NR2F1,TP53,NCOA2,ALDH3A2,MAPK8,TGFB3,SLC35A2,ALDH7A1,ARNT 
Lymphotoxin Œ≤ Receptor 
Signaling 1.57E+00 8.20E-02 IKBKG,NFKBIA,PIK3C2A,PIK3C3,PIK3CD 
G-Protein Coupled 
Receptor Signaling 1.57E+00 5.45E-02 
ADCY9,HRH1,RAF1,IKBKG,NFKBIA,PIK3C2A,PIK3C3,CREB1,HTR1F,PIK3CD,RGS12,PRK
CA 
Colorectal Cancer 
Metastasis Signaling 1.52E+00 5.22E-02 
ADCY9,TP53,SIAH1,PIK3C2A,MAPK8,GNG5,APPL1,MSH2,PIK3C3,FZD3,TGFB3,PIK3CD,F
ZD2 
FcŒ≥RIIB Signaling in B 
Lymphocytes 1.51E+00 7.14E-02 PIK3C2A,PIK3C3,MAPK8,PIK3CD 
Docosahexaenoic Acid 
(DHA) Signaling 1.51E+00 8.33E-02 FOXO1,PIK3C2A,PIK3C3,PIK3CD 
Hereditary Breast Cancer 
Signaling 1.51E+00 6.20E-02 TP53,HDAC4,MSH2,PIK3C2A,PIK3C3,FANCF,MRE11A,PIK3CD 
Role of Osteoblasts, 
Osteoclasts and 
Chondrocytes in 
Rheumatoid Arthritis 1.50E+00 5.26E-02 
IKBKG,NFKBIA,FOXO1,PIK3C2A,BMPR1A,MAP3K7,PIK3C3,FZD3,MAPK8,PIK3CD,PPP3CC
,FZD2 
HGF Signaling 1.48E+00 6.80E-02 RAF1,PIK3C2A,MAP3K7,PIK3C3,MAPK8,PIK3CD,PRKCA 
PPARŒ±/RXRŒ± 
Activation 1.45E+00 5.49E-02 ADCY9,RAF1,IKBKG,NFKBIA,MAP3K7,MAPK8,TGFB3,PLCH2,PLCL1,PRKCA 
Role of PKR in Interferon 
Induction and Antiviral 
Response 1.44E+00 8.70E-02 TP53,IKBKG,NFKBIA,MAP3K7 
IL-8 Signaling 1.43E+00 5.38E-02 RAF1,IKBKG,MYL2,PIK3C2A,GNA12,PIK3C3,MAPK8,PIK3CD,GNG5,PRKCA 
Endothelin-1 Signaling 1.42E+00 5.41E-02 ADCY9,RAF1,PIK3C2A,GNA12,PIK3C3,MAPK8,PIK3CD,PLCH2,PLCL1,PRKCA 
Regulation of IL-2 
Expression in Activated 
and Anergic T 
Lymphocytes 1.40E+00 6.67E-02 RAF1,IKBKG,NFKBIA,MAPK8,TGFB3,PPP3CC 
IL-10 Signaling 1.40E+00 7.14E-02 IKBKG,NFKBIA,BLVRA,MAP3K7,MAPK8 
Estrogen-Dependent 
Breast Cancer Signaling 1.40E+00 7.14E-02 PIK3C2A,PIK3C3,CREB1,IGF1R,PIK3CD 
Axonal Guidance Signaling 1.40E+00 4.47E-02 
RAF1,PIK3C2A,MYL2,GNA12,SEMA6A,PPP3CC,DPYSL5,GNG5,SUFU,SEMA6D,PIK3C3,FZ
D3,PIK3CD,SEMA3B,SEMA4A,FZD2,VASP,PRKCA 
Melanocyte Development 
and Pigmentation Signaling 1.38E+00 6.82E-02 ADCY9,RAF1,PIK3C2A,PIK3C3,CREB1,PIK3CD 
Role of NFAT in Regulation 
of the Immune Response 1.37E+00 5.10E-02 RAF1,IKBKG,NFKBIA,PIK3C2A,GNA12,PIK3C3,PIK3CD,PPP3CC,GNG5,CABIN1 
IL-15 Signaling 1.37E+00 7.46E-02 STAT6,RAF1,PIK3C2A,PIK3C3,PIK3CD 
Renin-Angiotensin 
Signaling 1.36E+00 5.83E-02 ADCY9,RAF1,PIK3C2A,PIK3C3,MAPK8,PIK3CD,PRKCA 
EIF2 Signaling 1.33E+00 6.00E-02 RAF1,EIF2S2,EIF2C4,PIK3C2A,PIK3C3,PIK3CD 
Regulation of eIF4 and 
p70S6K Signaling 1.32E+00 5.38E-02 RAF1,EIF2S2,EIF2C4,EIF4EBP2,PIK3C2A,PIK3C3,PIK3CD 
Glycerolipid Metabolism 1.32E+00 4.49E-02 AGPAT4,PPAP2A,ALDH3A2,DAGLB,DGKG,AGPAT3,ALDH7A1 
Macropinocytosis Signaling 1.30E+00 6.94E-02 PIK3C2A,PIK3C3,USP6NL,PIK3CD,PRKCA 
Production of Nitric Oxide 1.30E+00 4.86E-02 IKBKG,NFKBIA,PIK3C2A,MAP3K7,PIK3C3,MAPK8,IFNGR2,PIK3CD,PRKCA 
and Reactive Oxygen 
Species in Macrophages 
Cleavage and 
Polyadenylation of Pre-
mRNA 1.28E+00 1.67E-01 PAPOLA,NUDT21 
TR/RXR Activation 1.27E+00 6.19E-02 PIK3C2A,PIK3C3,STRBP,PIK3CD,ME1,TBL1XR1 
PAK Signaling 1.27E+00 5.88E-02 RAF1,MYL2,PIK3C2A,PIK3C3,MAPK8,PIK3CD 
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Polyamine Regulation in 
Colon Cancer 2.88E+00 2.27E-01 TCF4,MAX,SAT2,CTNNB1,ODC1 
Axonal Guidance Signaling 2.47E+00 8.68E-02 
NTF3,RND1,ITSN1,EPHB2,LIMK2,CRK,WNT8B,LIMK1,EFNB2,WNT7A,NFAT5,GLI3,A
DAM28,NGFR,PFN4,SMO,ADAM23,GNA13,RASA1,SEMA3E,SEMA3G,PAK6,NFATC1,P
PP3CC,MYL6B,GNG5,EFNA1,EPHA6,SDCBP,PAK3,NTRK3,SEMA6D,PRKCD,SEMA7A,
NTN3 
Actin Cytoskeleton 
Signaling 2.17E+00 9.44E-02 
MYH4,MYH6,PAK6,RDX,LIMK2,CRK,MYL6B,SSH1,LIMK1,FGF17,PIP5K1A,PAK3,PFN4
,PPP1R12B,FGF3,VCL,GNA13,NCKAP1L,PIP4K2A,ACTN1,IQGAP3,MYH1 
Semaphorin Signaling in 
Neurons 1.96E+00 1.54E-01 RND1,PAK6,PAK3,RHOT1,LIMK2,FNBP1,SEMA7A,LIMK1 
Nicotinate and 
Nicotinamide Metabolism 1.82E+00 8.82E-02 DAPK1,ADH7,NEK2,MAP3K6,PAK3,PIM1,PRKCD,PRKAA2,PNP,LIMK2,LIMK1,DYRK1A 
Tight Junction Signaling 1.57E+00 9.58E-02 
MYH4,MYH6,TGFBR1,MLLT4,CASK,MYL6B,CPSF6,EPB41,NGFR,PPM1L,TGFB2,VCL,T
NFRSF1B,CTNNB1,CSTF3,MYH1 
Regulation of Actin-based 
Motility by Rho 1.55E+00 1.09E-01 PIP5K1A,PAK6,PAK3,RHOT1,PFN4,PPP1R12B,MYL6B,PIP4K2A,FNBP1,LIMK1 
Cleavage and 
Polyadenylation of Pre-
mRNA 1.51E+00 2.50E-01 PAPOLA,CPSF6,CSTF3 
Germ Cell-Sertoli Cell 
Junction Signaling 1.51E+00 9.49E-02 
TGFBR1,PAK6,MAP3K6,MLLT4,LIMK2,LIMK1,CDH2,PAK3,RHOT1,SORBS1,PPAP2B,T
GFB2,CTNNB1,ACTN1,FNBP1 
Wnt/Œ≤-catenin Signaling 1.47E+00 9.52E-02 
SOX4,TCF4,TGFBR1,ACVR1,TLE1,MDM2,SOX11,WNT8B,CSNK2A2,CDH2,WNT7A,PP
M1L,SMO,TGFB2,CTNNB1,TCF7L2 
Type I Diabetes Mellitus 
Signaling 1.36E+00 9.57E-02 IL12A,NFKBIA,CD80,HLA-E,NGFR,SOCS2,APAF1,TNFRSF1B,STAT1,PTPRN,HLA-C 
Protein Kinase A Signaling 1.34E+00 7.94E-02 
MYH4,TGFBR1,CREM,PDE7A,NFKBIA,NFAT5,GLI3,PDE3B,NGFR,TGFB2,SMO,RYR1,Y
WHAQ (includes 
EG:22630),GNA13,CTNNB1,YWHAG,HIST1H1E,PDE10A,NFATC1,PPP3CC,GNG5,MYL
6B,PRKCD,ADCY1,AKAP9 
Calcium Signaling 1.31E+00 7.80E-02 
MYH4,MYH6,CHRNA4,ATP2C1,TNNT2,TRDN,NFATC1,PPP3CC,MYL6B,ATP2A2,NFAT5
,HDAC7,RYR1,RCAN3,CAMKK2,MYH1 
Inositol Phosphate 
Metabolism 1.24E+00 7.39E-02 
DAPK1,MAP3K6,LIMK2,LIMK1,PIP5K1A,INPP4B,NEK2,PAK3,PIM1,PRKCD,PRKAA2,P
IP4K2A,DYRK1A 
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Ingenuity Canonical 
Pathways 
 -log(p-
value) Ratio Molecules 
Molecular Mechanisms of 
Cancer 6.51E+00 2.39E-01 
GAB2,JAK1,MAPK1,HRAS,CCND1,E2F6,CAMK2A,CAMK2D,PLCB1,GSK3B,GNA13,HI
PK2,SMAD1,RASA1,PRKD1,ATM,TP53,AKT2,CCNE2,PRKCQ,CASP3,CDK6,RAPGEF3,
GNAZ,APC,PIK3R3,BMPR1B,CBL,MAX,RND3,IRS1,CDK4,FZD6,FZD3,PRKCH,MAP2K
3,PAK7,CFLAR,NOTCH1,GNAL,CAMK2G,TCF4,PIK3CA,RALA,PA2G4,CRK,PSEN2,PSE
NEN,FZD1,HIF1A,SMAD5,EP300,BRAF,AKT1,NFKBIA,MAP3K7,RHOU,TGFB2,BID,AD
CY8,CAMK2B,SRC,PRKDC,ADCY2,PAK2,RHOC,ADCY6,MAPK8,SMAD7,GNAQ,XIAP,G
NAI2,GNAS,PLCB4,ARHGEF10,RRAS2,FOXO1,PAK3,RASGRP1,CDKN1A,ADCY1,RAS
GRF1,ADCY7,ATR,BCL2L11,LRP1,CTNND1,RAPGEF1,PRKCB 
Axonal Guidance Signaling 6.06E+00 2.33E-01 
GLI2,MAPK1,ITSN1,NFATC3,GNB5,HRAS,SEMA6B,NCK1,WNT9A,NTN1,LIMK1,VEGF
A,GNB4,MICAL1,SEMA3D,ABLIM3,BAIAP2,PLCB1,ADAM23,SRGAP2,GNA13,GSK3B,
PLXNB3,RASA1,PRKD1,AKT2,PRKCQ,SEMA5A,VEGFC,HHIP,PPP3CC,GNAZ,MYL9 
(includes 
EG:10398),PIK3R3,SRGAP3,MYL12B,SEMA6D,FZD6,FZD3,RTN4,PRKCH,PAK7,GNG
2,GNAL,ADAM17,PIK3CA,PLXNA3,UNC5A,ARPC1B,SEMA6A,EGF,CRK,PLXNA2,FZD1
,WNT8B,ABLIM1,EIF4E,WNT7A,AKT1,WASL (includes 
EG:8976),GNG11,PPP3CB,IGF1,SDC2,EFNA5,DCC,SEMA4A,GNG4,ITGB1,SEMA3E,P
AK2,PLXNC1,NRP2,SHANK2,GNAQ,SLIT2,EPHA3,ROCK1,GNAI2,GNAS,SEMA3A,PLC
B4,NTRK2,RRAS2,GLIS2,MAG,PAK3,NTRK3,PLXNB1,EPHA5,SEMA4G,EPHB3,SEMA3
C,PRKCB 
Role of NFAT in Cardiac 
Hypertrophy 5.43E+00 2.56E-01 
CAMK1D,MAPK1,GNB5,HRAS,CABIN1,HDAC6,GNB4,CAMK2A,CAMK2D,PLCB1,GSK3
B,PLCL1,PRKD1,AKT2,PRKCQ,PPP3CC,PIK3R3,RCAN3,MAP2K3,PRKCH,GNG2,CAMK
2G,IL6ST,PIK3CA,CAMK4,PDIA3,EP300,AKT1,GNG11,IGF1,PPP3CB,MAP3K7,TGFB2
,CAMK1G,IGF1R,ADCY8,GNG4,CAMK2B,SRC,ADCY2,HDAC1,GNAQ,MAPK8,ADCY6,P
LCG1,GNAI2,GNAS,PLCB4,RRAS2,ADCY1,MEF2C,ADCY7,PRKCB 
Breast Cancer Regulation 
by Stathmin1 5.20E+00 2.66E-01 
CAMK1D,MAPK1,GNB5,HRAS,LIMK1,E2F6,GNB4,STMN1,CAMK2A,CAMK2D,PPM1L,P
LCB1,TUBA1C,GNA13,PRKD1,TP53,PPP1R14C,CCNE2,PRKCQ,TUBB2A,PPP1R14A,PI
K3R3,PPP2R3A,PPP1R12A,PRKCH,GNG2,CAMK2G,PIK3CA,CAMK4,PPP1R3C,PPP1CB
,GNG11,CAMK1G,PPP2R2C,ADCY8,GNG4,CAMK2B,ADCY2,PPP2R5C,TUBB2C,GNAQ,
ADCY6,ROCK1,GNAI2,GNAS,PLCB4,ARHGEF10,RRAS2,ADCY1,CDKN1A,ADCY7,PPP
2R1B,PRKCB 
Thrombin Signaling 5.17E+00 2.65E-01 
CAMK1D,MAPK1,GNB5,HRAS,MYLK,IKBKB,GNB4,CAMK2A,CAMK2D,PLCB1,GNA13,
PLCL1,PRKD1,AKT2,PRKCQ,GNAZ,MYL9 (includes 
EG:10398),PIK3R3,RND3,MYL12B,PPP1R12B,PPP1R12A,PRKCH,GNG2,ARHGEF9,G
NAL,CAMK2G,PIK3CA,CAMK4,PDIA3,EGF,AKT1,GNG11,CAMK1G,RHOU,GATA6,ADC
Y8,GNG4,CAMK2B,SRC,ADCY2,RHOC,GNAQ,ADCY6,PLCG1,ROCK1,GNAI2,GNAS,PL
CB4,RRAS2,ARHGEF10,ADCY1,ADCY7,PRKCB 
Reelin Signaling in 
Neurons 4.72E+00 3.46E-01 
APOE,PIK3CA,MAPT,DAB1,CDK5R1,MAP3K10,YES1,AKT1,GSK3B,ITGB1,SRC,MAP3
K9,CNR1,MAPK8IP2,MAPK8,ITGA6,MAPK8IP3,VLDLR,MAPK8IP1,PIK3R3,ARHGEF10
,NDEL1,LRP8,PAFAH1B1,DCX,ARHGEF9,PAFAH1B3 
CXCR4 Signaling 4.50E+00 2.63E-01 
PIK3CA,MAPK1,CD4,GNB5,HRAS,CRK,GNB4,GNG11,AKT1,RHOU,PLCB1,GNA13,AD
CY8,GNG4,PRKD1,SRC,ADCY2,AKT2,PAK2,PRKCQ,RHOC,EGR1,GNAQ,MAPK8,ADCY
6,GNAZ,GNAI2,ROCK1,PIK3R3,MYL9 (includes 
EG:10398),GNAS,PLCB4,RRAS2,RND3,PAK3,MYL12B,ADCY1,PAK7,PRKCH,GNG2,E
LMO1,ADCY7,GNAL,PRKCB 
Synaptic Long Term 
Potentiation 4.41E+00 2.92E-01 
CAMK4,MAPK1,GRM3,PPP1R1A,PPP1R3C,HRAS,PPP1CB,EP300,CAMK2D,CAMK2A,P
PP3CB,PLCB1,ADCY8,PRKD1,CAMK2B,GRIN2B,PPP1R14C,PRKCQ,GNAQ,GRIA2,PPP
1R14A,RAPGEF3,GRM4,PPP3CC,GRIN3A,ATF2,PLCB4,RRAS2,ADCY1,PPP1R12A,PRK
CH,PRKCB,CAMK2G 
CREB Signaling in Neurons 4.41E+00 2.40E-01 
PIK3CA,POLR2F,POLR2D,CAMK4,MAPK1,PDIA3,GRM3,GNB5,HRAS,EP300,GNB4,CA
MK2D,CAMK2A,AKT1,POLR2A,GNG11,PLCB1,GNA13,GRIK2,PLCL1,ADCY8,GNG4,P
RKD1,CAMK2B,AKT2,ADCY2,PRKCQ,ADCY6,GRIA2,GNAQ,PLCG1,GRM4,GNAZ,ATF2
,GNAI2,PIK3R3,GNAS,PLCB4,RRAS2,ADCY1,PRKCH,GNG2,POLR2I,ADCY7,GNAL,CA
MK2G,PRKCB 
Ephrin Receptor Signaling 4.38E+00 2.45E-01 
ARPC1B,ITSN1,MAPK1,PTPN13,GNB5,EGF,HRAS,MAP4K4,CRK,NCK1,LIMK1,VEGFA,
GNB4,GNG11,WASL (includes 
EG:8976),AKT1,SORBS1,SDC2,EFNA5,GNA13,RASA1,GNG4,ITGB1,SRC,GRIN2B,A
KT2,PAK2,ANGPT1,GNAQ,VEGFC,GNAZ,EPHA3,FGF1,GRIN3A,ATF2,ROCK1,GNAI2,
GNAS,RRAS2,ABI1,PAK3,ACP1,EPHA5,EPHB3,PAK7,GNG2,GNAL,RAPGEF1 
Glioma Signaling 4.36E+00 2.77E-01 
PIK3CA,CAMK4,MAPK1,CAMK1D,PA2G4,EGF,HRAS,CCND1,E2F6,MTOR,AKT1,CAMK
2D,CAMK2A,IGF1,CAMK1G,IGF1R,PRKD1,CAMK2B,PDGFRB,TP53,AKT2,PRKCQ,CD
K6,PLCG1,PIK3R3,RRAS2,CDK4,CDKN1A,PRKCH,PRKCB,CAMK2G 
Protein Kinase A Signaling 4.23E+00 2.32E-01 
CREM,MAPK1,NFATC3,GNB5,NTN1,TCF7,MYLK,GNB4,CAMK2A,CAMK2D,PDE7B,PLC
B1,GNA13,GSK3B,ANAPC11,PLCL1,PRKD1,PPP1R14C,PRKCQ,ADD2,PDE10A,PPP1R
1B,YWHAB,YWHAZ,PPP1R14A,PPP3CC,ATF2,PDE8A,MYL9 (includes 
EG:10398),AKAP13,ANAPC4,MYL12B,PDE1B,PPP1R12A,PRKCH,GNG2,CAMK2G,AK
AP12,HIST1H1C,FLNB,CAMK4,PDE7A,PDIA3,PPP1R3C,PPP1CB,PDE1A,BRAF,NFKBI
A,GNG11,PPP3CB,DCC,TGFB2,RYR1,CHUK,ADCY8,GNG4,CAMK2B,ADCY2,ADCY6,G
NAQ,PLCG1,PYGL,AKAP6,PYGB,GNAI2,ROCK1,GNAS,AKAP2,PLCB4,ADCY1,ADD1,A
DCY7,PRKCB 
cAMP-mediated Signaling 4.20E+00 2.73E-01 
AKAP12,CAMK4,CREM,CAMK1D,PDE7A,HTR4,MAPK1,GRM3,DUSP6,HTR1D,PDE1A,
BRAF,CAMK2A,CAMK2D,PPP3CB,PDE7B,CAMK1G,ADORA2B,RGS14,ADCY8,CAMK2
B,SRC,ADCY2,PDE10A,ADCY6,RGS4,AKAP6,RAPGEF3,GRM4,PPP3CC,DRD2,ATF2,G
NAI2,PDE8A,GNAS,AKAP13,AKAP2,DUSP1,PKIB,ADCY1,PDE1B,ADCY7,AGTR1,CAM
K2G 
PPARŒ±/RXRŒ± 
Activation 4.15E+00 2.53E-01 
PPARA,GPD1,MAPK1,PDIA3,HRAS,MAP4K4,CYP2C44,ACVR2B,ABCA1,EP300,IKBKB,
NFKBIA,HSP90AB1,MAP3K7,GPD2,LPL,TGFB2,PRKAA2,PLCB1,NCOR1,CHUK,PLCL1,
ADCY8,ACVR1C,ITGB5,ADCY2,ACAA1,MED1,MAPK8,ADCY6,GNAQ,PLCG1,MED12,G
NAS,PLCB4,ACADL,GHR,RRAS2,IRS1,ADCY1,MAP2K3,NCOR2,ADCY7,TGS1,PPARG
C1A,PRKCB 
RAR Activation 4.15E+00 2.54E-01 
NSD1,PIK3CA,NR2F2,SMAD5,RBP1,SMARCA4,EP300,VEGFA,NR2F1,AKT1,ALDH1A1
,RARB,TGFB2,CSNK2A1,GTF2H5,NCOR1,ADCY8,MAPKAPK2,ZBTB16,SMAD1,RDH1
3,PRKD1,SRC,ADCY2,AKT2,PRKCQ,MED1,CDK7,SMAD7,MAPK8,ADCY6,PIK3R3,CS
NK2A2,RXRG,DUSP1,SMARCA2,ALDH1A2,ADCY1,PRKCH,NCOR2,NRIP1,ADCY7,SC
AND1,PPARGC1A,RBP4,PRKCB 
Aryl Hydrocarbon Receptor 
Signaling 4.05E+00 2.53E-01 
TRIP11,NFIX,GSTM5,MAPK1,ALDH1L1,CCND1,SMARCA4,EP300,ARNT,NR2F1,ALDH
1A1,SP1,HSP90AB1,GSTA4,ALDH3A2,RARB,TGFB2,NFE2L2,GSTK1,ATM,TP53,SRC,
MGST1,CCNE2,MED1,CDK6,MAPK8,ALDH9A1,RXRG,NFIA,CDK4,CDKN1A,ALDH1A2,
ALDH18A1,NFIB,NCOR2,NRIP1,ATR,MGST3 
Wnt/Œ≤-catenin Signaling 3.90E+00 2.68E-01 
TCF4,CSNK1G1,SOX1,ACVR2B,FZD1,BCL9,WNT9A,WNT8B,CCND1,EP300,SOX2,W
NT7A,AKT1,MAP3K7,DKK3,RARB,PPM1L,TGFB2,CSNK2A1,PPP2R2C,GSK3B,ACVR1
C,SOX5 (includes 
EG:6660),TP53,SOX4,SRC,GJA1,AKT2,PPP2R5C,PPARD,HDAC1,GNAQ,SOX11,APC,
CSNK2A2,SOX6,PPP2R3A,TLE3,FZD3,FZD6,SOX8,SFRP1,PPP2R1B,LRP1,TCF7L2 
CDK5 Signaling 3.88E+00 3.01E-01 
MAPK1,PPP1R3C,MAPT,HRAS,PPP1CB,CDK5R1,PPM1L,LAMB1,PPP2R2C,ADCY8,ITG
B1,PPP1R14C,ADCY2,PPP2R5C,PPP1R1B,EGR1,ITGA6,ADCY6,PPP1R14A,GNAS,NTR
K2,RRAS2,PPP2R3A,ADCY1,PPP1R12A,PPP2R1B,ADCY7,GNAL 
B Cell Receptor Signaling 3.80E+00 2.60E-01 
GAB2,PIK3CA,CAMK4,MAPK1,NFATC3,HRAS,INPPL1,FCGR2B,PTPRC,IKBKB,MAP3K
10,MTOR,CAMK2A,NFKBIA,CAMK2D,AKT1,PPP3CB,MAP3K7,RPS6KB2,GSK3B,CHUK
,CAMK2B,MAP3K9,PTPN6,AKT2,PRKCQ,FCGR2A,EGR1,MAPK8,PPP3CC,MALT1,ATF2
,PIK3R3,RRAS2,DAPP1,VAV3,MAP2K3,MAP3K3,CAMK2G,PRKCB 
NRF2-mediated Oxidative 
Stress Response 3.75E+00 2.51E-01 
FTL,PIK3CA,GSTM5,MAPK1,MAF,HSPB8,GCLC,HRAS,EP300,AKT1,GSTA4,MAP3K7,A
BCC1,DNAJC8,DNAJC1,UBE2K,DNAJA2,FMO1,GCLM,TXN,GSK3B,NFE2L2,PRKD1,AC
TA1,GSTK1,MGST1,PRKCQ,DNAJB12,SOD1,ACTB,DNAJC19,MAPK8,DNAJB14,TXNR
D1,BACH1,PIK3R3,RRAS2,CAT,MAP2K3,PRKCH,AOX1,DNAJB6,MAP2K5,MGST3,EPH
X1,PRKCB 
Huntington's Disease 
Signaling 3.72E+00 2.33E-01 
POLR2F,POLR2D,MAPK1,GNB5,HRAS,CDK5R1,HDAC6,NSF,MAP3K10,GNB4,CPLX2,
PLCB1,TCERG1,RASA1,PRKD1,CAPN5,TP53,AKT2,PRKCQ,CASP3,RPH3A,ATF2,PIK3
R3,CACNA1B,PENK,HTT,PRKCH,CAPN2,CAPN7,GNG2,POLR2I,PIK3CA,EGF,EP300,M
TOR,AKT1,GNG11,POLR2A,SP1,IGF1,IGF1R,NCOR1,GOSR1,GNG4,NEUROD1,GRIN
2B,YKT6,HDAC1,GNAQ,MAPK8,HIP1,RCOR1,PLCB4,HAP1,NCOR2,PRKCB 
Melatonin Signaling 3.54E+00 2.99E-01 
CAMK4,PRKCQ,MAPK1,PDIA3,GNAQ,PLCG1,BRAF,GNAI2,PLCB4,CAMK2A,CAMK2D,
ARAF,RORA,PLCB1,MAP2K3,PRKCH,PLCL1,RORB,MAP2K5,PRKD1,CAMK2G,CAMK2B
,PRKCB 
IL-8 Signaling 3.46E+00 2.37E-01 
PIK3CA,MAPK1,GNB5,EGF,HRAS,MAP4K4,CCND1,LIMK1,IRAK1,VEGFA,BRAF,IKBK
B,GNB4,MTOR,AKT1,GNG11,RHOU,GNA13,CHUK,GNG4,PRKD1,SRC,VCAM1,AKT2,
PRKCQ,PAK2,ANGPT1,RHOC,MAPK8,VEGFC,PLD1,CSTB,GNAI2,ROCK1,PIK3R3,GNA
S,RRAS2,ARAF,RND3,MYL12B,PRKCH,PTGS2,GNG2,PRKCB 
Cardiac Œ≤-adrenergic 
Signaling 3.37E+00 2.39E-01 
AKAP12,PDE7A,PPP1R1A,PPP1R3C,GNB5,PPP1CB,PDE1A,GNB4,GNG11,PDE7B,PPM
1L,PPP2R2C,ADCY8,GNG4,PPP1R14C,ADCY2,PPP2R5C,PDE10A,ADRBK2,ADCY6,PP
P1R14A,AKAP6,PDE8A,AKAP13,GNAS,AKAP2,PPP2R3A,PKIB,ADCY1,PDE1B,PPP1R1
2A,GNG2,PPP2R1B,ADCY7 
G-Protein Coupled 
Receptor Signaling 3.30E+00 2.32E-01 
MAPK1,GRM3,HRAS,IKBKB,CAMK2D,CAMK2A,PDE7B,PLCB1,RGS14,ADORA2B,RAS
A1,AKT2,PDE10A,RGS4,RAPGEF3,GRM4,DRD2,ATF2,PIK3R3,PDE8A,DUSP1,PDE1B,
AGTR1,CAMK2G,PIK3CA,CAMK4,GPR12,PDE7A,HTR4,DUSP6,HTR1D,PDE1A,BRAF,
AKT1,NFKBIA,CHUK,ADCY8,CAMK2B,SRC,ADCY2,EDNRB,ADCY6,GNAQ,GNAI2,GNA
S,PLCB4,RRAS2,RASGRP1,ADCY1,ADCY7,PRKCB 
GNRH Signaling 3.23E+00 2.36E-01 
MAPK1,EGF,HRAS,MAP3K10,CAMK2D,CAMK2A,MAP3K7,PLCB1,ADCY8,PRKD1,CAM
K2B,SRC,MAP3K9,ADCY2,PRKCQ,PAK2,EGR1,GNAQ,MAPK8,ADCY6,ATF2,GNAI2,G
NAS,PLCB4,RRAS2,PAK3,ADCY1,MAP2K3,PAK7,PRKCH,ADCY7,MAP3K3,PRKCB,CA
MK2G 
Neuropathic Pain Signaling 
In Dorsal Horn Neurons 3.17E+00 2.72E-01 
PIK3CA,CAMK4,MAPK1,CAMK1D,GRM3,PDIA3,CAMK2D,CAMK2A,GPR37,CAMK1G,P
LCB1,KCNQ3,PLCL1,PRKD1,CAMK2B,GRIN2B,SRC,PRKCQ,GRIA2,PLCG1,GRM4,GRI
N3A,PIK3R3,PLCB4,NTRK2,PRKCH,PRKCB,CAMK2G 
Nicotinate and 
Nicotinamide Metabolism 3.14E+00 2.13E-01 
MAPK1,IRAK1,LIMK1,BRAF,PRKX,NEK2,PRPF4B,PRKAA2,MAP3K9,CDK18,AKT2,DAP
K1,ENPP1,PAK2,PRKCQ,CDK7,MAPK8,CDK6,PAK3,ARAF,NT5E,CDK4,MAP2K3,PRKC
H,PAK7,DUSP18,AOX1,NMNAT3 (includes EG:349565),DUSP16 
FcŒ≥ Receptor-mediated 
Phagocytosis in 
Macrophages and 
Monocytes 3.05E+00 2.67E-01 
GAB2,MAPK1,ARPC1B,DGKB,CRK,NCK1,ARF6,YES1,AKT1,EZR,RPS6KB2,PRKD1,AC
TA1,SRC,AKT2,PRKCQ,FCGR2A,ACTB,PLCG1,PLD1,MYO5A,PIK3R3,PIP5K1A,CBL,VA
V3,PRKCH,PRKCB 
Inositol Phosphate 
Metabolism 2.99E+00 2.05E-01 
MINPP1,PIK3CA,MAPK1,PDIA3,INPPL1,LIMK1,IRAK1,BRAF,PRKX,NEK2,PRPF4B,PRK
AA2,PLCB1,PLCL1,ATM,CDK18,MAP3K9,DAPK1,AKT2,PAK2,PRKCQ,CDK7,MAPK8,C
DK6,PLCG1,ITPKA,PIK3R3,PIP5K1A,PLCB4,ARAF,PAK3,CDK4,PAK7,MAP2K3,PRKCH
,PIP4K2A 
HER-2 Signaling in Breast 
Cancer 2.96E+00 2.91E-01 
TP53,ITGB1,PIK3CA,CCNE2,AKT2,PRKCQ,CDK6,HRAS,EGF,PLCG1,PARD6B,CCND1,
PIK3R3,AKT1,RRAS2,FOXO1,CDKN1A,PRKCH,GSK3B,PARD3,ITGB5,PRKD1,PRKCB 
RhoA Signaling 2.96E+00 2.73E-01 
ARPC1B,SEPT3,LIMK1,MYLK,IGF1,EZR,CIT,BAIAP2,IGF1R,CDC42EP1,GNA13,ACTA
1,SEPT8,ACTB,RDX,SEPT4,ANLN,DLC1,PLD1,ROCK1,MYL9 (includes 
EG:10398),KTN1,PIP5K1A,RHPN2,LPAR1,MYL12B,PPP1R12B,PPP1R12A,PIP4K2A,M
SN 
Small Cell Lung Cancer 
Signaling 2.93E+00 2.47E-01 
TP53,TRAF3,PIK3CA,CCNE2,FHIT,AKT2,PA2G4,CDK6,CCND1,SKP2,PIK3R3,RXRG,I
KBKB,AKT1,MAX,NFKBIA,CDK4,RARB,CKS1B,BID,CHUK,PTGS2 
Chemokine Signaling 2.93E+00 2.93E-01 SRC,CAMK4,MAPK1,CAMK1D,GNAQ,MAPK8,PPP1CB,HRAS,PLCG1,LIMK1,GNAI2,PL
CB4,RRAS2,CAMK2D,CAMK2A,PPP1R12B,CAMK1G,PLCB1,PPP1R12A,CAMK2B,CAM
K2G,PRKCB 
PTEN Signaling 2.93E+00 2.52E-01 
PIK3CA,MAPK1,HRAS,INPPL1,CCND1,IKBKB,AKT1,CSNK2A1,RPS6KB2,CHUK,GSK3
B,PDGFRB,ITGB1,AKT2,CASP3,PIK3R3,CSNK2A2,BMPR1B,GHR,MAGI1,RRAS2,CBL,
FOXO1,CDKN1A,MAGI2,BCL2L11 
Cardiac Hypertrophy 
Signaling 2.91E+00 2.18E-01 
MAPK1,GNB5,HRAS,MAP3K10,GNB4,PLCB1,GNA13,GSK3B,PLCL1,MAP3K9,GNAZ,P
PP3CC,ATF2,MYL9 (includes 
EG:10398),PIK3R3,RND3,MYL12B,IRS1,MAP2K3,GNG2,GNAL,PIK3CA,CAMK4,PDIA
3,EIF4E,EP300,MTOR,AKT1,GNG11,IGF1,PPP3CB,MAP3K7,IGF1R,RHOU,TGFB2,MA
PKAPK2,ADCY8,GNG4,ADCY2,RHOC,GNAQ,MAPK8,ADCY6,PLCG1,ROCK1,GNAI2,G
NAS,PLCB4,RRAS2,ADCY1,MEF2C,ADCY7,MAP3K3 
14-3-3-mediated Signaling 2.76E+00 2.63E-01 
PIK3CA,MAPK1,PDIA3,MAPT,HRAS,AKT1,PLCB1,GFAP,TUBA1C,GSK3B,PLCL1,PRKD
1,SRC,AKT2,PRKCQ,TUBB2C,YWHAB,TUBB2A,YWHAZ,MAPK8,PLCG1,VIM,PIK3R3,P
LCB4,CBL,RRAS2,FOXO1,YAP1,PRKCH,PRKCB 
Colorectal Cancer 
Metastasis Signaling 2.73E+00 2.17E-01 
JAK1,MAPK1,MMP16,GNB5,HRAS,WNT9A,CCND1,TCF7,VEGFA,GNB4,GSK3B,TP53,
AKT2,CASP3,ADRBK2,VEGFC,APC,PIK3R3,RND3,FZD3,FZD6,GNG2,PTGER2,IL6ST,
SIAH1,PIK3CA,MMP14,EGF,FZD1,WNT8B,MLH1,BRAF,APPL1,WNT7A,AKT1,GNG11,
DCC,RHOU,TGFB2,ADCY8,STAT1,GNG4,SRC,ADCY2,RHOC,MAPK8,ADCY6,GNAS,R
RAS2,ADCY1,MSH6,PTGS2,ADCY7,LRP1 
Synaptic Long Term 
Depression 2.69E+00 2.25E-01 
MAPK1,GRM3,HRAS,PRKG1,IGF1,PPM1L,IGF1R,RYR1,PLCB1,PPP2R2C,GNA13,ADC
Y8,PRKD1,TMEM87B,ADCY2,PRKCQ,PPP2R5C,GUCY1A3,GNAQ,GRIA2,YWHAZ,ADC
Y6,GNAZ,GRM4,GNAI2,PLA2G4A,GNAS,PLCB4,RRAS2,PPP2R3A,PRKCH,PPP2R1B,A
DCY7,NPR2,GNAL,PRKCB 
Glioblastoma Multiforme 
Signaling 2.69E+00 2.27E-01 
PIK3CA,MAPK1,PDIA3,NF2,EGF,HRAS,FZD1,WNT9A,WNT8B,CCND1,E2F6,MTOR,AK
T1,WNT7A,IGF1,RHOU,IGF1R,PLCB1,GSK3B,PLCL1,PDGFRB,TP53,SRC,AKT2,RHOC
,CDK6,PLCG1,APC,PIK3R3,PLCB4,RRAS2,FOXO1,RND3,CDK4,CDKN1A,FZD3,FZD6 
p70S6K Signaling 2.66E+00 2.44E-01 
PIK3CA,JAK1,MAPK1,PDIA3,MAPT,HRAS,MTOR,AKT1,PPM1L,PLCB1,PPP2R2C,PLCL1
,PRKD1,SRC,AKT2,PRKCQ,PPP2R5C,YWHAB,GNAQ,YWHAZ,PLCG1,PLD1,GNAI2,PIK
3R3,PLCB4,RRAS2,PPP2R3A,IRS1,PRKCH,PPP2R1B,AGTR1,PRKCB 
Antiproliferative Role of 
Somatostatin Receptor 2 2.63E+00 2.69E-01 
SRC,PTPN6,ADCY2,PIK3CA,MAPK1,GUCY1A3,GNB5,ADCY6,HRAS,BRAF,PIK3R3,GN
B4,RRAS2,GNG11,CDKN1A,SST,GNG2,ADCY8,GNG4,ADCY7,NPR2 
Production of Nitric Oxide 
and Reactive Oxygen 
Species in Macrophages 2.57E+00 2.05E-01 
PPARA,PIK3CA,JAK1,MAPK1,PPP1R3C,PPP1CB,ARG2,IKBKB,MAP3K10,AKT1,NFKBI
A,MAP3K7,PPM1L,RHOU,PPP2R2C,CHUK,STAT1,PRKD1,PPP1R14C,MAP3K9,PTPN6,
AKT2,PRKCQ,PPP2R5C,RHOC,IFNGR2,MAPK8,PLCG1,PPP1R14A,PIK3R3,RND3,PPP2
R3A,CAT,PPP1R12A,PRKCH,PPP2R1B,MAP3K3,PRKCB 
CCR3 Signaling in 
Eosinophils 2.57E+00 2.42E-01 
PIK3CA,CAMK4,MAPK1,GNB5,HRAS,PPP1CB,LIMK1,MYLK,GNB4,GNG11,PLCB1,GN
G4,PRKD1,PAK2,PRKCQ,ROCK1,GNAI2,PIK3R3,PLA2G4A,GNAS,PLCB4,RRAS2,PAK
3,PPP1R12B,PPP1R12A,PAK7,PRKCH,GNG2,PRKCB 
PI3K/AKT Signaling 2.49E+00 2.26E-01 
GAB2,PIK3CA,JAK1,MAPK1,HRAS,INPPL1,CCND1,EIF4E,IKBKB,MTOR,AKT1,NFKBIA
,HSP90AB1,PPM1L,RPS6KB2,PPP2R2C,GSK3B,CHUK,TP53,ITGB1,AKT2,PPP2R5C,Y
WHAB,YWHAZ,MAPK8IP1,PIK3R3,RRAS2,FOXO1,PPP2R3A,CDKN1A,PPP2R1B 
Germ Cell-Sertoli Cell 
Junction Signaling 2.47E+00 2.34E-01 
PIK3CA,MAPK1,MYO7A,PVRL3,HRAS,IQGAP1,LIMK1,MAP3K10,WASL (includes 
EG:8976),AKT1,MAP3K7,SORBS1,PPAP2B,TGFB2,RHOU,TUBA1C,ACTA1,ITGB1,MA
P3K9,SRC,PAK2,RHOC,TUBB2C,ACTB,TUBB2A,ITGA6,MAPK8,GSN,PIK3R3,RRAS2,
RND3,PAK3,ZYX,MAP2K3,PAK7,MAP3K3,CTNND1 
Growth Hormone Signaling 2.46E+00 2.71E-01 
PTPN6,PIK3CA,PRKCQ,MAPK1,SOCS2,PLCG1,ONECUT1,PIK3R3,GHR,IGF1,IRS1,IG
F1R,RPS6KB2,RPS6KA4,RPS6KA5,PRKCH,STAT1,PRKD1,PRKCB 
G Beta Gamma Signaling 2.44E+00 2.10E-01 
MAPK1,GNB5,HRAS,GNB4,GNG11,AKT1,GNA13,GNG4,PRKD1,SRC,ADCY2,AKT2,PR
KCQ,GNAQ,PLCG1,KCNJ3,GNAZ,GNAI2,GNAS,RRAS2,ADCY1,PRKCH,GNG2,GNAL,P
RKCB 
Relaxin Signaling 2.43E+00 2.15E-01 
PIK3CA,PDE7A,MAPK1,GNB5,PDE1A,VEGFA,BRAF,GNB4,GNG11,AKT1,NFKBIA,PDE
7B,GNA13,ADCY8,GNG4,ADCY2,AKT2,GUCY1A3,PDE10A,GNAQ,ADCY6,GNAZ,PDE8
A,GNAI2,PIK3R3,GNAS,ADCY1,PDE1B,GNG2,NPR2,ADCY7,GNAL 
Ovarian Cancer Signaling 2.43E+00 2.37E-01 
PIK3CA,MAPK1,PA2G4,EGF,HRAS,FZD1,WNT9A,WNT8B,CCND1,TCF7,MLH1,VEGFA
,BRAF,MTOR,WNT7A,AKT1,RPS6KB2,GSK3B,TP53,SRC,GJA1,AKT2,PTGS1,VEGFC,A
PC,PIK3R3,RRAS2,CDK4,FZD3,MSH6,FZD6,PTGS2 
Sphingosine-1-phosphate 
Signaling 2.41E+00 2.41E-01 
PIK3CA,MAPK1,PDIA3,AKT1,RHOU,PLCB1,GNA13,PLCL1,ADCY8,SMPD3,PDGFRB,A
DCY2,AKT2,CASP3,S1PR5,RHOC,GNAQ,ADCY6,PLCG1,SMPD2,GNAI2,PIK3R3,S1PR
3,PLCB4,RND3,ADCY1,ADCY7 
Macropinocytosis Signaling 2.37E+00 2.64E-01 
ITGB1,SRC,PIK3CA,PRKCQ,USP6NL,HRAS,EGF,PLCG1,CSF1R,PIK3R3,ANKFY1,ARF
6,RRAS2,ABI1,CSF1,PRKCH,ITGB5,PRKD1,PRKCB 
Valine, Leucine and 
Isoleucine Degradation 2.34E+00 1.80E-01 
ACAA1,ECH1,ACAD9,ALDH9A1,ELOVL6,ACAA1B,HIBCH,HADHB,ACADL,ALDH1A1,P
CCA,ACADVL,ALDH3A2,ALDH1A2,DBT,OXCT1,MCCC1,AOX1,ACADM,HADH 
Endothelin-1 Signaling 2.33E+00 2.16E-01 
PIK3CA,MAPK1,PDIA3,HRAS,SHC3,BRAF,PLCB1,GNA13,ADCY8,PLCL1,PRKD1,TME
M87B,SRC,ADCY2,PRKCQ,EDNRB,CASP3,GUCY1A3,PTGS1,GNAQ,YWHAZ,MAPK8,A
DCY6,PLCG1,GNAZ,PLD1,GNAI2,PIK3R3,PLA2G4A,GNAS,PLCB4,RRAS2,ARAF,ADCY
1,PRKCH,PTGS2,PTGER2,ADCY7,GNAL,PRKCB 
Œ±-Adrenergic Signaling 2.32E+00 2.26E-01 
ADCY2,CAMK4,PRKCQ,MAPK1,GNAQ,ADCY6,GNB5,HRAS,PLCG1,PYGB,PYGL,GNAI2
,GNAS,GNB4,GNG11,RRAS2,ADCY1,PRKCH,GNG2,ADCY8,GNG4,ADCY7,PRKD1,PR
KCB 
mTOR Signaling 2.31E+00 2.18E-01 
PIK3CA,MAPK1,FKBP1A,HRAS,HIF1A,RICTOR,EIF4E,VEGFA,MTOR,AKT1,EIF3D,PPM
1L,PRKAA2,RPS6KB2,EIF3A,RHOU,PPP2R2C,PRKD1,AKT2,PRKCQ,PPP2R5C,RHOC,V
EGFC,PLD1,PIK3R3,RRAS2,RND3,PPP2R3A,IRS1,RPS6KA4,RPS6KA5,PRKCH,PPP2R
1B,PRKCB 
Angiopoietin Signaling 2.29E+00 2.57E-01 
PIK3CA,AKT2,PAK2,ANGPT1,HRAS,CRK,NCK1,PIK3R3,IKBKB,TNIP1,NFKBIA,AKT1,
RRAS2,FOXO1,PAK3,IKBKAP,PAK7,CHUK,RASA1 
Role of NFAT in Regulation 
of the Immune Response 2.19E+00 2.04E-01 
PIK3CA,CAMK4,CSNK1G1,MAPK1,NFATC3,CD4,GNB5,HRAS,FCGR2B,CABIN1,IKBK
B,GNB4,NFKBIA,GNG11,AKT1,PPP3CB,PLCB1,GSK3B,GNA13,CHUK,GNG4,HLA-
DMA,AKT2,PRKCQ,FCGR2A,GNAQ,PLCG1,GNAZ,PPP3CC,ATF2,GNAI2,PIK3R3,GNAS
,PLCB4,RRAS2,RCAN3,IKBKAP,MEF2C,GNG2,GNAL 
p53 Signaling 2.19E+00 2.61E-01 
TP53,WT1,PRKDC,PIK3CA,AKT2,JMY,MED1,RRM2B,HDAC1,MAPK8,C12ORF5,RPRM,
CCND1,EP300,CCNG1,PIK3R3,PCNA,AKT1,CDK4,CDKN1A,GSK3B,HIPK2,ATR,ATM 
Integrin Signaling 2.18E+00 2.20E-01 
PIK3CA,RALA,ARPC1B,MAPK1,HRAS,PPP1CB,MYLK,BRAF,ARF6,WASL (includes 
EG:8976),AKT1,ITGA9,RHOU,GSK3B,ITGB5,ACTA1,ITGB1,CAPN5,SRC,PARVA,AKT
2,PAK2,RHOC,ASAP1,ACTB,ITGA6,MAPK8,PLCG1,TNK2,ROCK1,PIK3R3,RRAS2,RND
3,PAK3,ARF3,MYL12B,PPP1R12B,PPP1R12A,ZYX,PAK7,CAPN2,CAPN7,TSPAN6,RAP
GEF1 
Estrogen Receptor 
Signaling 2.16E+00 2.35E-01 
TAF4B,POLR2F,TAF11,POLR2D,MAPK1,HRAS,TAF7,SMARCA4,EP300,PGR,SPEN,POL
R2A,PCK2,CTBP2,GTF2H5,NCOR1,PRKDC,SRC,MED1,TAF15,CDK7,TAF1,RRAS2,NC
OR2,NRIP1,TRRAP,POLR2I,PPARGC1A 
Melanocyte Development 
and Pigmentation 
Signaling 2.15E+00 2.50E-01 
SRC,PTPN6,ADCY2,PIK3CA,MAPK1,MITF,ADCY6,HRAS,PLCG1,CRK,ATF2,EP300,PIK
3R3,KITLG,GNAS,RRAS2,ADCY1,RPS6KB2,RPS6KA4,RPS6KA5,ADCY8,ADCY7 
Role of PKR in Interferon 
Induction and Antiviral 
Response 2.13E+00 2.83E-01 
TP53,TRAF3,CASP3,RNASEL,ATF2,IKBKB,AKT1,NFKBIA,MAP3K7,BID,MAP2K3,CHU
K,STAT1 
IL-1 Signaling 2.12E+00 2.26E-01 
ADCY2,GNAQ,ADCY6,MAPK8,GNB5,GNAZ,IRAK1,GNAI2,GNB4,IKBKB,GNAS,NFKBI
A,GNG11,MAP3K7,ADCY1,MAP2K3,CHUK,GNA13,GNG2,ADCY8,IL1RAP,GNG4,ADCY
7,GNAL 
SAPK/JNK Signaling 2.12E+00 2.45E-01 
TP53,MAP3K9,PIK3CA,NFATC3,MAPK8IP2,MAPK8,HRAS,CRK,MAP4K4,MAPK8IP3,M
APK8IP1,ATF2,MAP4K3,PIK3R3,TRADD,MAP3K10,GNG11,RRAS2,MAP3K7,IRS1,ZA
K,GNA13,GNG2,MAP3K3 
Renal Cell Carcinoma 
Signaling 2.06E+00 2.64E-01 
PIK3CA,AKT2,PAK2,MAPK1,HRAS,CRK,HIF1A,ARNT,EP300,PIK3R3,VEGFA,TCEB2,R
RAS2,AKT1,PAK3,TGFA,EGLN3,PAK7,RAPGEF1 
Androgen Signaling 2.04E+00 1.94E-01 
POLR2F,POLR2D,CAMK4,MAPK1,GNB5,CCND1,EP300,GNB4,TGFB1I1,AR,GNG11,P
OLR2A,GTF2H5,GNA13,GNG4,PRKD1,SRC,PRKCQ,CDK7,GNAQ,GNAZ,GNAI2,GNAS
,PRKCH,GNG2,POLR2I,GNAL,PRKCB 
Phospholipase C Signaling 2.00E+00 1.98E-01 
MAPK1,NFATC3,GNB5,HRAS,HDAC6,GNB4,PLCB1,GNA13,PRKD1,PRKCQ,PPP1R14A
,RAPGEF3,PPP3CC,PLD1,ATF2,MYL9 (includes 
EG:10398),RND3,MYL12B,PPP1R12B,PPP1R12A,PRKCH,GNG2,RALA,CAMK4,PPP1C
B,FCGR2B,EP300,GNG11,PPP3CB,RHOU,ADCY8,GNG4,ITGB1,SRC,ADCY2,RHOC,FC
GR2A,HDAC1,ADCY6,GNAQ,PLCG1,PLA2G4A,GNAS,PLCB4,ARHGEF10,RRAS2,ADCY
1,MEF2C,ADCY7,PRKCB 
Renin-Angiotensin 
Signaling 1.99E+00 2.17E-01 
PIK3CA,MAPK1,SHC3,HRAS,ADCY8,STAT1,PRKD1,PTPN6,ADCY2,PAK2,PRKCQ,MAP
K8,ADCY6,GNAQ,PLCG1,ATF2,PIK3R3,RRAS2,PAK3,ADCY1,PRKCH,PAK7,PTGER2,A
DCY7,AGTR1,PRKCB 
IL-3 Signaling 1.99E+00 2.64E-01 
GAB2,PTPN6,PIK3CA,AKT2,JAK1,PRKCQ,MAPK1,HRAS,PPP3CC,PIK3R3,AKT1,RRAS
2,FOXO1,PPP3CB,PRKCH,STAT1,PRKD1,RAPGEF1,PRKCB 
Non-Small Cell Lung 
Cancer Signaling 1.94E+00 2.28E-01 
TP53,PIK3CA,FHIT,AKT2,PA2G4,MAPK1,CDK6,HRAS,EGF,PLCG1,CCND1,PIK3R3,RX
RG,RRAS2,AKT1,CDK4,RARB,TGFA 
Melanoma Signaling 1.94E+00 2.83E-01 
TP53,PIK3CA,AKT2,MAPK1,MITF,HRAS,CCND1,PIK3R3,BRAF,AKT1,RRAS2,CDK4,C
DKN1A 
Role of BRCA1 in DNA 1.91E+00 2.62E-01 TP53,RBBP8,RFC1,RFC5,SMARCA4,MLH1,BACH1,E2F6,POU2F1,SMARCA2,CDKN1A,
Damage Response MSH6,BLM,STAT1,ATR,ATM 
Cell Cycle: G1/S 
Checkpoint Regulation 1.91E+00 2.71E-01 
TP53,CCNE2,PA2G4,HDAC1,CDK6,CCND1,SKP2,HDAC6,E2F6,MAX,CDK4,CDKN1A,
TGFB2,GSK3B,ATR,ATM 
Prostate Cancer Signaling 1.90E+00 2.19E-01 
TP53,PIK3CA,CCNE2,AKT2,PA2G4,MAPK1,HRAS,CCND1,ATF2,PIK3R3,MTOR,AR,RR
AS2,NFKBIA,AKT1,FOXO1,HSP90AB1,CDKN1A,NKX3-1,CHUK,GSK3B 
Notch Signaling 1.90E+00 2.79E-01 
ADAM17,NOTCH2,CNTN1,DTX1,DTX4,MAG,HES5,PSEN2,PSENEN,JAG1,NOTCH1,HE
Y1 
Regulation of Actin-based 
Motility by Rho 1.89E+00 2.39E-01 
PAK2,ARPC1B,RHOC,ACTB,PPP1CB,GSN,LIMK1,MYL9 (includes 
EG:10398),ROCK1,MYLK,PIP5K1A,WASL (includes 
EG:8976),RND3,PAK3,MYL12B,BAIAP2,PPP1R12B,RHOU,PPP1R12A,PAK7,PIP4K2A,
ACTA1 
Xenobiotic Metabolism 
Signaling 1.89E+00 2.02E-01 
FTL,MAPK1,CAMK1D,MAF,HRAS,GCLC,CHST15,ARNT,MAP3K10,CAMK2A,CAMK2D,
ALDH1A1,ALDH3A2,PPM1L,PRKD1,GSTK1,MAP3K9,MGST1,PRKCQ,MED1,GRIP1,UG
T1A1,ALDH9A1,PIK3R3,PPP2R3A,ALDH1A2,PRKCH,ALDH18A1,MAP2K3,CYP2B6,ND
ST1,MGST3,MAP2K5,CAMK2G,GAL3ST2,PIK3CA,CAMK4,GSTM5,ALDH1L1,EP300,H
SP90AB1,GSTA4,MAP3K7,CAMK1G,FMO1,PPP2R2C,NFE2L2,CAMK2B,PPP2R5C,MAP
K8,RRAS2,CAT,NRIP1,NCOR2,PPP2R1B,MAP3K3,SCAND1,PRKCB,PPARGC1A 
Factors Promoting 
Cardiogenesis in 
Vertebrates 1.84E+00 2.36E-01 
CCNE2,PRKCQ,SMAD5,FZD1,ACVR2B,TCF7,APC,ATF2,BMPR1B,MAP3K7,FZD6,TGFB
2,FZD3,MEF2C,PRKCH,GSK3B,ACVR1C,SMAD1,LRP1,PRKD1,PRKCB 
TR/RXR Activation 1.83E+00 2.27E-01 
AKT2,PIK3CA,CAMK4,MED1,GRIP1,ME1,HIF1A,DIO2,NRGN,EP300,PIK3R3,RXRG,K
LF9,MTOR,AKT1,SLC16A2,SYT2,ACACA,NCOR1,STRBP,NCOR2,PPARGC1A 
FAK Signaling 1.83E+00 2.24E-01 
ITGB1,CAPN5,SRC,PIK3CA,AKT2,PAK2,MAPK1,ASAP1,ACTB,HRAS,EGF,PLCG1,CRK,
PIK3R3,AKT1,RRAS2,PAK3,PAK7,CAPN2,CAPN7,TNS1,ACTA1 
PAK Signaling 1.83E+00 2.16E-01 
ITGB1,PIK3CA,PAK2,MAPK1,CASP3,PAK1IP1,MAPK8,HRAS,EPHA3,NCK1,LIMK1,MY
LK,MYL9 (includes EG:10398),PIK3R3,WASL (includes 
EG:8976),RRAS2,PAK3,MYL12B,EPHB3,DSCAM,PAK7,PDGFRB 
NF-Œ∫B Activation by 
Viruses 1.79E+00 2.35E-01 
ITGB1,PIK3CA,AKT2,PRKCQ,MAPK1,CD4,ITGA6,HRAS,PIK3R3,IKBKB,NFKBIA,AKT1
,RRAS2,IKBKAP,PRKCH,CHUK,ITGB5,PRKD1,PRKCB 
Hereditary Breast Cancer 
Signaling 1.79E+00 2.17E-01 
POLR2F,PIK3CA,POLR2D,HRAS,CCND1,MLH1,SMARCA4,EP300,HDAC6,POLR2A,AK
T1,BLM,ATM,TP53,AKT2,HDAC1,CDK6,RFC1,RFC5,PIK3R3,RRAS2,SMARCA2,H2AFX
,CDK4,CDKN1A,MSH6,ATR,POLR2I 
Œ≤-alanine Metabolism 1.78E+00 1.53E-01 
DPYD,DPYSL3,ECH1,ACAD9,ALDH9A1,UPB1,HIBCH,HADHB,ACADL,ALDH1A1,ACAD
VL,ALDH3A2,ALDH1A2,MYO5B,ACADM 
VDR/RXR Activation 1.78E+00 2.50E-01 
WT1,PRKCQ,CCNC,PPARD,MED1,KLF4,EP300,RXRG,SP1,FOXO1,CDKN1A,TGFB2,C
SNK2A1,NCOR1,PRKCH,NCOR2,CALB1,CST6,PRKD1,PRKCB 
ERK5 Signaling 1.74E+00 2.54E-01 
IL6ST,SRC,YWHAB,GNAQ,YWHAZ,HRAS,EGF,ATF2,AKT1,RRAS2,RPS6KB2,WNK1,M
EF2C,RPS6KA4,RPS6KA5,GNA13,MAP3K3,MAP2K5 
PDGF Signaling 1.74E+00 2.37E-01 
SRC,PIK3CA,JAK1,MAPK1,MAPK8,HRAS,PLCG1,CRK,INPPL1,PIK3R3,CSNK2A2,RRA
S2,ACP1,CSNK2A1,STAT1,RASA1,PDGFRB,PRKCB 
CNTF Signaling 1.73E+00 2.69E-01 IL6ST,PIK3CA,JAK1,MAPK1,HRAS,PIK3R3,LIFR,MTOR,AKT1,RRAS2,RPS6KB2,RPS6
KA5,RPS6KA4,STAT1 
Hypoxia Signaling in the 
Cardiovascular System 1.67E+00 2.57E-01 
TP53,UBE2A,UBE2L3,UBE2V2,HIF1A,UBE2D1,ATF2,ARNT,EP300,VEGFA,NFKBIA,AK
T1,UBE2B,HSP90AB1,UBE2G1,UBE2E3,UBE2I,ATM 
Protein Ubiquitination 
Pathway 1.67E+00 2.04E-01 
USP21 (includes 
EG:27005),USP24,USP18,UBE2A,PSMD7,CDC20,PSMB10,UBE2L3,PSMD9,FBXW7,U
BE2V2,USP54,USP2,USP8,TCEB2,UBE2B,STUB1,UBE2E3,USP40,NEDD4L,ANAPC11
,HLA-
C,PSMD13,USP36,USP1,UBE3A,UBE2D1,XIAP,PSMD8,SKP2,ANAPC4,PSME1,CBL,PS
MB2,UBE2G1,PSMD1,USP46,SMURF2,PSMD4,USP34,UBE2I 
Cholecystokinin/Gastrin-
mediated Signaling 1.67E+00 2.31E-01 
SRC,CREM,PRKCQ,MAPK1,RHOC,GNAQ,MAPK8,HRAS,ATF2,ROCK1,PLCB4,RRAS2,R
ND3,IL1F5,RHOU,PLCB1,SST,MAP2K3,MEF2C,PRKCH,GNA13,MAP2K5,PRKD1,PRKC
B 
Neuregulin Signaling 1.66E+00 2.18E-01 
ITGB1,SRC,ADAM17,AKT2,PRKCQ,MAPK1,HRAS,EGF,PLCG1,CRK,CDK5R1,PIK3R3,
MTOR,AKT1,RRAS2,HSP90AB1,NRG3,RPS6KB2,TGFA,PRKCH,PRKD1,PRKCB 
Apoptosis Signaling 1.66E+00 2.33E-01 
TP53,CAPN5,PRKCQ,MAPK1,CASP3,MAPK8,HRAS,PLCG1,LMNA,MAP4K4,XIAP,ACIN
1,ROCK1,IKBKB,RRAS2,NFKBIA,BID,CAPN2,CHUK,SPTAN1,CAPN7 
Pantothenate and CoA 
Biosynthesis 1.66E+00 1.25E-01 PANK1,ENPP1,DPYD,DPYSL3,COASY,PANK4,UPB1,ILVBL 
Glycerophospholipid 
Metabolism 1.62E+00 1.56E-01 
DGKD,GPD1,PDIA3,DGKB,PGS1,LPIN1,PCYT1B,GPD2,PPAP2B,PLCB1,MGLL,LPIN2,P
LCL1,TMEM87B,YWHAZ,DGKE,PLCG1,ACHE,ETNK1,CERK,CDS2,PLD1,ELOVL6,AGP
AT4,PLA2G4A,PLCB4,LPCAT1,DGKK,DBT,CHKB 
Propanoate Metabolism 1.56E+00 1.31E-01 
ACAA1,SUCLG2,ACSS1,ECH1,ACAD9,ALDH9A1,HIBCH,HADHB,ACADL,ALDH1A1,PC
CA,ACADVL,ALDH3A2,ALDH1A2,ACACA,ACADM,ACSL1 
Role of Osteoblasts, 
Osteoclasts and 
Chondrocytes in 
Rheumatoid Arthritis 1.54E+00 1.93E-01 
PIK3CA,ADAM17,CAMK4,MAPK1,NFATC3,MMP14,FZD1,SMAD5,WNT9A,WNT8B,TCF
7,IKBKB,TRADD,NFKBIA,AKT1,WNT7A,PPP3CB,IGF1,MAP3K7,DKK3,GSK3B,CHUK,
SMAD1,ADAMTS4,ITGB1,SRC,AKT2,MAPK8,PPP3CC,GSN,CSF1R,XIAP,APC,PIK3R3,
BMPR1B,CBL,FOXO1,CSF1,IL1F5,FZD3,FZD6,MAP2K3,SFRP1,LRP1 
G Protein Signaling 
Mediated by Tubby 1.54E+00 2.44E-01 GNAS,GNB4,PLCB4,GNG11,GNB5,GNAQ,PLCG1,PLCB1,GNG2,GNG4 
ERK/MAPK Signaling 1.53E+00 1.98E-01 
PIK3CA,MAPK1,PPP1R3C,DUSP6,HRAS,PPP1CB,CRK,EIF4E,BRAF,PPM1L,PPP2R2C,S
TAT1,ITGB1,PPP1R14C,SRC,PAK2,PPP2R5C,YWHAB,YWHAZ,PLCG1,PPP1R14A,RAP
GEF3,ATF2,PIK3R3,PLA2G4A,RRAS2,ARAF,PAK3,DUSP1,PPP2R3A,PPP1R12A,RPS6
KA4,PAK7,RPS6KA5,PPP2R1B,ELK3,RAPGEF1,PRKCB 
DNA Methylation and 
Transcriptional Repression 
Signaling 1.52E+00 3.04E-01 CHD3,DNMT3A,CHD4,HDAC1,SAP130,ARID4B,RBBP4 
HGF Signaling 1.52E+00 2.23E-01 
MAP3K9,PIK3CA,AKT2,PRKCQ,MAPK1,MAPK8,HRAS,PLCG1,CCND1,ATF2,PIK3R3,M
AP3K10,RRAS2,AKT1,MAP3K7,CDKN1A,PRKCH,PTGS2,MAP3K3,ELK3,PRKD1,RAPG
EF1,PRKCB 
Amyotrophic Lateral 
Sclerosis Signaling 1.51E+00 1.96E-01 
TP53,CAPN5,GRIN2B,PIK3CA,SOD1,CASP3,GRIA2,VEGFC,NEFH,XIAP,GRIN3A,PIK3
R3,VEGFA,IGF1,HECW1,RAB5C,CAT,SLC1A2,BID,CAPN2,GRIK2,CAPN7 
Clathrin-mediated 
Endocytosis Signaling 1.51E+00 2.04E-01 
PIK3CA,EPS15,STON2,ARPC1B,SH3GLB1,EGF,VEGFA,CD2AP,ARF6,WASL (includes 
EG:8976),IGF1,PPP3CB,RAB5C,CSNK2A1,STAM,FGF3,AAK1,ITGB5,ACTA1,ITGB1,M
YO6,SRC,ACTB,FGF14,VEGFC,PPP3CC,HIP1,FGF1,PIK3R3,CSNK2A2,CBL,CLTA,TFR
C,MYO1E 
PPAR Signaling 1.50E+00 2.14E-01 
PPARA,MAPK1,PPARD,MED1,HRAS,MAP4K4,EP300,NR2F1,IKBKB,NFKBIA,RRAS2,H
SP90AB1,MAP3K7,IL1F5,NCOR1,CHUK,NCOR2,NRIP1,SCAND1,PPARGC1A,PDGFRB 
Butanoate Metabolism 1.50E+00 1.21E-01 
ACAA1,NLGN1,SUCLG2,ECH1,ALDH9A1,ELOVL6,HADHB,BDH1,ALDH1A1,ALDH3A2,
ALDH1A2,OXCT1,DBT,MYO5B,HADH,ILVBL 
GM-CSF Signaling 1.50E+00 2.39E-01 
PIK3CA,AKT2,MAPK1,HRAS,PPP3CC,CCND1,PIK3R3,CAMK2A,CAMK2D,AKT1,RRAS
2,PPP3CB,STAT1,PRKCB,CAMK2G,CAMK2B 
Cdc42 Signaling 1.49E+00 2.03E-01 
RALA,ARPC1B,PPP1CB,IQGAP1,LIMK1,MYLK,WASL (includes 
EG:8976),BAIAP2,GSK3B,RASA1,ITGB1,SRC,PAK2,MAPK8,TNK2,APC,ATF2,MYL9 
(includes EG:10398),CDC42BPA,EXOC4,PAK3,MYL12B,PPP1R12A,PRKCH,PARD3 
EGF Signaling 1.48E+00 2.45E-01 
PIK3R3,CSNK2A2,PIK3CA,JAK1,MAPK1,MAPK8,CSNK2A1,PLCG1,EGF,HRAS,STAT1,
RASA1 
ILK Signaling 1.46E+00 2.04E-01 
FLNB,PIK3CA,MAPK1,HIF1A,CCND1,VEGFA,TGFB1I1,MTOR,AKT1,PPAP2B,PPM1L,R
HOU,PPP2R2C,GSK3B,DSP,ITGB5,ACTA1,ITGB1,PARVA,AKT2,FBLIM1,PPP2R5C,RH
OC,ACTB,MAPK8,VIM,VEGFC,ATF2,PIK3R3,MYL9 (includes 
EG:10398),RND3,PPP2R3A,IRS1,MYH9,RPS6KA4,RPS6KA5,PTGS2,PPP2R1B 
RANK Signaling in 
Osteoclasts 1.45E+00 2.19E-01 
SRC,MAP3K9,PIK3CA,AKT2,CAMK4,MAPK1,MITF,MAPK8,PPP3CC,GSN,XIAP,PIK3R3
,IKBKB,MAP3K10,AKT1,CBL,NFKBIA,PPP3CB,MAP3K7,CHUK,MAP3K3 
Glutamate Receptor 
Signaling 1.44E+00 2.14E-01 
GRIN2B,CAMK4,HOMER2,GRM3,GRIA2,SLC1A3,SLC1A1,GRIP1,GRM4,GRIN3A,GNG
11,SLC1A2,GRIK2,GNG2,HOMER1 
Cell Cycle: G2/M DNA 
Damage Checkpoint 
Regulation 1.42E+00 2.56E-01 TP53,PRKDC,YWHAB,CDK7,CDKN1A,YWHAZ,RPRM,ATR,SKP2,ATM,EP300 
Chronic Myeloid Leukemia 
Signaling 1.41E+00 2.10E-01 
TP53,GAB2,PIK3CA,AKT2,PA2G4,MAPK1,HDAC1,CDK6,HRAS,CRK,CCND1,PIK3R3,
HDAC6,IKBKB,E2F6,AKT1,RRAS2,CDK4,CDKN1A,CTBP2,TGFB2,CHUK 
Cellular Effects of 
Sildenafil (Viagra) 1.41E+00 1.92E-01 
CAMK4,PDIA3,PPP1CB,PDE1A,PRKG1,CACNG2,MYLK,GPR37,PLCB1,KCNQ3,PLCL1,
CACNG8,ADCY8,ACTA1,ADCY2,GUCY1A3,ACTB,ADCY6,PLCG1,MYL9 (includes 
EG:10398),GNAS,PLCB4,MYL12B,PDE1B,ADCY1,PPP1R12B,MYH9,PPP1R12A,ADCY
7 
Interferon Signaling 1.40E+00 3.00E-01 IFIT3,JAK1,PTPN2,PIAS1,IFNGR2,IFI35,STAT1,IFNAR2,IFNAR1 
fMLP Signaling in 
Neutrophils 1.39E+00 1.92E-01 
PIK3CA,CAMK4,PRKCQ,MAPK1,ARPC1B,NFATC3,GNB5,HRAS,PPP3CC,PIK3R3,GNAI
2,GNB4,GNAS,PLCB4,GNG11,RRAS2,NFKBIA,PPP3CB,PLCB1,PRKCH,GNG2,GNG4,P
RKD1,PRKCB 
Dopamine Receptor 
Signaling 1.39E+00 1.94E-01 
PPP1R14C,ADCY2,PPP2R5C,PPP1R1B,DDC,PPP1R3C,ADCY6,PPP1CB,PPP1R14A,DR
D2,PPP2R3A,ADCY1,PPM1L,PPP1R12A,PPP2R2C,ADCY8,ADCY7,PPP2R1B 
Lymphotoxin Œ≤ Receptor 
Signaling 1.39E+00 2.30E-01 
TRAF3,PIK3CA,AKT2,VCAM1,CASP3,MAPK1,RELB,EP300,PIK3R3,IKBKB,AKT1,NFKB
IA,IKBKAP,CHUK 
Cell Cycle Regulation by 1.37E+00 2.78E-01 E2F6,CCNE2,PPP2R5C,PPP2R3A,CDK4,PPM1L,PPP2R2C,PPP2R1B,CCND1,CCRN4L 
BTG Family Proteins 
T Cell Receptor Signaling 1.37E+00 2.06E-01 
PIK3CA,CAMK4,PRKCQ,MAPK1,NFATC3,CD4,MAPK8,HRAS,PLCG1,PPP3CC,MALT1,P
IK3R3,PTPRC,IKBKB,RRAS2,CBL,NFKBIA,PPP3CB,VAV3,RASGRP1,CHUK,RASA1 
Erythropoietin Signaling 1.33E+00 2.11E-01 
SRC,PIK3CA,AKT2,PTPN6,PRKCQ,MAPK1,HRAS,PLCG1,PIK3R3,NFKBIA,AKT1,RRAS
2,CBL,PRKCH,PRKD1,PRKCB 
Virus Entry via Endocytic 
Pathways 1.30E+00 2.08E-01 
ITGB1,FLNB,SRC,PIK3CA,PRKCQ,ITSN1,ACTB,ITGA6,HRAS,PLCG1,PIK3R3,RRAS2,
CLTA,TFRC,PRKCH,ACTA1,ITGB5,PRKD1,HLA-C,PRKCB 
CD27 Signaling in 
Lymphocytes 1.27E+00 2.28E-01 
MAP3K9,CASP3,MAPK8,IKBKB,MAP3K10,NFKBIA,MAP3K7,BID,IKBKAP,MAP2K3,CH
UK,MAP3K3,MAP2K5 
Pancreatic 
Adenocarcinoma Signaling 1.25E+00 1.98E-01 
TP53,PIK3CA,AKT2,RALA,JAK1,PA2G4,MAPK1,MAPK8,EGF,VEGFC,CCND1,PLD1,VE
GFA,PIK3R3,E2F6,AKT1,CDK4,CDKN1A,TGFA,TGFB2,PTGS2,STAT1,NOTCH1 
FGF Signaling 1.25E+00 2.16E-01 
PTPN6,PIK3CA,AKT2,MAPK1,FGFR1,FGF14,MAPK8,HRAS,PLCG1,CRK,ATF2,FGF1,PI
K3R3,FGFR3,AKT1,MAP2K3,RPS6KA5,FGF3,MAPKAPK2 
Insulin Receptor Signaling 1.24E+00 2.00E-01 
PIK3CA,JAK1,MAPK1,PPP1R3C,HRAS,PPP1CB,INPPL1,CRK,STXBP4,NCK1,EIF4E,MT
OR,AKT1,RPS6KB2,STX4,GSK3B,PPP1R14C,AKT2,MAPK8,PPP1R14A,PIK3R3,RRAS2
,CBL,FOXO1,IRS1,PPP1R12A,PRKCH,RAPGEF1 
Role of NANOG in 
Mammalian Embryonic 
Stem Cell Pluripotency 1.22E+00 2.11E-01 
TP53,PIK3CA,AKT2,JAK1,MAPK1,HRAS,SMAD5,FZD1,WNT9A,WNT8B,APC,SOX2,LI
FR,PIK3R3,BMPR1B,WNT7A,AKT1,RIF1,RRAS2,FZD3,FZD6,GATA6,GSK3B,SMAD1 
Semaphorin Signaling in 
Neurons 1.21E+00 2.50E-01 
ITGB1,PAK2,MAPK1,DPYSL3,RHOC,LIMK1,ROCK1,SEMA3A,RND3,PAK3,PLXNB1,RH
OU,PAK7 
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Leukocyte Extravasation 
Signaling 2.96E+00 3.09E-02 WIPF1,CLDN23,ACTN2,VAV3,RAPGEF3,DLC1 
Integrin Signaling 2.15E+00 2.50E-02 WIPF1,RND3,ARF3,ACTN2,TSPAN6 
G Protein Signaling 
Mediated by Tubby 1.74E+00 4.88E-02 GNG5,GNG4 
Serotonin Receptor 
Signaling 1.74E+00 4.35E-02 MAOB,DDC 
Phenylalanine Metabolism 1.67E+00 1.83E-02 MAOB,DDC 
Notch Signaling 1.62E+00 4.65E-02 APH1B,JAG1 
Axonal Guidance Signaling 1.56E+00 1.49E-02 NTNG1,WIPF1,BMP2,WNT8B,GNG5,GNG4 
Histidine Metabolism 1.36E+00 1.67E-02 MAOB,DDC 
Aryl Hydrocarbon 
Receptor Signaling 1.28E+00 1.95E-02 NR2F1,MGST1,GSTA4 
Phospholipase C Signaling 1.26E+00 1.58E-02 RND3,RAPGEF3,GNG5,GNG4 
Colorectal Cancer 
Metastasis Signaling 1.24E+00 1.61E-02 RND3,WNT8B,GNG5,GNG4 
Molecular Mechanisms of 
Cancer 1.23E+00 1.34E-02 APH1B,RND3,BMP2,BID,RAPGEF3 
Basal Cell Carcinoma 
Signaling 1.20E+00 2.94E-02 BMP2,WNT8B 
Glutathione Metabolism 1.20E+00 2.04E-02 MGST1,GSTA4 
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LPS/IL-1 Mediated 
Inhibition of RXR 
Function 
3.50E+
00 2.33E-02 MGST1,JUN,FABP7,HS3ST3A1,ABCA1 
IGF-1 Signaling 
2.55E+
00 3.00E-02 IGFBP4,IGFBP6,JUN 
Aryl Hydrocarbon 
Receptor Signaling 
2.09E+
00 1.95E-02 NR2F1,MGST1,JUN 
GABA Receptor 
Signaling 
2.05E+
00 3.64E-02 GABRA5,GABRG1 
PPAR Signaling 
1.53E+
00 2.04E-02 NR2F1,JUN 
Corticotropin 
Releasing Hormone 
Signaling 
1.34E+
00 1.47E-02 JUN,CNR1 
Relaxin Signaling 
1.25E+
00 1.34E-02 JUN,PDE10A 
	  
YAC	  23	  month	  D1	  IPA	  Analysis	  
Ingenuity Canonical 
Pathways  -log(p-value) Ratio Molecules 
Molecular Mechanisms 
of Cancer 4.36E+00 5.91E-02 
PRKDC,TCF4,STK36,TGFBR1,RHOC,BMP2,RALB,FZD1,RASGRF2,CAMK2D,
CBL,RND3,SUFU,GNAO1,RHOU,E2F5,TGFB2,PAK7,GNA13,CDKN1B,HIPK2,
BRCA1 
Semaphorin Signaling 
in Neurons 3.49E+00 1.35E-01 RND3,DPYSL3,RHOC,RHOU,PAK7,SEMA7A,NRP1 
Axonal Guidance 
Signaling 2.96E+00 4.96E-02 
SEMA3E,SLIT3,PLXNC1,STK36,BMP2,UNC5B,FZD1,ABLIM1,GNG5,GNB4,
WIPF1,NFAT5,SUFU,GNAO1,PAK7,SEMA4A,GNA13,GNG4,SEMA7A,NRP1 
Cardiac Hypertrophy 
Signaling 2.80E+00 5.76E-02 
TGFBR1,RHOC,PLCH2,GNG5,CACNA1A,GNB4,PLCE1,RND3,GNAO1,RHOU,
TGFB2,GNA13,GNG4,ADRA1A 
ILK Signaling 2.70E+00 6.45E-02 
FLNB,PARVA,RND3,PPP2R3A,RHOC,ACTN2,PPAP2B,RHOU,MYH3,RPS6KA4
,RPS6KA5,DSP 
mTOR Signaling 2.58E+00 6.41E-02 
MAPKAP1,PLD2,EIF4G2,RND3,PPP2R3A,RHOC,RHOU,RPS6KA4,RPS6KA5,
RICTOR 
Glycine, Serine and 2.57E+00 4.67E-02 MAOB,PLCE1,CHDH,GLYCTK,PDPR,PLCH2,GATM 
Threonine Metabolism 
Phospholipase C 
Signaling 2.27E+00 5.14E-02 
PLD2,HDAC8,RHOC,RALB,PPP1R14A,GNG5,GNB4,NFAT5,PLCE1,RND3,RH
OU,GNA13,GNG4 
Protein Kinase A 
Signaling 2.07E+00 4.76E-02 
FLNB,HIST1H1C,TGFBR1,PPP1R14A,PLCH2,PDE1A,GNG5,GNB4,NFAT5,PL
CE1,CAMK2D,TGFB2,RYR1,GNA13,GNG4 
Thrombin Signaling 2.06E+00 5.39E-02 
GNB4,PLCE1,CAMK2D,RND3,RHOC,GNAO1,RHOU,GNA13,PLCH2,GNG5,G
NG4 
Integrin Signaling 2.01E+00 5.50E-02 
PARVA,WIPF1,RND3,ITGA9,RHOC,ACTN2,RALB,RHOU,PAK7,LIMS1,TSPAN
6 
CXCR4 Signaling 1.82E+00 5.39E-02 GNB4,RND3,RHOC,GNAO1,RHOU,PAK7,GNA13,GNG5,GNG4 
Aminoacyl-tRNA 
Biosynthesis 1.74E+00 4.82E-02 WARS2,IARS2,LARS2,HARS2 
Growth Hormone 
Signaling 1.66E+00 7.14E-02 IGFBP3,RPS6KA4,SOCS4,RPS6KA5,ONECUT1 
Wnt/Œ≤-catenin 
Signaling 1.61E+00 5.36E-02 TCF4,TGFBR1,PPP2R3A,GNAO1,TLE3,TGFB2,KREMEN1,FZD1,TCF7L2 
IL-1 Signaling 1.55E+00 5.66E-02 GNB4,GNAO1,GNA13,GNG5,GNG4,IL1RAP 
Glioblastoma 
Multiforme Signaling 1.50E+00 4.91E-02 PLCE1,RND3,RHOC,E2F5,RHOU,FZD1,CDKN1B,PLCH2 
Cardiac Œ≤-
adrenergic Signaling 1.48E+00 4.93E-02 GNB4,PPP2R3A,PPP1R14A,PDE1A,GNG5,GNG4,CACNA1A 
Germ Cell-Sertoli Cell 
Junction Signaling 1.44E+00 5.06E-02 TGFBR1,RND3,RHOC,ACTN2,PPAP2B,RHOU,TGFB2,PAK7 
Role of NFAT in 
Cardiac Hypertrophy 1.39E+00 4.35E-02 GNB4,PLCE1,TGFBR1,CAMK2D,HDAC8,TGFB2,PLCH2,GNG5,GNG4 
Valine, Leucine and 
Isoleucine 
Biosynthesis 1.38E+00 4.55E-02 IARS2,LARS2 
Chondroitin Sulfate 
Biosynthesis 1.37E+00 5.97E-02 B3GAT1,CSGALNACT1,HS3ST3A1,SULT2B1 
Sphingosine-1-
phosphate Signaling 1.36E+00 5.36E-02 PLCE1,RND3,RHOC,RHOU,GNA13,PLCH2 
Breast Cancer 
Regulation by 
Stathmin1 1.35E+00 4.52E-02 GNB4,CAMK2D,PPP2R3A,E2F5,PPP1R14A,GNA13,CDKN1B,GNG5,GNG4 
Histidine Metabolism 1.34E+00 3.33E-02 PRPS2,MAOB,METTL1,HARS2 
G Protein Signaling 
Mediated by Tubby 1.30E+00 7.32E-02 GNB4,GNG5,GNG4 
Cell Cycle: G1/S 
Checkpoint Regulation 1.27E+00 6.78E-02 HDAC8,E2F5,TGFB2,CDKN1B 
IL-8 Signaling 1.21E+00 4.30E-02 GNB4,PLD2,RND3,RHOC,RHOU,GNA13,GNG5,GNG4 
CREB Signaling in 
Neurons 1.21E+00 4.08E-02 GNB4,PLCE1,CAMK2D,GNAO1,GNA13,PLCH2,GNG5,GNG4 
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PPARŒ±/RXRŒ± 
Activation 3.71E+00 7.14E-02 
GPD1,SMAD3,PRKAR2A,NR2C2,PLCH2,IKBKG,ACADL,JUN,NFKBIA,ADCY5,SO
S1,TGFB2,INSR 
CD27 Signaling in 
Lymphocytes 2.86E+00 1.05E-01 TRAF2,IKBKG,JUN,CASP9,NFKBIA,MAP3K3 
Small Cell Lung 
Cancer Signaling 2.79E+00 7.87E-02 PTK2,NOS1,TRAF2,IKBKG,CASP9,NFKBIA,SIN3A 
IGF-1 Signaling 2.76E+00 8.00E-02 PTK2,IGFBP4,JUN,CASP9,SOS1,PRKAR2A,IGFBP5,NEDD4 
Role of PKR in 
Interferon Induction 
and Antiviral 
Response 2.57E+00 1.09E-01 FADD,TRAF2,IKBKG,CASP9,NFKBIA 
Death Receptor 
Signaling 2.57E+00 9.38E-02 FADD,TRAF2,IKBKG,CASP9,NFKBIA,XIAP 
Induction of 
Apoptosis by HIV1 2.53E+00 9.23E-02 FADD,TRAF2,IKBKG,CASP9,NFKBIA,XIAP 
4-1BB Signaling in T 
Lymphocytes 2.30E+00 1.18E-01 TRAF2,IKBKG,JUN,NFKBIA 
RANK Signaling in 
Osteoclasts 2.26E+00 7.29E-02 TRAF2,IKBKG,JUN,NFKBIA,GSN,MAP3K3,XIAP 
IL-1 Signaling 2.18E+00 6.60E-02 IKBKG,JUN,NFKBIA,ADCY5,PRKAR2A,GNG5,GNG4 
April Mediated 
Signaling 1.92E+00 9.52E-02 TRAF2,IKBKG,JUN,NFKBIA 
Role of NFAT in 
Cardiac Hypertrophy 1.90E+00 4.83E-02 HDAC4,ADCY5,SOS1,PRKAR2A,TGFB2,SLC8A2,ITPR1,PLCH2,GNG5,GNG4 
Regulation of IL-2 
Expression in 
Activated and Anergic 
T Lymphocytes 1.89E+00 6.67E-02 IKBKG,JUN,NFKBIA,SMAD3,SOS1,TGFB2 
B Cell Activating 
Factor Signaling 1.84E+00 9.09E-02 TRAF2,IKBKG,JUN,NFKBIA 
Hepatic Cholestasis 1.84E+00 4.79E-02 TRAF2,IKBKG,CYP7B1,JUN,NFKBIA,ADCY5,PRKAR2A,INSR 
Molecular 1.79E+00 4.03E-02 SMAD3,PRKAR2A,ARHGEF1,AURKA,XIAP,SIN3A,FADD,PTK2,JUN,CASP9,NFK
Mechanisms of 
Cancer 
BIA,RND3,ADCY5,SOS1,TGFB2 
PPAR Signaling 1.72E+00 6.12E-02 TRAF2,IKBKG,JUN,NFKBIA,SOS1,INSR 
Œ±-Adrenergic 
Signaling 1.70E+00 5.66E-02 ADCY5,PRKAR2A,SLC8A2,ITPR1,GNG5,GNG4 
Angiopoietin Signaling 1.69E+00 6.76E-02 PTK2,IKBKG,CASP9,NFKBIA,SOS1 
SAPK/JNK Signaling 1.64E+00 6.12E-02 FADD,TRAF2,JUN,SOS1,GNG5,MAP3K3 
Chronic Myeloid 
Leukemia Signaling 1.57E+00 5.71E-02 IKBKG,HDAC4,SMAD3,SOS1,TGFB2,SIN3A 
Role of RIG1-like 
Receptors in Antiviral 
Innate Immunity 1.57E+00 7.69E-02 FADD,TRAF2,IKBKG,NFKBIA 
Antiproliferative Role 
of Somatostatin 
Receptor 2 1.56E+00 6.41E-02 NOS1,SSTR2,ADCY5,GNG5,GNG4 
Protein Kinase A 
Signaling 1.55E+00 4.13E-02 
PPP1R14C,CREM,SMAD3,PRKAR2A,ITPR1,PLCH2,GNG5,PTK2,NFKBIA,ADCY5
,TGFB2,GNG4,ANAPC1 
GNRH Signaling 1.54E+00 4.86E-02 PTK2,JUN,ADCY5,SOS1,PRKAR2A,ITPR1,MAP3K3 
Cholecystokinin/Gastr
in-mediated Signaling 1.48E+00 5.77E-02 PTK2,CREM,JUN,RND3,SOS1,ITPR1 
Reelin Signaling in 
Neurons 1.45E+00 6.41E-02 YES1,HCK,ARHGEF1,LRP8,DCX 
Renin-Angiotensin 
Signaling 1.41E+00 5.00E-02 PTK2,JUN,ADCY5,SOS1,PRKAR2A,ITPR1 
Pancreatic 
Adenocarcinoma 
Signaling 1.41E+00 5.17E-02 CASP9,SMAD3,TGFB2,BRCA2,HBEGF,SIN3A 
Thrombin Signaling 1.40E+00 4.41E-02 PTK2,RND3,ADCY5,SOS1,ARHGEF1,ITPR1,PLCH2,GNG5,GNG4 
Type I Diabetes 
Mellitus Signaling 1.39E+00 5.22E-02 FADD,TRAF2,IKBKG,CASP9,NFKBIA,ICA1 
Lymphotoxin Œ≤ 
Receptor Signaling 1.38E+00 6.56E-02 TRAF2,IKBKG,CASP9,NFKBIA 
Glioma Invasiveness 
Signaling 1.38E+00 7.02E-02 PTK2,TIMP3,RND3,CD44 
Cardiac Hypertrophy 
Signaling 1.36E+00 4.12E-02 JUN,RND3,ADCY5,SOS1,PRKAR2A,TGFB2,PLCH2,GNG5,GNG4,MAP3K3 
G Protein Signaling 
Mediated by Tubby 1.35E+00 7.32E-02 INSR,GNG5,GNG4 
Cell Cycle: G1/S 
Checkpoint 
Regulation 1.33E+00 6.78E-02 HDAC4,SMAD3,TGFB2,SIN3A 
Colorectal Cancer 
Metastasis Signaling 1.27E+00 4.02E-02 JUN,CASP9,RND3,ADCY5,SMAD3,SOS1,PRKAR2A,TGFB2,GNG5,GNG4 
Methane Metabolism 1.25E+00 3.03E-02 CYP7B1,SHMT1 
CD40 Signaling 1.24E+00 5.97E-02 TRAF2,IKBKG,JUN,NFKBIA 
Calcium Signaling 1.23E+00 3.90E-02 TNNT1,HDAC4,TPM3,PRKAR2A,TPM2,SLC8A2,TRPC6,ITPR1 
IL-6 Signaling 1.22E+00 5.38E-02 TRAF2,IKBKG,JUN,NFKBIA,SOS1 
GŒ±12/13 Signaling 1.20E+00 4.80E-02 PTK2,CDH2,IKBKG,JUN,NFKBIA,ARHGEF1 
	  
Appendix	  III:	  qPCR	  
Confirmed	  Genes	  
Date Model 
Cell 
Type Age Method 
Sample 
size? Gene 
Array Fold 
Change 
qPCR Fold 
Change Confirmed? 
Reference 
Gene 
4/14/09 R6-2 D2 
14 
weeks Pooled n=1 Ppap2b 0.769230769 0.89 Y Map2 
4/14/09 R6-2 D2 
14 
weeks Pooled n=1 SGPL1 1.1 4.2 Y Map2 
4/14/09 R6-2 D2 
14 
weeks Pooled n=1 Sulf2 1.05 2.4 Y Map2 
4/17/09 R6-2 D2 
14 
weeks Pooled n=1 Smpd1 1.082159664 1.399729693 Y Map2 
4/17/09 R6-2 D2 
14 
weeks Pooled n=1 Ugt8a 1.166292442 0.935350022 Y Map2 
4/17/09 R6-2 D2 
14 
weeks Pooled n=1 Ddost 0.571428571 0.413476431 Y Map2 
4/17/09 R6-2 D2 
14 
weeks Pooled n=1 Rpn2 0.80705191 0.710149782 Y Map2 
5/7/09 R6-2 D2 
14 
weeks Pooled n=1 Actb 0.806451613 0.623206672 Y Atp5b 
5/7/09 R6-2 D2 
14 
weeks Pooled n=1 Ubc 0.555555556 0.127560229 Y Atp5b 
5/7/09 R6-2 D2 
14 
weeks Pooled n=1 Atp5b 0.980392157 1 Y Atp5b 
5/7/09 R6-2 D2 
14 
weeks Pooled n=1 Acin1 1.7 1.717002234 Y Atp5b 
5/7/09 R6-2 D2 
14 
weeks Pooled n=1 Casp3 2.24 1.805956947 Y Atp5b 
5/7/09 R6-2 D2 
14 
weeks Pooled n=1 Garnl1 1.2 1.794057442 Y Atp5b 
5/7/09 R6-2 D2 
14 
weeks Pooled n=1 Penk1 0.476190476 0.213401381 Y Atp5b 
5/11/09 R6-2 D1 
4 
weeks Pooled n=2 SGPL1 (20ng) 1.2 3.548383843 Y Eif4a2/Atp5b 
5/11/09 R6-2 D1 
4 
weeks Pooled n=2 Ugt8 1.08 1.199675068 Y Eif4a2/Atp5b 
5/11/09 R6-2 D1 
4 
weeks Pooled n=2 Ddost 1.14 2.416403414 Y Eif4a2/Atp5b 
5/11/09 R6-2 D1 4 Pooled n=2 Rpn1 1.2 1.304021883 Y Eif4a2/Atp5b 
weeks 
5/11/09 R6-2 D1 
4 
weeks Pooled n=2 Rpn2 1.2 1.214125941 Y Eif4a2/Atp5b 
5/11/09 R6-2 D1 
4 
weeks Pooled n=2 TUSC3 1.18 1.230570088 Y Eif4a2/Atp5b 
5/11/09 R6-2 D1 
4 
weeks Pooled n=2 CHUK 0.917431193 0.589830193 Y Eif4a2/Atp5b 
5/12/09 R6-2 D1 
4 
weeks Pooled n=2 Acin1 0.925925926 0.766674054 Y Eif4a2/Atp5b 
5/12/09 R6-2 D1 
4 
weeks Pooled n=2 CyclinD1 0.925925926 0.692784598 Y Eif4a2/Atp5b 
5/12/09 R6-2 D1 
4 
weeks Pooled n=2 Garnl1 1 0.947672686 Y Eif4a2/Atp5b 
5/12/09 R6-2 D1 
4 
weeks Pooled n=2 Gsn 1.08 1.450764664 Y Eif4a2/Atp5b 
5/12/09 R6-2 D1 
4 
weeks Pooled n=2 Aplp2 1.2 1.277988861 Y Eif4a2/Atp5b 
5/11/09 R6-2 D2 
4 
weeks Pooled n=1 SGPL1 (20ng) 1.2 4.152241957 Y Eif4a2/Atp5b 
5/11/09 R6-2 D2 
4 
weeks Pooled n=1 Ugt8 1.4 1.704230545 Y Eif4a2/Atp5b 
5/11/09 R6-2 D2 
4 
weeks Pooled n=1 TUSC3 1.3 1.218353693 Y Eif4a2/Atp5b 
5/11/09 R6-2 D2 
4 
weeks Pooled n=1 PPARalpha 1.2 4.024697949 Y Eif4a2/Atp5b 
5/11/09 R6-2 D2 
4 
weeks Pooled n=1 CHUK 1.3 2.106307782 Y Eif4a2/Atp5b 
5/12/09 R6-2 D2 
4 
weeks Pooled n=2 Acin1 0.769230769 0.639953167 Y Eif4a2/Atp5b 
5/12/09 R6-2 D2 
4 
weeks Pooled n=2 CyclinD1 1 1.178844956 Y Eif4a2/Atp5b 
5/12/09 R6-2 D2 
4 
weeks Pooled n=2 Garnl1 1 1.586486489 Y Eif4a2/Atp5b 
5/12/09 R6-2 D2 
4 
weeks Pooled n=2 PPARGC1alpha 1 0.870973503 Y Eif4a2/Atp5b 
5/12/09 R6-2 D2 
4 
weeks Pooled n=2 Aplp2 1.07 1.064202158 Y Eif4a2/Atp5b 
5/12/09 R6-2 D2 
4 
weeks Pooled n=2 Hnrnpu 1 1.099359307 Y Eif4a2/Atp5b 
5/12/09 R6-2 D1 
4 
weeks Pooled n=2 Ubc 1.2 5.880303971 Y Eif4a2/Atp5b 
5/8/09 R6-2 D1 
4 
weeks Pooled n=2 SGPL1 1.16 3.715273471 Y Eif4a2/Atp5b 
5/8/09 R6-2 D1 
4 
weeks Pooled n=2 Akt2 1 1.167330258 Y Eif4a2/Atp5b 
5/8/09 R6-2 D1 
4 
weeks Pooled n=2 GBA 1.1 2.391942829 Y Eif4a2/Atp5b 
5/8/09 R6-2 D1 
4 
weeks Pooled n=2 SMPD1 1.1 1.501846543 Y Eif4a2/Atp5b 
5/8/09 R6-2 D2 
4 
weeks Pooled n=1 SGPL1 1.2 5.114830301 Y Eif4a2/Atp5b 
5/8/09 R6-2 D2 
4 
weeks Pooled n=1 SMPD1 1.27 1.078988789 Y Eif4a2/Atp5b 
12/3/09 R6-2 D1 
4 
weeks Single n=4 Sphk1 1 #DIV/0! Y Eif4a2 
12/3/09 R6-2 D2 
4 
weeks Single n=4 Sphk1 1.1 #DIV/0! Y Eif4a2 
2/26/10 YAC128 D1 
13 
months Single n=3 Sphk2 1 1.349454344 Y Eif4a2 
2/26/10 YAC128 D2 
13 
months Single n=3 Sphk1 0.943396226 #DIV/0! Y Eif4a2 
11/11/09 YAC128 D1 
13 
months Single n=3 IGFBP4 0.384615385 0.384592669 Y Eif4a2 
11/11/09 YAC128 D1 
13 
months Single n=3 TTR 1.06 1.152349825 Y Eif4a2 
11/11/09 YAC128 D2 
13 
months Single n=3 IGFBP4 0.37037037 0.236194073 Y Eif4a2 
11/11/09 YAC128 D2 
13 
months Single n=3 TTR 0.666666667 0.303815806 Y Eif4a2 
8/30/10 R6-2 D2 
4.5 
weeks Single 
n=3 or 
4 PENK1 0.980392157 0.935672084 Y Eif4a2 
8/30/10 R6-2 D2 
4.5 
weeks Single 
n=3 or 
4 Sphk1 "41" 1.08 #DIV/0! Y Eif4a2 
8/30/10 R6-2 D2 
4.5 
weeks Single 
n=3 or 
4 
Sphk2 
Mm00445020_m1 1.3 2.068550363 Y Eif4a2 
8/30/10 R6-2 D2 
4.5 
weeks Single 
n=3 or 
4 
Sphk2 
Mm00445021_m1  1.3 2.55828979 Y Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Rprm 2.86 16.58424868 Y Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Igfbp4 0.333333333 0.410214767 Y Eif4a2 
11/15/10 YAC128 D1 13 Single n=4 Sox11 1.3 4.420514111 Y Eif4a2 
months 
11/15/10 YAC128 D1 
13 
months Single n=4 Mprl13 1.15 1.098504541 Y Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Pcdh20 2.1 11.33039564 Y Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Pkp2 0.344827586 0.345732947 Y Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Ppp1r9a 0.588235294 0.557679251 Y Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Actn2 0.571428571 0.402287714 Y Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Mapkbp1 0.952380952 0.772060379 Y Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Ntrk3 0.833333333 0.840539972 Y Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Igfbp5 0.909090909 0.944631576 Y Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Tmem183a 1.08 1.118417753 Y Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Pea15a 0.8 0.861685463 Y Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Rprm 1.4 1.735154647 Y Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 B3gat1 1.1 1.459853991 Y Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Thtpa 0.996412914 0.91093704 Y Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Agfg2 0.854700855 0.954266743 Y Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Igfbp4 0.35971223 0.266217303 Y Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Sox11 1.3 3.73540995 Y Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Bcl11a 1.15 1.011950578 Y Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Mgst1 2.2 1.32267245 Y Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Jun  0.454545455 0.352470499 Y Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Pkp2 0.588235294 0.018121244 Y Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 WT1 0.980392157 #DIV/0! Y Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Ppp1r9a 0.740740741 0.595880077 Y Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Actn2 0.714285714 0.557737011 Y Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Mapkbp1 0.925925926 0.647535301 Y Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Igfbp5 1.08 3.832218754 Y Eif4a2 
	  
qPCR:	  Unconfirmed	  Genes	  
Date Model 
Cell 
Type Age Method 
Sample 
size? Gene 
Array Fold 
Change 
qPCR Fold 
Change Confirmed? 
Reference 
Gene 
4/14/09 R6-2 D2 
14 
weeks Pooled n=1 GBA 1.07 0.670216217 N Map2 
4/17/09 R6-2 D2 
14 
weeks Pooled n=1 Rpn1 0.887519484 1.103251149 N Map2 
4/17/09 R6-2 D2 
14 
weeks Pooled n=1 Tusc3 1.106960555 0.837248766 N Map2 
5/7/09 R6-2 D2 
14 
weeks Pooled n=1 Eif4a 0.970873786 1.116182552 N Atp5b 
5/7/09 R6-2 D2 
14 
weeks Pooled n=1 CyclinD1 Var 3.441397602 N Atp5b 
5/7/09 R6-2 D2 
14 
weeks Pooled n=1 Gsn 0.666666667 1.022378687 N Atp5b 
5/7/09 R6-2 D2 
14 
weeks Pooled n=1 PPARGC1alpha 1.5 0.64015278 N Atp5b 
5/11/09 R6-2 D1 
4 
weeks Pooled n=2 PPARalpha 0.980392157 152.5044685 N Eif4a2/Atp5b 
5/11/09 R6-2 D1 
4 
weeks Pooled n=2 CASP3 0.952380952 7.486508046 N Eif4a2/Atp5b 
5/12/09 R6-2 D1 
4 
weeks Pooled n=2 PPARGC1alpha 0.980392157 1.330167347 N Eif4a2/Atp5b 
5/12/09 R6-2 D1 
4 
weeks Pooled n=2 Calpain2 0.862068966 1.568453775 N Eif4a2/Atp5b 
5/12/09 R6-2 D1 
4 
weeks Pooled n=2 Hnrnpu 0.980392157 1.358907623 N Eif4a2/Atp5b 
5/12/09 R6-2 D1 
4 
weeks Pooled n=2 Ubc 1 36.2454797 N Eif4a2/Atp5b 
5/11/09 R6-2 D2 
4 
weeks Pooled n=1 Ddost 1.3 0.830498671 N Eif4a2/Atp5b 
5/11/09 R6-2 D2 
4 
weeks Pooled n=1 Rpn1 1.5 0.872429231 N Eif4a2/Atp5b 
5/11/09 R6-2 D2 
4 
weeks Pooled n=1 Rpn2 1.3 0.293014358 N Eif4a2/Atp5b 
5/11/09 R6-2 D2 
4 
weeks Pooled n=1 CASP3 1 0.232427111 N Eif4a2/Atp5b 
5/12/09 R6-2 D2 
4 
weeks Pooled n=2 Gsn 1.4 0.491110725 N Eif4a2/Atp5b 
5/12/09 R6-2 D2 4 Pooled n=2 Calpain2 1.07 0.86241907 N Eif4a2/Atp5b 
weeks 
5/8/09 R6-2 D1 
4 
weeks Pooled n=2 SULF2 1 0.606060945 N Eif4a2/Atp5b 
5/8/09 R6-2 D1 
4 
weeks Pooled n=2 PPAP2b 1.2 0.774489874 N Eif4a2/Atp5b 
5/8/09 R6-2 D1 
4 
weeks Pooled n=2 Penk1 0.909090909 1.03065655 N Eif4a2/Atp5b 
5/8/09 R6-2 D2 
4 
weeks Pooled n=1 SULF2 1.2 0.47270028 N Eif4a2/Atp5b 
5/8/09 R6-2 D2 
4 
weeks Pooled n=1 PPAP2b 1.25 0.351235452 N Eif4a2/Atp5b 
5/8/09 R6-2 D2 
4 
weeks Pooled n=1 Akt2 1 0.670351243 N Eif4a2/Atp5b 
5/8/09 R6-2 D2 
4 
weeks Pooled n=1 Penk1 1.2 0.911081409 N Eif4a2/Atp5b 
5/8/09 R6-2 D2 
4 
weeks Pooled n=1 Htt  #DIV/0! N Eif4a2/Atp5b 
5/8/09 R6-2 D2 
4 
weeks Pooled n=1 GBA 1.2 0.291528559 N Eif4a2/Atp5b 
12/3/09 R6-2 D1 
4 
weeks Single n=4 SGPL1 1 50.73284812 N Eif4a2 
12/3/09 R6-2 D1 
4 
weeks Single n=4 Sphk2 1.3 0.448867505 N Eif4a2 
12/3/09 R6-2 D2 
4 
weeks Single n=4 SGPL1 1 64.04803093 N Eif4a2 
12/3/09 R6-2 D2 
4 
weeks Single n=4 Sphk2 1.15 0.029226435 N Eif4a2 
2/26/10 YAC128 D1 
13 
months Single n=3 Sphk1 1.01 #DIV/0! N Eif4a2 
2/26/10 YAC128 D2 
13 
months Single n=3 SGPL1 1 2.44701792 N Eif4a2 
2/26/10 YAC128 D2 
13 
months Single n=3 Sphk2 1.01 0.619613794 N Eif4a2 
2/26/10 YAC128 D2 
13 
months Single n=3 SGPL1 1.07 0.490449056 N Eif4a2 
11/11/09 YAC128 D1 
13 
months Single n=3 SGPL1 1 0.202129435 N Eif4a2 
11/11/09 YAC128 D2 
13 
months Single n=3 SGPL1 1 1.564710131 N Eif4a2 
8/30/10 R6-2 D2 
4.5 
weeks Single 
n=3 or 
4 
SGPL1 
Mm1149898_m1 1 0.64569466 N Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Tmem183a 1.1 0.934857849 N Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Pea15a 1.05 0.838178933 N Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 B3gat1 1.03 0.894291457 N Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Thtpa 1.06 0.546563333 N Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Agfg2 0.869565217 1.291687206 N Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Gpr56 0.952380952 4.279516569 N Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Bcl11a 1.2 0.815485521 N Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Mrpl22 1.1 0.940328935 N Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 hexb 1.2 0.734682933 N Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Spata5 
(up 1.7 in 
one probe, 
down 1.7 in 
another) 0.479906192 N Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Mgst1 1.5 0.585286943 N Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Jun  0.769230769 1.62525743 N Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Lsm10 0.970873786 2.36144879 N Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Fxc1 1.05 0.862545669 N Eif4a2 
11/15/10 YAC128 D1 
13 
months Single n=4 Mtap1a 0.833333333 1.524723791 N Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Gpr56 0.991080278 0.130614601 N Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Mprl13 1.06 0.844212883 N Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Mrpl22 1.06 0.596827017 N Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 hexb 1.2 0.873986257 N Eif4a2 
11/14/10 YAC128 D2 13 Single n=4 Spata5 varies  0.441653878 N Eif4a2 
months 
11/14/10 YAC128 D2 
13 
months Single n=4 Lsm10 1.1 0.595337461 N Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Ntrk3 1.05 0.684477805 N Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Fxc1 1.06 0.970738029 N Eif4a2 
11/14/10 YAC128 D2 
13 
months Single n=4 Mtap1a 1.01 0.629813535 N Eif4a2 
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